Document:

EX-10.1

 Exhibit 10.1 

[***] Certain information in this document has been excluded pursuant to Regulation S-K, Item 601(b)(10). Such
excluded information is not material and would likely cause competitive harm to the registrant if publicly disclosed. 
 Execution
Copy 
 COLLABORATIVE RESEARCH, DEVELOPMENT AND COMMERCIALIZATION 

AGREEMENT 
 This
COLLABORATIVE RESEARCH, DEVELOPMENT AND COMMERCIALIZATION AGREEMENT (this “Agreement”) is entered into as of June 8, 2018 (the “Execution Date”), by and between Revolution Medicines, Inc., a corporation
organized and existing under the laws of Delaware, having its principal place of business at 700 Saginaw Dr. Redwood City, CA 94063, USA (“RevMed”), and Aventis, Inc., a corporation organized and existing under the laws of
Pennsylvania, having offices at 55 Corporate Drive, Bridgewater, NJ 08807 (“Sanofi”). Sanofi and RevMed are referred to in this Agreement individually as a “Party” and collectively as the “Parties.”

 RECITALS 
 WHEREAS,
RevMed has developed expertise in cancer biology and related drug discovery and precision medicine capabilities enabling RevMed to design and optimize drug candidates that inhibit the activity of the cancer target known as Src homology region 2-containing protein tyrosine phosphatase 2; 
 WHEREAS, Sanofi is a pharmaceutical company working to
develop and commercialize novel therapies; 
 WHEREAS, RevMed and Sanofi desire to establish a collaboration for the research, development
and potential commercialization of such drug candidates and biologic compounds that inhibit the activity of such cancer target for the treatment of cancer, and potentially other indications; and 

WHEREAS, Sanofi desires to acquire from RevMed, and RevMed desires to grant to Sanofi, certain licenses with regard to SHP2 Inhibitors and
Products (as defined below), as further described herein. 
 NOW, THEREFORE, in consideration of the foregoing premises and the mutual
covenants contained herein, the receipt and sufficiency of which are hereby acknowledged, RevMed and Sanofi hereby agree: 
 Article I. 

DEFINITIONS 
 The terms in
this Agreement with initial letters capitalized shall have the meanings set forth below, or the meaning as designated in the indicated places throughout this Agreement. 

1.1 “Accounting Standards” means, with respect to a Party or its Affiliate or Sublicensee, IFRS or GAAP, as such
Person uses for its financial reporting obligations, consistently applied. 

 1.2 “Acquired Party Family” means in the case of a Change of Control
of a Party or its Affiliate, such Party or such Affiliate existing immediately prior to the Change of Control transaction and any subsidiaries thereof (then existing or thereafter created). 

1.3 “Acquiror Family” means in the case of a Change of Control of a Party or any of its
Affiliates, the Acquiror and its Affiliates existing immediately prior to the closing of the Change of Control transaction together with any future Affiliates other than the Acquired Party Family. 

1.4 “Act” means the United States Federal Food, Drug, and Cosmetic Act, as amended, and the rules, regulations,
guidance, guidelines and requirements promulgated thereunder (including all additions, supplements, extensions and modifications) in effect from time to time. 

1.5 “Affiliate” means, with respect to a Party or other Person, any corporation or other business
entity that, directly or indirectly, through one or more intermediaries, controls, is controlled by, or is under common control with that Party or other Person for so long as such Party or other Person controls, is controlled by or is under common
control with such corporation or other business entity. For the purpose of this definition only, “control” (including, with correlative meaning, the terms “controlled by” and “under the common control”) means the actual
power, either directly or indirectly through one or more intermediaries, to direct or cause the direction of the management and policies of such Party or other Person, whether by the ownership of 50% or more of the voting equity of such Party or
other Person, by contract or otherwise. Notwithstanding the foregoing, solely with respect to Sections 1.61 (Major Biopharmaceutical Company), and 3.1 (Licenses to Sanofi), “Affiliates” will not include (a) with respect to an entity,
its bona fide venture capital or private equity investors, (b) with respect to an entity, its bona fide institutional investors, provided that such institutional investors routinely make venture capital investments for the potential financial
return on such investments and for so long as such institutional investors do not (x) obtain any rights (including options, rights to negotiate, rights of first refusal or other contingent rights) to acquire control of such entity or its assets
or (y) enter into or agree to enter into any research, development, commercial, license or other strategic transaction with such entity (each investor in clause (a) and (b), an “Excluded Investor”), or (c) Affiliates
of such venture capital, private equity or institutional investors that do not otherwise qualify as Affiliates of such entity under this Section 1.5 (i.e., for a reason other than by virtue of their status as Affiliates of such investors).
 
 1.6 “Ancillary Agreement” means the Co-Promotion Agreement, the
Pharmacovigilance Agreement, the Profit/Loss Share Agreement, any Supply Agreement, any Quality Agreement and any other agreement entered into between the Parties (or their respective Affiliates) pursuant to this Agreement. 

1.7 “Antitrust Law” means the Hart-Scott-Rodino Antitrust Improvements Act of 1976 and the rules and regulations
promulgated thereunder (the “HSR Act”), the Sherman Act, as amended, the Clayton Act, as amended, the Federal Trade Commission Act, as amended, and any other Applicable Laws related to merger control or designed to prohibit,
restrict or regulate actions having the purpose or effect of monopolization or restraint of trade. 

  
 2 

 1.8 “Applicable Law” means (a) any federal, state, local,
foreign or multinational law, statute, standard, ordinance, code, rule, regulation, resolution or promulgation (including written governmental interpretations thereof, the guidance related thereto), (b) any judicial, governmental or administrative
order, judgment, decree or ruling by any Governmental Authority, or (c) any license, franchise, permit or similar right granted under any of the foregoing, or any similar provision having the force or effect of law, in each case (a), (b) and
(c) that may be in effect from time to time and as applicable to the subject matter and the Persons at issue. 
 1.9
“Business Day” means a day other than a Saturday or Sunday or a day on which banking institutions in San Francisco, California or in Paris, France are permitted or required to be closed. 

1.10 “Calendar Quarter” means each successive period of three calendar months commencing on
January 1, April 1, July 1 and October 1, except that the first Calendar Quarter of the Term shall commence on the Effective Date and end on the day immediately prior to the first to occur of January 1, April 1,
July 1 or October 1 after the Effective Date, and the last Calendar Quarter shall end on the last day of the Term. 
 1.11
“Calendar Year” means each successive period of 12 calendar months commencing on January 1 and ending on December 31, except that the first Calendar Year of the Term shall commence on the Effective Date and end on
December 31 of the year in which the Effective Date occurs and the last Calendar Year of the Term shall commence on January 1 of the year in which the Term ends and end on the last day of the Term. 

1.12 “Change of Control” means with respect to a Party (a) any sale, exchange, transfer, or
issuance to or acquisition in one transaction or a series of related transactions by one or more Third Parties of units and/or shares of equity (as applicable) representing 50% or more of the aggregate ordinary voting power entitled to vote for the
election of directors or managers represented by the issued and outstanding units of equity of such Party (or any Affiliate that directly or indirectly controls such Party (such Affiliate, the “Parent”)), whether such sale,
exchange, transfer, issuance or acquisition is made directly or indirectly, by merger or otherwise, or beneficially or of record (collectively, a “Stock Sale”); (b) a merger or consolidation under Applicable Law of such Party or a
Parent with a Third Party, other than a merger or consolidation in which the units and/or shares of equity of such Party or Parent outstanding immediately prior to such merger or consolidation continue to represent, or are converted into or are
exchanged for units and/or shares of equity which represent, immediately following such merger or consolidation, 50% or more of the aggregate ordinary voting power of such units and/or shares of equity of the surviving or resulting entity or a
parent entity of such surviving or resulting entity, whether direct or indirect (collectively, a “Merger”); (c) a sale, lease, transfer, exclusive license or other disposition of all or substantially all of the assets of such Party
or a Parent to one or more Third Parties in one transaction or a series of related transactions (collectively, the “Asset Transfer”). Notwithstanding the foregoing, a purchase of shares in a Stock Sale by one or more Third Parties
in a bona fide financing transaction the primary purpose of which is to raise working capital for RevMed or to acquire assets from a Third Party (in either case including one or more public offerings) shall not constitute a Change of Control even if
such Third Parties collectively negotiate or receive their rights as security holders in such financing transaction(s), except that such exemption shall not apply with respect to any Change of Control that would result in any Major Biopharmaceutical
Company having more than 50% of the aggregate ordinary voting power in RevMed or its Parent. The Parent of a Party for purposes of this Section 1.12 shall not include any 

  
 3 

 
Excluded Investor, provided that the applicable Stock Sale, Merger or Asset Transfer does not result in any Major Biopharmaceutical Company having more than 50% of the aggregate ordinary voting
power in, or control over all or substantially all of the assets of, RevMed or its Parent or any surviving or resulting entity or a parent entity of such surviving or resulting entity. 

1.13 “Clinical Trial” means any clinical investigation conducted on human subjects, as that term is defined in FDA
regulations at 21 C.F.R. § 312.3. Without limiting the foregoing, Clinical Trial includes any Phase 1 Clinical Trial, Phase 2 Clinical Trial, Phase 3 Clinical Trial, Phase 4 Study or variations of the foregoing. 

1.14 “Collaboration” means the collaboration of the Parties with respect to the Research, Development, Manufacture and
Commercialization of Products in the Field, as and to the extent set forth in this Agreement and the Ancillary Agreements. 
 1.15
“Combination Product” means any pharmaceutical preparation in final form containing a SHP2 Inhibitor in combination with one or more additional active ingredients, for sale by prescription or any other method either as a fixed dose
or unit or as separate doses or units in a single package. 
 1.16 “Commercialization” means the marketing,
promotion, sale or distribution of Products (or Companion Diagnostics for Products in accordance with this Agreement) in the Field, including: (a) commercial activities conducted in preparation for commercial launch of a Product;
(b) strategic marketing, sale force detailing, advertising, medical education and liaison; (c) any Phase 4 Studies, except Required Phase 4 Studies; and (d) all customer support, product distribution, invoicing and other sales
activities. “Commercialize” and “Commercializing” have a correlative meaning. 
 1.17
“Commercially Reasonable Efforts” means: (a) with respect to Sanofi, [***], consistent with [***] that [***], taking into account [***], including [***] and (b) with respect to RevMed, [***], consistent with [***] that
[***], taking into account [***], including [***]. 
 1.18 “Committee” means the JSC, JRDC, JCC, JPC or any
subcommittee established under Article II, as applicable. 
 1.19 “Companion Diagnostic” means, with respect to a
Product, (a) a companion diagnostic approved by the applicable Regulatory Authority that provides information essential to the safe and effective use of such Product or is otherwise necessary for the Regulatory Approval of such Product, or
(b) a complementary diagnostic that provides information helpful to the safe and effective use of such Product but is not a companion diagnostic referred to in the foregoing clause (a). 

1.20 “Competing Product” means, other than a Product, any pharmaceutical preparation [***] that satisfies the criteria
[***], alone or in combination with one or more additional active ingredients, for sale by prescription or any other method. 

  
 4 

 1.21 “Confidential Information” of a Party means all proprietary Know-How, unpublished patent applications and other non-public information and data of a financial, commercial, business, operational or technical nature of such Party that is
disclosed by or on behalf of such Party, its Affiliates or its or their Sublicensees, or otherwise made available to the other Party, its Affiliates or its or their Sublicensees, prior to, on or after the Effective Date, whether made available
orally, in writing or in electronic form in connection with this Agreement or any Ancillary Agreement, including the terms of this Agreement and any Ancillary Agreements, information comprising or relating to concepts, discoveries, inventions, data,
designs or formulae in connection with this Agreement or any Ancillary Agreement. All (a) RevMed Licensed Know-How to the extent relating to SHP2 Inhibitors or Products, (b) Joint Program Know-How, and (c) the terms of this Agreement and any Ancillary Agreements, shall be deemed to be the Confidential Information of both Parties (and both Parties shall be deemed to be the Receiving Party and the
Disclosing Party with respect thereto). All RevMed Licensed Know-How to the extent relating to RevMed’s products and product candidates (other than SHP2 Inhibitors or Products) shall not be deemed
Confidential Information of both Parties. 
 1.22 “Control” or “Controlled” means, with respect to
any item of Know-How, Patent Right, other intellectual property right or Regulatory Material, a Party has the ability (whether by sole, joint or other ownership interest, license, sublicense or otherwise, and
including any such abilities which are contingent) (other than by operation of the licenses granted in this Agreement) to grant a license, sublicense, access or right to use (as applicable) under such item of
Know-How, Patent Right, other intellectual property right or Regulatory Material to the other Party on the terms and conditions set forth herein at the time of such grant, in each case without breaching the
terms of any agreement with a Third Party.  
 1.23 “Correspondence” means that certain letter between Sanofi
and RevMed dated as of the Execution Date.  
 1.24 “Decision-Making Committee” means each Committee (other
than the JPC and JMC). 
 1.25 “Designated Senior Officer” means: (a) with respect to RevMed, [***] and,
(b) with respect to Sanofi, [***]. 
 1.26 “Detail” means, with respect to a
Co-Promotion Product in the Co-Promotion Territory, a face-to-face contact between a
sales representative and a physician or other medical professional licensed or authorized to prescribe drugs, during which a primary position detail or a secondary position detail is made to such person, in each case as measured by each Party’s
internal recording of such activity in accordance with the Co-Promotion Agreement; provided that such meeting is consistent with and in accordance with the requirements of Applicable Law, this Agreement and
the Co-Promotion Agreement. For the avoidance of doubt, the following activities will not constitute Details: e-details; sample drops; reminder details; activities
conducted at conventions, exhibit booths, speaker meetings or similar gatherings; and activities performed by market development specialists, managed care account directors and other personnel not performing face-to-face sales calls or not specifically trained with respect to a Co-Promotion Product. The definition of “Detail” may be further refined in the Co-Promotion Agreement. When used as a verb, “Detail” means to engage in a Detail. 

  
 5 

 1.27 “Development” means all development activities for any Product
(or a Companion Diagnostic for such Product in accordance with this Agreement) that are directed to obtaining Regulatory Approval(s) of such Product, including: all non-clinical, preclinical and clinical
activities conducted in support of Regulatory Approval (including any Required Phase 4 Studies); testing and studies of such Product (including IND-enabling studies and translational research); toxicology,
pharmacokinetic and pharmacological studies; manufacture and distribution of such Product for use in Clinical Trials (including comparators, process development and scale up, and Combination Therapies); statistical analyses; assay development;
instrument design and development; protocol design and development; quality assurance and control; report writing; the preparation, filing and prosecution of any MAA for such Product; development activities directed to label expansion or obtaining
Regulatory Approval for one or more additional indications following initial Regulatory Approval; health economic studies relating to the indication for which the applicable Product is being developed conducted prior to Regulatory Approval; and all
regulatory affairs related to any of the foregoing. “Develop” and “Developing” have a correlative meaning.  

1.28 “Dollars” means the U.S. dollar, and “$” shall be interpreted accordingly. 

1.29 “Drug Treatment Regimen” means either (a) SHP2 Inhibitor monotherapy, or (b) SHP2 Inhibitor Combination
Therapy.  
 1.30 “EMA” means the European Medicines Agency or any successor entity thereto. 

1.31 “EU” or the “European Union” means the economic, scientific and political organization of
European Union member states as it may be constituted from time to time, which as of the Effective Date consists of: Austria, Belgium, Bulgaria, Croatia, Cyprus, Czech Republic, Denmark, Estonia, Finland, France, Germany, Greece, Hungary, Ireland,
Italy, Latvia, Lithuania, Luxemburg, Malta, Netherlands, Poland, Portugal, Romania, Slovakia, Slovenia, Spain, Sweden and the United Kingdom, as well as Norway and Iceland. For purposes of this Agreement, the “EU” shall continue to include
each foregoing territory whether or not such territory is a participating member state as of the applicable time. 
 1.32
“Excluded List” means any of the United States Department of Health and Human Service’s List of Excluded Individuals/Entities or the United States General Services Administration’s Lists of Parties Excluded from Federal
Procurement and Non-Procurement Programs. 
 1.33 “FCPA” means the U.S.
Foreign Corrupt Practices Act of 1977, as amended, including the rules and regulations thereunder. A summary of the FCPA and related information can be found at http://www.justice.gov/criminal/fraud/fcpa. 

1.34 “FDA” means the United States Food and Drug Administration or any successor entity thereto. 

1.35 “FFDCA” means the United States Federal Food, Drug, and Cosmetic Act, 21 U.S.C. 301, et. seq., as it may be
amended from time to time, and the rules, regulations, guidance, guidelines, and requirements promulgated or issued thereunder. 

1.36 “Field” means any and all uses. 

  
 6 

 1.37 “First Commercial Sale” means, with respect to any Product in
any country or jurisdiction, the first sale for monetary value of such Product to a Third Party for distribution, use or consumption in such country or jurisdiction after Marketing Approval has been obtained for such Product in such country or
jurisdiction. Sales prior to receipt of Marketing Approval for such Product, such as so-called “treatment IND sales,” “named patient sales,” and “compassionate use sales,” shall
not be construed as a First Commercial Sale.  
 1.38 “FTE” means a full time equivalent person year
(consisting of [***] hours per year) of work as an employee or contractor [***] hereunder as tracked by each Party using its respective standard practice and methodologies. For clarity, [***] will not constitute FTEs. Notwithstanding the foregoing,
the time of a single individual will not account for more than one FTE for a given Calendar Year (or applicable pro-rata portion of an FTE during any Calendar Quarter or other period of less than a Calendar
Year).  
 1.39 “FTE Costs” means, with respect to a Party for any period, the applicable FTE Rate multiplied
by the applicable number of FTEs of such Party performing the applicable activity described hereunder during such period. 
 1.40
“FTE Rate” means the applicable rate set forth in Exhibit A of the Correspondence or in any Ancillary Agreement or exhibit thereto, which rate shall be adjusted annually, with each annual adjustment
effective as of January 1 of each Calendar Year, with the first such annual adjustment to be made as of January 1, 2019, to correspond with respect to Research, Development, Manufacturing or Commercialization activities under the
Collaboration by or on behalf of a Party, [***] preceding each such January 1. 
 1.41 “GAAP” means the U.S.
generally accepted accounting principles.  
 1.42 “Generic Product” means, with respect to a Product, any
pharmaceutical or biological product (a) that is sold by a Person other than a Party or its Affiliates or Sublicensees, which Person did not purchase such product in a chain of distribution that included such Party or its Affiliate or
Sublicensee as intentional participants, (b) contains, for a pharmaceutical product, the same or a bioequivalent SHP2 Inhibitor or, for a biologic product, a biosimilar or interchangeable SHP2 Inhibitor, to such Product[***]. 

1.43 “Genotype” means one or more [***]. In the cases where such [***].  

1.44 “Good Clinical Practice” or “GCP” means the then-current standards for Clinical Trials for
pharmaceuticals, as set forth in the Act or other Applicable Law, and such standards of good clinical practice as are required by the Regulatory Authorities of the European Union and other organizations and Governmental Authorities in countries for
which the SHP2 Inhibitor or Product is intended to be Developed, to the extent such standards are not less stringent than United States GCP. 

1.45 “Good Laboratory Practice” or “GLP” means the then-current standards for laboratory activities
for pharmaceuticals, as set forth in the Act or other Applicable Law, and such standards of good laboratory practice as are required by the Regulatory Authorities of the European Union and other organizations and Governmental Authorities in
countries for which the applicable SHP2 Inhibitor or Product is intended to be Developed, to the extent such standards are not less stringent than United States GLP. 

  
 7 

 1.46 “Good Manufacturing Practice” or “GMP” means
the current good manufacturing practices applicable from time to time to the manufacturing of a SHP2 Inhibitor, Product or any intermediate thereof pursuant to Applicable Law. 

1.47 “Governmental Authority” means any multi-national, federal, national, state, provincial, local, municipal or
other government authority of any nature (including any governmental division, subdivision, commission, department, bureau, prefecture, agency, branch, office, governmental arbitrator or arbitral body, council, court or other tribunal entitled to
exercise any administrative, executive, judicial, legislative, police, regulatory or taxing authority or power). 
 1.48
“IFRS” means the International Financial Reporting Standards.  
 1.49 “Immuno-Oncology
Agent” means any treatment [***]. For clarity, Immuno-Oncology Agent shall include any treatment that primarily targets [***].  

1.50 “IND” means (a) in the United States, an Investigational New Drug Application, as
defined in the Act, that is required to be filed with the FDA before conducting a Clinical Trial (including all supplements and amendments that may be filed with respect to the foregoing); and (b) any foreign counterpart of the foregoing
filed with a Regulatory Authority in conformance with the requirements of such Regulatory Authority. 
 1.51
“Indication” means a type of cancer for which Regulatory Approval for a Product is being sought that (i) is distinct from other types of cancer by [***].  

1.52 “Initial R&D Term” means the first [***] of the Term. 

1.53 “Initiation” means, with respect to a Clinical Trial of a Product, [***] subject for such Clinical Trial. 

1.54 “Joint Program Patents” means any Patent Right covering or claiming the Joint Program Know-How. 
 1.55 “Joint Program Technology” means Joint Program Know-How and Joint Program Patents. 
 1.56 “Knowledge” means, with respect to a
Party, the actual knowledge of such Party, or what such Party should have known after due inquiry.  
 1.57 “Know-How” means any information and materials, including but not limited to discoveries, inventory, information, regulatory filings, processes, formulae, data, databases, protocols, inventions
(whether patentable or not), improvements (whether patentable or not), invention disclosures, developments, skills, experience, know-how and trade secrets (whether patentable or not), including without
limitation, all chemical, pharmaceutical, toxicological, biochemical, and biological, technical and non-technical data, and information relating to the results of tests, assays, methods, techniques, and
processes, and specifications or other documents containing information and related data, and any preclinical, clinical, assay control, manufacturing, regulatory and any other data or information, but excluding any Patent Rights.  

  
 8 

 1.58 “Licensed Territory” means all countries and territories of the
world. 
 1.59 “Line of Therapy” means the treatment with a Product [***]. 

1.60 “Losses” means any and all liability, loss, damage, injury, costs or expenses (including reasonable
attorneys’ fees and expenses of litigation) of any kind. 
 1.61 “MAA” or “Marketing Authorization
Application” means an application to the appropriate Regulatory Authority for Marketing Approval (but excluding pricing approval) in the Field in any particular jurisdiction (including, without limitation, a New Drug Application in the
U.S.) and all amendments and supplements thereto. 
 1.62 “Major Biopharmaceutical Company”
means (a) any entity that develops or commercializes healthcare products for human consumption that has a fully diluted market capitalization of at least $[***] as measured at the closing price on the last day of the preceding Calendar
Quarter during which the measurement is taken or any Affiliate of such entity or (b) any entity that has [***]. 
 1.63
“Major Market Countries” means the [***]. 
 1.64 “Manufacture” and “Manufacturing”
mean activities directed to manufacturing, processing, filling, finishing, packaging, labeling, quality assurance testing and release, storing and transporting any Product, SHP2 Inhibitors or any intermediate or component thereof, including
manufacturing and analytical development, process and formulation development, process qualification, process validation, scale-up, pre-clinical, clinical and commercial
manufacture and analytic development, product characterization, stability testing, quality assurance and quality control, and chemistry, manufacturing and controls. 

1.65 “Manufacturing Costs” means, with respect to a Product, the costs incurred by a Party or its Affiliate or
Sublicensee in connection with Manufacturing or purchasing from a Third Party, as applicable, each Product that is either (a) supplied by a Third Party, or (b) manufactured directly by a Party or an Affiliate or Sublicensee of such Party,
determined as follows and in accordance with Accounting Standards: 
 In the case of clause (a) above, Manufacturing Costs means [***]. To the extent
any non-refundable or non-creditable value added or similar tax is due with respect to amounts paid to such Third Party for Manufacture of any portion of a Product, such
amounts shall be considered Manufacturing Costs under this clause (a). 
 In the case of clause (b) above, Manufacturing Costs means: (i) [***] and a
reasonable allocation of [***], which allocation is made [***]; (ii) [***]; and (iii) a reasonable allocation of [***]. All components of Manufacturing Costs shall be allocated [***]. 

Such Party may elect, in its sole discretion, to [***] the above Manufacturing Cost definition. 

  
 9 

 Third Party payments shall be included on a pass-through basis for purposes of clause (a) or clause
(b) above. 
 1.66 “Marketing Approval” means all Regulatory Approvals necessary for the commercial sale of a
Product in the Field in a given country or regulatory jurisdiction, including pricing and reimbursement approval. 
 1.67
“Material Adverse Event” means any event, occurrence, condition, change, circumstance, development, effect or state of facts that has had or would reasonably be expected to have, individually or in the
aggregate, materially adverse to [***]; provided, however, that “Material Adverse Effect” shall not include the effect of any event, occurrence, condition, change, circumstance, development, effect or state of facts arising out of or
attributable to any of the following, either alone or in combination: [***], in each case of clauses (i), (ii) or (iv) only to the extent such event, occurrence, condition, change, circumstance, development, effect or state of facts has a
disproportionate effect on a Party or its Affiliates as compared to other participants operating in the biopharmaceutical industry in the same markets in which such Party or its Affiliates conduct their businesses. 

1.68 “NDA” means (a) in the United States, a New Drug Application or Biologics License Application that is
submitted to the FDA for Regulatory Approval for a Product, and (b) any foreign counterpart of either of the foregoing filed with a Regulatory Authority in conformance with the requirements of such Regulatory Authority.  

1.69 “Net Sales” means, with respect to a Product for any period, the gross amount billed or invoiced by Sanofi, its
Affiliates or its or their Sublicensees for the sale of a Product to Third Parties (including Distributors) commencing with the First Commercial Sale of such Product less the following deductions determined in accordance with Accounting Standards
from such gross amounts which are actually incurred, allowed, accrued or specifically allocated:  
  

	 	(a)	 [***] 

  

	 	(b)	 [***] 

  

	 	(c)	 [***] 

  

	 	(d)	 [***] 

  

	 	(e)	 [***] 

  

	 	(f)	 [***] 

  

	 	(g)	 [***] 

  

	 	(h)	 [***] 

  

	 	(i)	 [***] and 

  

	 	(j)	 [***]. 

  
 10 

 Any of the deductions listed above that involves a payment by such Party, its Affiliates or its or their
Sublicensees shall be taken as a deduction in the Calendar Quarter in which the payment is accrued by such entity. For purposes of determining Net Sales, a Product shall be deemed to be sold when [***]. Net Sales shall not include [***]. Such
Party’s, its Affiliates’ or its or their Sublicensees’ transfer of any Product to an Affiliate or Sublicensee shall not result in any Net Sales unless the transferee is an end user. 

In the event that a Product is sold in any country in the form of a Combination Product, Net Sales of such Combination Product shall be adjusted by [***];
provided that the invoice price [***]. If either such Product that contains the SHP2 Inhibitor(s) as its sole active ingredient or any such product that contains active ingredient(s) other than the SHP2 Inhibitor(s) is not sold separately in a
particular country, then the adjustment to Net Sales shall be [***]. 
 In the case of pharmacy incentive programs, hospital performance incentive programs,
chargebacks, disease management programs, similar programs or discounts on portfolio product offerings, [***]; provided that [***] shall be done in accordance with Applicable Law, including any price reporting laws, rules and regulations. 

Subject to the above, Net Sales shall be calculated [***]. 

1.70 “Non-SHP2 Collaboration Product” means for any Drug Treatment Regimen under the
Collaboration that is [***]. 
 1.71 “Non-SHP2 Same Class Product” means, with
respect to a Non-SHP2 Collaboration Product, any [***]. 
 1.72 “Other SHP2
Inhibitor” means any small molecule or biologic compound that (a) satisfies the criteria specified in the SHP2 Inhibitor Criteria and (b) is not a SHP2 Inhibitor that is Controlled by RevMed or its Affiliates. 

1.73 “Patent Rights” means any and all national, regional and international (a) issued patents and pending patent
applications (including provisional patent applications), (b) patent applications filed either from the foregoing or from an application claiming priority to the foregoing, including all provisional applications, converted provisionals,
substitutions, continuations, continuations-in-part, divisions, renewals and continued prosecution applications, and all patents granted thereon, (c) patents-of-addition, revalidations, reissues, reexaminations and extensions or restorations by existing or future extension or restoration mechanisms, including
patent term adjustments, patent term extensions, supplementary protection certificates or the equivalent thereof, (d) inventor’s certificates, utility models, petty patents, innovation patents and design patents, (e) other forms of
government-issued rights substantially similar to any of the foregoing, including so-called pipeline protection or any importation, revalidation, confirmation or introduction patent or registration patent or
patent of additions to any of such foregoing and (f) United States and foreign counterparts of any of the foregoing. 
 1.74
“Permitted Contractors or Researchers” means (a) any Third Party independent contractor that RevMed has entered into a written agreement with prior to the Effective Date and which Person is listed on
Exhibit B of the Correspondence, (b) any other Third Party to which Sanofi consents in writing as a subcontractor of RevMed pursuant to Section 3.4, and (c) any named Third Party set forth in the Research Plan or Development
Plan. 

  
 11 

 1.75 “Person” means any individual, partnership, limited liability
company, firm, corporation, association, trust, unincorporated organization or other entity. 
 1.76 “Phase 1 Clinical
Trial” means a Clinical Trial of a Product that generally provides for the first introduction into humans of such Product, with the primary purpose of determining metabolism and pharmacokinetic properties and side effects of such product,
in a manner that is generally consistent with 21 C.F.R. § 312.21(a), as amended (or its successor regulation), excluding, for clarity, any investigator-initiated Clinical Trials unless agreed to by the JRDC.  

1.77 “Phase 2 Clinical Trial” means a Clinical Trial of a Product conducted on a sufficient number of subjects for
evaluating (and the principal purpose of which is to evaluate) the effectiveness of a pharmaceutical product for its particular intended use and obtaining (and to obtain) information about side effects and other risks associated with the drug, in a
manner that is generally consistent with 21 C.F.R. § 312.21(b), as amended (or its successor regulation), or a similar clinical study prescribed by the Regulatory Authorities in a country or jurisdiction outside the United States, to permit the
design of further Clinical Trials of such Product, excluding, for clarity, any investigator-initiated Clinical Trials unless agreed to by the JRDC. 

1.78 “Phase 3 Clinical Trial” means a pivotal Clinical Trial of a Product with a defined dose or a set of defined
doses of such Product and conducted on a sufficient number of subjects for ascertaining (and that is designed to ascertain) the overall risk-benefit relationship of the Product for its intended use and determining (and to determine) warnings,
precautions, and adverse reactions that are associated with such Product in the dosage range to be prescribed, in a manner that is generally consistent with 21 C.F.R. § 312.21(c), as amended (or its successor regulation), or a similar clinical
study prescribed by the Regulatory Authorities in a country or jurisdiction outside the United States, which trial is necessary to support Regulatory Approval of such Product, excluding, for clarity, any investigator-initiated Clinical Trials unless
agreed to by the JRDC. 
 1.79 “Phase 4 Study” means a Clinical Trial or data collection effort with respect to any
Product that is commenced after the receipt of Regulatory Approval in the country where such trial is conducted.  
 1.80
“PMDA” means Japan’s Pharmaceuticals and Medical Devices Agency and any successor thereto. 
 1.81
“Pre-Registrational Meeting” means the meeting with the FDA or the equivalent meeting with the EMA or PMDA or other Regulatory Authority (as applicable) to be conducted to discuss the requirements of the FDA, EMA, or PMDA or other
Regulatory Authority (as applicable) for a Registration Program for a given Product to support Marketing Approval, e.g., end-of-Phase 2 or
pre-Phase 3 meetings. 
 1.82 “Product” means any pharmaceutical preparation
in final form containing a SHP2 Inhibitor, alone or in the form of a Combination Product.  

  
 12 

 1.83 “Program Inventions” means any
Know-How conceived, reduced to practice, developed, made or otherwise generated by or on behalf of a Party or its Affiliates or Sublicensees in connection with the Research, Development, Manufacture or
Commercialization of SHP2 Inhibitors or Products under this Agreement or any Ancillary Agreement, including all rights, title and interest in and to the intellectual property rights therein. 

1.84 “Publication” means any release of information, including any presentation, which information (a) has not
been disclosed pursuant to Section 11.3 or (b) has not previously been publicly disclosed. 
 1.85 “Registrational
Clinical Trial” means a Clinical Trial of a Product designed to be adequate to achieve Regulatory Approval of such Product and that would satisfy the requirements of 21 C.F.R 312.21(c), as amended, or corresponding foreign regulations,
regardless of whether such trial is referred to as a “phase 2b clinical trial”, “phase 2b/3 clinical trial” or “phase 3 clinical trial”, but excluding, for clarity, any investigator-initiated Clinical Trials. 

1.86 “Regulatory Approval” means, with respect to a country or jurisdiction, any and all approvals (including
Marketing Approvals), licenses, registrations or authorizations of any Regulatory Authority necessary to commercially distribute, sell or market a Product in such country or jurisdiction, including, where applicable, (a) pricing or
reimbursement approval in such country or jurisdiction, (b) pre- and post-approval marketing authorizations (including any prerequisite Manufacturing approval or authorization related thereto) and
(c) labeling approval.  
 1.87 “Regulatory Authority” means any applicable Governmental Authority
involved in the granting Regulatory Approvals for the Products or otherwise exercising authority with respect to biopharmaceutical products in the applicable country or jurisdiction, including the FDA, the EMA, the PMDA and any corresponding
national or regional regulatory authorities. 
 1.88 “Regulatory Exclusivity” means any rights or protections which
are recognized, afforded or granted by the FDA or any other Regulatory Authority in any country or region of the Territory pursuant to Applicable Laws of such country or region, in association with the marketing authorization of the Product,
providing the Product[***] a period of marketing exclusivity, during which a Regulatory Authority recognizing, affording or granting such marketing exclusivity will refrain from either reviewing or approving a marketing authorization application or
similar regulatory submission, submitted by a Third Party seeking to market a Generic Product of such Product[***].  
 1.89
“Regulatory Materials” all (a) applications (including all INDs), registrations, licenses, authorizations and approvals (including MAAs and Regulatory Approvals), (b) correspondence and reports submitted to or received from
Regulatory Authorities (including minutes and official contact reports relating to any communications with any Regulatory Authority) and all supporting documents with respect thereto, including all adverse event files and complaint files,
(c) clinical and other data contained, referenced or otherwise relied upon in any of the foregoing, and (d) for clarity, any drug master file.  

1.90 “Required Phase 4 Studies” means any Phase 4 Studies that are required by the applicable Regulatory Authority to
be conducted as a condition for Regulatory Approval, including Regulatory Approval for a label expansion, whether or not also required for pricing or reimbursement approval. 

  
 13 

 1.91 “Research” means all research activities conducted by or on
behalf of either Party or the Parties jointly pursuant to the Research Plan. 
 1.92 “Research and Development Costs”
means all RevMed R&D Costs and Sanofi R&D Costs. 
 1.93 “Residual Knowledge” means intangible Know-How (but, for the avoidance of doubt, not Patents) relating to the Collaboration or otherwise to this Agreement or any Ancillary Agreement that has been retained in the unaided memories of any employees of a
Party.  
 1.94 “RevMed Background Know-How” means, subject to
Section 3.1(b), all Know-How that is (a) Controlled by RevMed or its Affiliates as of the Effective Date or during the Term, excluding the RevMed Sole Program
Know-How and Joint Program Know-How; and (b) necessary or useful for the Research, Development, Manufacture, Commercialization or other exploitation of any Product
in the Field.  
 1.95 “RevMed Background Patents” means, subject to Section 3.1(b), any Patent Right
(a) (i) that is Controlled by RevMed or its Affiliates as of the Effective Date; or (ii) that comes into the Control of RevMed or its Affiliates during the Term, excluding the RevMed Sole Program Patents and Joint Program Patents; and
[***].  
 1.96 “RevMed Background Technology” means RevMed Background Patents and RevMed Background Know-How. 
 1.97 “RevMed Licensed Know-How”
means RevMed Background Know-How and RevMed Sole Program Know-How. 

1.98 “RevMed Licensed Patent” means RevMed Background Patents and RevMed Sole Program Patents. 

1.99 “RevMed Licensed Technology” means RevMed Background Technology, RevMed Sole Program Technology and RevMed’s
undivided one-half ownership of the full right, title and interest in and to the Joint Program Technology.  

1.100 “RevMed R&D Costs” means RevMed R&D FTE Costs and RevMed R&D Out-Of-Pocket Costs. 
 1.101 “RevMed R&D FTE Costs” means FTE Costs
incurred by or on behalf of RevMed or its Affiliates in the Research or Development of Product in the Field in accordance with the Research Plan or Development Plan for such Product, as applicable.  

1.102 “RevMed R&D Out-Of-Pocket Costs”
means amounts paid by RevMed in cash to Third Parties for goods and services required in order for RevMed to conduct Research or Development of Product in the Field in accordance with the Research Plan or Development Plan for such Product, as
applicable. 

  
 14 

 1.103 “RevMed Sole Program
Know-How” means all Program Inventions owned solely by RevMed pursuant to Section 10.1(a). 

1.104 “RevMed Sole Program Patents” means any Patent Right covering or claiming the RevMed Sole Program Know-How. 
 1.105 “RevMed Sole Program Technology” means RevMed Sole Program
Patents and RevMed Sole Program Know-How. 
 1.106 “Sanofi R&D Costs”
means Sanofi R&D FTE Costs and Sanofi R&D Out-Of-Pocket Costs.  

1.107 “Sanofi R&D FTE Costs” means FTE Costs incurred by or on behalf of Sanofi or its Affiliates in the Research
or Development of Product in the Field in accordance with the Research Plan or Development Plan for such Product, as applicable. 

1.108 “Sanofi R&D Out-Of-Pocket Costs”
means amount paid by Sanofi in cash to Third Parties for good and services required in order for Sanofi to conduct Research or Development of Product in the Field in accordance with the Research Plan or Development Plan for such Product, as
applicable. 
 1.109 “Sanofi Sole Program Know-How” means all Program
Inventions owned solely by Sanofi pursuant to Section 10.1(a). 
 1.110 “Sanofi Sole Program Patents” means any
Patent Right covering or claiming the Sanofi Sole Program Know-How. 
 1.111
“SHP1” means [***]. 
 1.112 “SHP1 Inhibitor” means [***].  

1.113 “SHP1 Inhibitor Criteria” means [***], as set forth in Exhibit C of the
Correspondence. 
 1.114 “SHP1-SHP2 Dual Inhibitor” means [***].  

1.115 “SHP1-SHP2 Dual Inhibitor Product” means any pharmaceutical preparation in final form containing a SHP1-SHP2
Dual Inhibitor, alone or in combination with one or more additional active ingredients, for sale by prescription, over-the-counter or any other method. 

1.116 “SHP1-SHP2 Dual Inhibitor Criteria” means [***], as set forth in Exhibit D of the
Correspondence. 
 1.117 “SHP2” means [***]. 

1.118 “SHP2 Inhibitor Combination Therapy” means [***]. 

1.119 “SHP2 Inhibitor” means [***]. 

  
 15 

 1.120 “SHP2 Inhibitor Criteria” means [***], as
set forth in Exhibit E of the Correspondence. 
 1.121 “Study Report” means a written report that contains
information required by ICH guidelines after the Clinical Trial in question is closed but before database lock for such Clinical Trial.  

1.122 “Sublicensees” means a Person, other than an Affiliate or a Distributor, that is granted a sublicense by a Party
or its Affiliate under the license grants in this Agreement. 
 1.123 “Subsidiary” means, with respect to a Party,
any corporation or other business entity that, directly or indirectly, through one or more intermediaries, is controlled by that Party for so long as such Party controls such corporation or other business entity. For the purpose of this definition
only, “control” (including, with correlative meaning, the terms “controlled by” and “under the common control”) means the actual power of such Party, either directly or indirectly through one or more intermediaries, to
direct or cause the direction of the management and policies of such corporation or other business entity, whether by the ownership of 50% or more of the voting equity of such corporation or other business entity, by contract or otherwise. 

 1.124 “Targeted Anti-Cancer Agent” means, other than an Immuno-Oncology Agent, any molecularly targeted therapy
that blocks the growth of cancer [***]. For clarity, Targeted Anti-Cancer Agent includes [***]. 
 1.125 “Third Party”
means any Person other than a Party or an Affiliate of a Party. 
 1.126 “Third Party Claims” means all Third
Party demands, claims, actions, investigations and proceedings (whether criminal or civil, in contract, tort or otherwise). 
 1.127
“Trademark” means any word, name, symbol, color, shape, designation or any combination thereof, including any trademark, service mark, trade name, brand name, sub-brand name, trade dress,
product configuration, program name, delivery form name, certification mark, collective mark, logo, tagline, slogan, design or business symbol, that functions as an identifier of source or origin, whether or not registered and all statutory and
common law rights therein and all registrations and applications therefor, together with all goodwill associated with, or symbolized by, any of the foregoing. 

1.128 “Tumor Type” means a cancer that differs from another type of cancer in [***]. 

1.129 “United States” or “U.S.” means the United States of America, including its territories and
possessions. 
 1.130 “Valid Claim” means [***]. 

  
 16 

 1.131 In addition to the foregoing definitions, the following table identifies the
location of the following definitions set forth in various other Sections of, or Exhibits to, the Agreement: 
  

			
	 Defined Term
	  	 Section

	Acquiror	  	Section 15.2(a)
	Agreement	  	Preamble
	Alliance Manager	  	Section 2.1
	Applicable Reduction Percentage	  	Section 9.3(c)(ii)
	Asset Transfer	  	Section 1.12
	Base Net Sales	  	Section 9.3(c)(ii)
	Closing Conditions	  	Section 13.6
	Co-Promotion Agreement	  	Section 8.7(c)
	Co-Promotion Option	  	Section 8.7(a)
	Co-Promotion Product	  	Section 8.7(a)
	Co-Promotion Territory	  	Section 8.7(a)
	Combination Therapy	  	Section 5.3(a)
	Commercialization Plan	  	Section 8.2
	Confidentiality Agreement	  	Section 15.9
	CREATE Act	  	Section 10.3
	Data Package	  	Section 5.2(c)
	Development Candidate	  	Section 4.3
	Development Budget	  	Section 5.2(a)
	Development Plan	  	Section 5.2(a)
	[***]	  	Section 5.2(b)
	Disclosing Party	  	Section 11.1(a)
	Dispute	  	Section 15.6(a)
	Distributor	  	Section 8.3
	Effective Date	  	Section 3.8
	Execution Date	  	Preamble
	Force Majeure	  	Section 15.1
	Indemnification Claim Notice	  	Section 14.3(a)
	Indemnified Party	  	Section 14.3(a)
	Indemnifying Party	  	Section 14.3(a)
	Indemnitee	  	Section 14.3(a)
	Initial Know-How	  	Section 3.7(a)
	Joint Commercialization Committee or JCC	  	Section 2.4
	Joint Research and Development Committee or JRDC	  	Section 2.3
	Joint Steering Committee or JSC	  	Section 2.2
	Joint Program Know-How	  	Section 10.1(a)
	Know-How Index	  	Section 3.7(a)
	Launch Quarter	  	Section 9.3(c)(ii)
	Merger	  	Section 1.12
	Milestone Event	  	Section 9.2
	Milestone Payment	  	Section 9.2
	Non-SHP2 Termination Product	  	Section 12.3(c)(ii)(A)
	Parent	  	Section 1.12
	Party or Parties	  	Preamble
	Pharmacovigilance Agreement	  	Section 6.5

  
 17 

			
	 Defined Term
	  	 Section

	Product Infringement	  	Section 10.4(a)
	Product Marks	  	Section 10.5(a)
	Profit/Loss Share Agreement	  	Section 9.4
	Quality Agreement	  	Section 7.3
	Receiving Party	  	Section 11.1(a)
	Remainder	  	Section 10.4(f)
	Remedial Action	  	Section 6.7
	Research Budget	  	Section 4.2(a)
	Research Plan	  	Section 4.1
	[***]	  	Section 4.2(b)
	RevMed	  	Preamble
	RevMed Commercialization Costs	  	Section 8.2
	RevMed Indemnitee	  	Section 14.2
	RevMed Program Invention	  	Section 12.3(c)(ii)
	RevMed Study	  	Section 5.6(b)
	Royalty Floor	  	Section 9.3(c)(iii)
	Royalty Term	  	Section 9.3(b)
	Sanofi	  	Preamble
	Sanofi Indemnitee	  	Section 14.1
	Sanofi Program Invention	  	Section 12.3(c)(ii)
	Sanofi Prosecuted Patents	  	Section 10.2(a)
	[***]	  	Section 12.3(c)(ii)
	[***]	  	Section 12.3(c)(ii)
	[***]	  	Section 12.3(c)(ii)
	SHP1-SHP2 Dual Inhibitor License Rights	  	Section 3.5(a)
	SHP1-SHP2 Dual Inhibitor Licensing Decision	  	Section 3.5(a)
	SHP1-SHP2 Dual Inhibitor Licensing Negotiation Period	  	Section 3.5(a)
	Stock Sale	  	Section 1.12
	Supply Agreement	  	Section 7.3
	Term	  	Section 12.1
	Third Party Right	  	Section 10.7(a)
	Termination Product	  	Section 12.3(c)(ii)(D)
	Third Party Right Notification	  	Section 10.7(a)
	VAT	  	Section 9.7(b)

 1.132 Interpretation. In this Agreement, unless otherwise specified: 

(a) The words “include”, “includes” and “including” shall be deemed to be followed by the phrase “without
limitation”; 
 (b) the words “will” and “shall” have the same meaning; 

  
 18 

 (c) the word “or” shall be interpreted to mean “and/or” unless the
context requires otherwise; 
 (d) words denoting the singular shall include the plural and vice versa and words denoting any gender shall
include all genders; 
 (e) words such as “herein”, “hereof”, and “hereunder” refer to this Agreement as a
whole and not merely to the particular provision in which such words appear; and 
 (f) the Exhibits and other attachments to this Agreement
and the Correspondence form part of the operative provision of this Agreement and references to “this Agreement” shall include references to such Exhibits and attachments. 

Article II. 
 GOVERNANCE

 2.1 Alliance Managers. Each Party hereby appoints the person listed on Exhibit F of the Correspondence to act as
its alliance manager under this Agreement as of the Effective Date (the “Alliance Manager”). Each Party’s Alliance Manager shall: (a) serve as the primary contact point between the Parties for the purpose of providing the
other Party with information on the progress of such Party’s activities under this Agreement; (b) be primarily responsible for facilitating the flow of information and otherwise promoting communication, coordination and collaboration
between the Parties; and (c) have the right to attend all Committee meetings, all as non-voting members. Without limiting the foregoing, the Alliance Managers (or their designees) shall be responsible for
(i) scheduling meetings of each Decision-Making Committee; (ii) setting agendas for meetings of each Decision-Making Committee with solicited input from members of the respective Committee, and (iii) preparing the draft minutes of
such meetings (with such responsibility alternating between the Alliance Managers), which minutes shall provide a description in reasonable detail of the discussion held at the meeting and a list of any actions, decisions or determinations approved
by the respective Committee. Each Party may replace its Alliance Manager at any time upon written notice to the other Party. 
 2.2
Joint Steering Committee. The Parties hereby establish an executive steering committee (the “Joint Steering Committee” or the “JSC”). 

(a) Composition. The JSC shall consist of three senior executives of each Party, with at least one such senior executive from each such
Party holding the position of vice president or above. 
 (b) Function and Powers. The JSC shall manage the overall Collaboration,
and shall in particular: 
 (i) coordinate the activities of the Parties under this Agreement, including facilitating
communications between the Parties with respect to the Research, Development, Manufacture and Commercialization of the SHP2 Inhibitors and Products; 

  
 19 

 (ii) provide a forum for discussion of matters relating to the Research,
Development, Manufacture and Commercialization of the SHP2 Inhibitors and Products presented to the JSC by the other Committees; 

(iii) direct and oversee the operation of the JRDC, JCC, JPC and any other joint subcommittee established by JSC, including
resolving any disputed matter of the JRDC, JCC, JPC and other subcommittees in accordance with Section 2.10, and promote effective member participation in each such Committee’s or subcommittee’s operations; 

(iv) approve each Research Plan and Development Plan prepared by the JRDC, and the Research Budget and Development Budget
therein, respectively, and amendments to the foregoing in accordance with Section 5.2(d); 
 (v) establish additional
subcommittees as appropriate; 
 (vi) [***]; and 

(vii) perform such other duties as are expressly assigned to the JSC in this Agreement, and perform such other functions as
appropriate to further the purposes of this Agreement as may be allocated to it by the Parties’ written agreement, except where in conflict with any provision of this Agreement. 

2.3 Joint Research and Development Committee. The Parties hereby establish a joint research committee (the “Joint
Research and Development Committee” or the “JRDC”). 
 (a) Composition. The JRDC shall consist of three
representatives of each Party that have knowledge and expertise in the Research and Development of pharmaceutical or biologic products in the Field. 

(b) Function and Powers. The JRDC shall have the following responsibilities: 

(i) prepare each Research Plan and Development Plan, and the Research Budget and Development Budget therein, respectively, and
amendments to the foregoing in accordance with Section 5.2(d); 
 (ii) oversee the implementation of each Research Plan
and Development Plan; 
 (iii) monitor, coordinate and evaluate the activities and performance of the Parties under each
Research Plan and Development Plan[***]; 
 (iv) following completion of early Development activities for a Product,
determine whether to further develop such Product for Regulatory Approval; 
 (v) if the JRDC determines to further Develop a
Product for Regulatory Approval, develop the Data Package for such Product in accordance with Section 5.2(c); 
 (vi)
provide a forum for and facilitate communications between the Parties with respect to the Research and Development of the SHP2 Inhibitors and Products; 

  
 20 

 (vii) review and approve a format for the expense reports to be provided by
RevMed to Sanofi pursuant to Section 4.5 and Section 5.5; 
 (viii) monitor and coordinate all regulatory actions,
communications and submissions for the SHP2 Inhibitors and Products allocated to each Party under the Development Plans; 

(ix) oversee and coordinate the Manufacturing of the SHP2 Inhibitors and Products for clinical supply in accordance with
Article VII, unless the JSC designates a manufacturing committee or subcommittee to perform such activities; 
 (x) establish
other subcommittees, as appropriate, to carry out its functions; and 
 (xi) perform such other functions as determined by
the JSC to further the purposes of this Agreement with respect to the Research and Development of SHP2 Inhibitors and Products, except where in conflict with any provision of this Agreement. 

(c) Decision-Making. Notwithstanding anything to the contrary in Section 2.10(a), if the JRDC is unable to reach unanimous
agreement on the following matters then such matters shall not be submitted for resolution to the JSC and shall instead be subject to Sanofi’s final decision-making power: [***]. 

2.4 Joint Commercialization Committee. The Parties shall establish a joint commercialization committee (the “Joint
Commercialization Committee” or “JCC”) no later than the date that is [***] prior to the anticipated submission of the first NDA for the first Product. 

(a) Composition. The JCC shall consist of three representatives of each Party that have knowledge and expertise in the
commercialization of pharmaceutical or biologic products in the Field. 
 (b) Function and Powers. The JCC shall monitor and oversee
the Commercialization activities (and certain Manufacturing activities as provided hereunder) of the SHP2 Inhibitors and Products and in particular have the following responsibilities: 

(i) coordinate the messaging and branding strategy for Products in the United States; 

(ii) coordinate the activities of the Parties under the Commercialization Plan and oversee the implementation of the
Commercialization Plan; 
 (iii) if the Co-Promotion Option has been exercised,
coordinate the activities of the Parties under the applicable Co-Promotion Agreement and oversee the implementation of such Co-Promotion Agreement; 

(iv) review and discuss the Commercialization Plans and amendments thereto in accordance with Section 8.2; 

  
 21 

 (v) provide a forum for and facilitate communications between the Parties
with respect to the Commercialization of the Products in the United States; 
 (vi) oversee and coordinate the Manufacturing
of the SHP2 Inhibitors and Products for commercial supply in the United States in accordance with Article VII, unless the JSC designates a manufacturing committee or subcommittee to perform such activities; 

(vii) establish subcommittees, as appropriate, to carry out its functions; and 

(viii) perform such other functions as determined by the JSC to further the purposes of this Agreement with respect to the
Commercialization of the Products, except where in conflict with any provision of this Agreement. 
 2.5 Joint Patent
Committee. The Parties shall establish a joint patent committee (“Joint Patent Committee” or “JPC”). 

(a) Composition. The JPC shall be composed of one patent counsel representing Sanofi, one patent counsel representing RevMed, (who may
be internal or outside counsel to RevMed), and up to two additional representatives of each Party that have knowledge and expertise in patent prosecution of pharmaceutical or biologic products. 

(b) No Power or Authority; Function. The JPC shall not have any power or authority (including decision making) with respect to
Collaboration matters. Rather, the JPC shall serve as an information-sharing forum for the Parties with respect to the following: 

(i) the filing, prosecution, and maintenance of the RevMed Licensed Patents and Joint Program Patents, including deadlines for
responses to patent authorities and Sanofi’s proposed timelines for submission of comments to patent authorities; 

(ii) any periodic reports or updates for Collaboration-related intellectual property matters as may be requested by the JRDC;

 (iii) strategy for patent term extensions to extend exclusivity in the Licensed Territory and for listings in the
FDA’s Approved Drug Products with Therapeutic Equivalence Evaluations (known as the “Orange Book”) and its foreign counterparts; 

(iv) confer regarding any related information to ensure the Parties’ compliance with the 37 C.F.R. 1.56 duty of disclosure
as it relates to SHP2 Inhibitors or SHP2 inhibition; and 
 (v) such other intellectual property-related matters as
determined by the JSC to further the purposes of this Agreement, except where in conflict with any provision of this Agreement. 

2.6 Joint Manufacturing Committee. The Parties shall establish a joint manufacturing committee (“Joint Manufacturing
Committee” or “JMC”). 

  
 22 

 (a) Composition. The JMC shall consist of three representatives of each Party that
have knowledge and expertise in the manufacture or supply management of pharmaceutical or biologic products in the Field. 
 (b) No Power
or Authority; Function. The JMC shall not have any power or authority (including decision making) with respect to Collaboration matters. Rather, the JMC shall serve as an information-sharing forum for the Parties with respect to the following:

 (i) transfer of the Manufacturing Know-How in accordance with Section 7.2
hereof; 
 (ii) periodic reports or updates for Collaboration-related Manufacturing matters as may be requested by the JSC;

 (iii) logistical strategies, capacity planning and inventory levels for each Product for consistency with the then-current
Development Plans and Commercialization Plans for such Product; 
 (iv) results of regulatory inspections related to Products
and steps taken by the concerned Party to address any Manufacturing deficiencies noted; 
 (v) such other functions as may be
agreed upon by the Parties to further the purposes of this Agreement, except where in conflict with any provision of this Agreement. 

2.7 Limitation of Committee Authority. Each Committee shall only have the powers expressly assigned to it in this Article II and
elsewhere in this Agreement and shall not have the authority to: (a) modify or amend the terms and conditions of this Agreement; (b) waive either Party’s compliance with the terms and conditions of this Agreement; or
(c) determine any issue in a manner that would conflict with the express terms and conditions of this Agreement. 
 2.8
Committee Membership and Meetings. 
 (a) Committee Members. The initial members of each Party on each Committee (other than
the JCC) as of the Effective Date are set forth in Exhibit F of the Correspondence. Each Party may replace its representatives on any Committee by written notice to the other Party. Each Committee representative shall have appropriate
knowledge and expertise and sufficient seniority within the applicable Party to make decisions arising within the scope of the applicable Committee’s responsibilities. A particular individual may serve as a Party’s representative on more
than one Committee, provided that such individual satisfies the requirements of the preceding sentence for each applicable Committee. Each Party shall appoint one of its representatives on each Committee to act as a
co-chairperson of such Committee. The Alliance Managers shall be responsible for calling any regularly scheduled meetings for each Decision-Making Committee on no less than [***] notice and shall also
jointly prepare and circulate agendas for each Decision-Making Committee meeting no less than [***] prior to such meeting. In addition, members of each Decision-Making Committee may request that the Alliance Managers schedule and facilitate ad hoc
meetings. The Alliance Managers shall jointly prepare and circulate reasonably detailed minutes for each Decision-Making Committee meeting within [***] of such meeting. For the avoidance of doubt, meetings of the JPC shall not require any formal
agenda or preparation or circulation of any minutes unless otherwise agreed by the Parties. 

  
 23 

 (b) Meetings. 

(i) Decision-Making Committees. Each Decision-Making Committee shall meet in accordance with a schedule established by
mutual written agreement of both Parties, but no less frequently than [***]. Meetings of any Decision-Making Committee will be held in person, at locations to be alternately selected by each Party, with [***] deciding the location for the first such
meeting of each Decision-Making Committee. Alternatively, each Decision-Making Committee may meet by means of teleconference, videoconference, or other similar communications equipment; provided, however, to the extent practicable at least [***]
meetings of each Decision-Making Committee per [***] should be conducted in-person. A meeting shall be deemed to be “in-person” as long as one representative
of each Party is participating in person; for clarity, other representatives of such Party may participate remotely during an “in person” meeting as provided under this subsection. Each Party shall be responsible for all of its own
expenses of participating in any Decision-Making Committee. No action taken at any meeting of a Decision-Making Committee shall be effective unless at least one representative of each Party is participating. 

(ii) JPC and JMC. The JPC and JMC shall hold meetings as agreed upon by both Parties but in no event less frequently
than [***]. Meetings of the JPC and JMC will be held by telephone, video conference or similar means in which each participant can hear what is said by, and be heard by, the other participants, unless the Parties agree to meet in person. 

(c) Non-Member Attendance. Each Party may from time to time invite a reasonable number of
participants, in addition to its representatives, to attend the Committee meetings in a non-voting capacity; provided that if either Party intends to have any Third Party (including any consultant) attend such
a meeting, such Party shall provide prior written notice to the other Party and shall ensure that such Third Party is bound by confidentiality and non-use obligations consistent with the terms of this
Agreement. 
 2.9 Continuity of Representation. Notwithstanding the Parties’ respective rights to replace its Alliance Manager
and members of Committees by written notification to the other Party, each Party shall strive to maintain continuity in the representation of such Alliance Manager and Committee members. 

2.10 Decision-Making. 

(a) All decisions of each Decision-Making Committee shall be made by unanimous vote, with each Party’s representatives collectively
having one vote (such vote to be cast by the Party’s co-chair to the extent such Party’s representatives do not unanimously agree on a decision). If after reasonable discussion and good faith
consideration of each Party’s view on a particular matter before a Decision-Making Committee, the representatives of the Parties cannot reach an agreement as to such matter within [***] after such matter was brought to such Decision-Making

  
 24 

 
Committee for resolution or after such matter has been referred to such Decision-Making Committee, such disagreement shall, upon the written request of either Party, be referred to the JSC (in
the case of disagreement of the JRDC, JCC or subcommittees of the JSC), or the Designated Senior Officers (in the case of disagreement of the JSC) for resolution, in each case, to discuss such matter in good faith for resolution. If the Designated
Senior Officers cannot resolve any matter referred to them by the JSC within [***] after such matter has been referred to them, then such matters shall be finally and definitively resolved as set forth in Section 2.10(b) or otherwise by
consensus. The Parties may by mutual written agreement determine to shorten the timeframes specified above in this Section 2.10. If any decision-making authority assigned to any Committee necessarily extends beyond the term of such Committee as
set forth in Section 2.11, then such decision making authority shall be automatically transferred to Sanofi. 
 (b) For any matters
submitted for resolution by the Designated Senior Officers, the Designated Senior Officer of Sanofi shall have final decision-making power with respect to such matter; provided that the Designated Senior Officer of Sanofi shall not have the
right to exercise its final decision-making authority without RevMed’s consent to: 
 (i) [***] 

(ii) [***] 

(iii) [***] or 

(iv) [***]. Notwithstanding anything to the contrary in this Agreement, except as expressly set forth in
Section 4.2(a)(i)(A) and, if applicable, Section 4.2(a)(i)(B), [***]: 
 A. Sanofi cannot without cause exercise such final
decision-making authority to [***] from one of its assigned activities under the applicable Research Plan or Development Plan and [***] similar activity; 

B. for any proposal to [***], the JRDC shall first use good faith efforts to [***], a pending amendment thereto or as otherwise determined by
the JRDC, that [***]; and 
 C. if [***] does not occur and if Sanofi [***] by [***] without RevMed’s consent, then [***] for a period
of [***] in which such [***], provided that RevMed shall use good faith efforts to [***] during [***], and provided further that Sanofi shall not be required to make any such [***] during [***]. Without limiting the foregoing, Sanofi shall be
deemed to have cause to [***], for example, in the case of [***]. 
 2.11 Discontinuation of Committees. The activities
to be performed by each Committee shall solely relate to governance under this Agreement, and are not intended to be or involve the delivery of services. Each Committee shall continue to exist until the Parties mutually agree to disband such
Committee, or if RevMed provides Sanofi with written notification of its decision to discontinue its participation in such Committee; provided that (a) the JPC shall disband upon [***], (b) the JCC shall disband if [***]; (c) the JRDC shall
disband upon [***]; and (d) the JMC shall disband upon [***]. If a Committee is so disbanded, such Committee shall have no further obligations under this Agreement and, thereafter, the Alliance Managers shall be the contact persons for the
exchange of information under this Agreement and decisions of such 

  
 25 

 
Committee shall be decisions of Sanofi. Upon disbandment of the JRDC, JCC, JPC or JMC or at any time in the JSC’s discretion, the JSC may assume from the JRDC, JCC, JPC or JMC any and all of
such Committees’ respective responsibilities. Notwithstanding anything to the contrary in Section 2.8(b)(i), following substantial completion of RevMed’s activities under the Research Plan and Development Plan, the JRDC shall meet no
less frequently than [***], provided that there are bona fide agenda items for such meetings. If RevMed undergoes a Change of Control following substantial completion of RevMed’s activities under the Research Plan and Development Plan, [***]
may, in its sole discretion, [***]. The JSC shall disband if all other Committees have disbanded. 
 Article III. 

LICENSE 
 3.1
Licenses and Option to Sanofi. 
 Licenses. Subject to the terms and conditions of this Agreement, RevMed hereby grants to Sanofi an
exclusive (even as to RevMed and its Affiliates), royalty-bearing license (which shall be sub-licensable solely as provided in Section 3.4) under the RevMed Licensed Technology, to Research, Develop,
Manufacture, use, sell, offer for sale, import and otherwise Commercialize and exploit Products (including, for clarity, any Companion Diagnostics with respect to such Products) in the Field in the Licensed Territory. 

(a) Option. 

(i) Option. Subject to the terms and conditions of this Agreement, RevMed hereby grants to Sanofi an exclusive option,
under the Patent Rights and Know-How claiming or embodied in the [***]. 
 (ii)
Exercise. Sanofi may exercise its Option at any time during the Term by providing RevMed with written notice of such exercise. During the Term prior to the Option exercise by Sanofi, RevMed shall provide to Sanofi any additional information
Controlled by RevMed that is reasonably requested by Sanofi in order to assist Sanofi in determining whether to exercise its Option. If Sanofi so exercises its Option pursuant to this Section 3.1(b)(ii), [***]. Upon Sanofi’s exercise of
the Option, [***] accordingly subject to the license granted to Sanofi under Section 3.1(a) and the payment obligations therefor pursuant to this Agreement. 

3.2 License to RevMed. Subject to the terms and conditions of this Agreement, Sanofi hereby grants to RevMed a non-exclusive, royalty-free sublicense (which shall only be further sub-licensable (a) to RevMed’s Subsidiaries, (b) to the Permitted Contractors or
Researchers, and (c) solely with Sanofi’s prior written consent, such consent not to be unreasonably withheld, delayed or conditioned, to Third Parties who are not Permitted Contractors or Researchers) under the rights exclusively licensed
to Sanofi pursuant to Section 3.1, solely to the extent necessary for RevMed to perform its obligations under this Agreement and the Ancillary Agreements. 

3.3 Retained Rights; Residuals. RevMed hereby retains subject to Section 3.5(b), all rights in and to the RevMed Licensed
Technology other than the rights expressly licensed to Sanofi thereunder pursuant to Section 3.1. Notwithstanding the foregoing, each Party shall have the right to use [***]. Notwithstanding anything to the contrary in this Agreement, nothing
shall [***]. 

  
 26 

 3.4 Sublicense and Subcontracting Rights. Subject to the terms and conditions
of this Agreement: 
 (a) Subject to Section 3.4(c) below, Sanofi may exercise its rights and perform its obligations under this
Agreement by itself or through the engagement of any of its Affiliates without RevMed’s consent. For the avoidance of doubt, RevMed shall not have any responsibility for any taxes relating to or arising out of the engagement of Sanofi’s
Affiliates or Sanofi’s use of subcontractors, except for any taxes to the extent that RevMed would have incurred such taxes even in the absence of such engagement of Sanofi’s Affiliates or Sanofi’s use of subcontractors.
 
 (b) Sanofi shall have the right to grant sublicenses (through multiple tiers) under the rights granted to it under
Section 3.1 to one or more Third Parties (i) outside of the United States, and (ii) in the United States; provided that for purposes of subsection (ii), Sanofi shall not sublicense substantially all of the rights granted to it under
Section 3.1 in the United States to Third Parties without RevMed’s prior written consent, such consent not to be unreasonably withheld, delayed or conditioned. 

(c) Subject to the remainder of this Section 3.4(c), (i) Sanofi may subcontract to Third Parties the performance of Sanofi’s tasks
and obligations with respect to the Research, Development, Manufacture and Commercialization of any Product as Sanofi deems appropriate (ii) RevMed may subcontract to the Permitted Contractors or Researchers listed on Exhibit B of the
Correspondence as of the Effective Date the performance of RevMed’s tasks and obligations with respect to the Research, Development, Manufacture and Commercialization of any Product, and (iii) RevMed shall not, without the prior written
approval of Sanofi, otherwise subcontract to Third Parties the performance of RevMed’s tasks and obligations with respect to the Research, Development, Manufacture and Commercialization of any Product. If Sanofi approves a Third Party
subcontractor of RevMed following the Effective Date, or such Third Party is named in the Research Plan or the Development Plan, then RevMed, unless otherwise explicitly waived by the Sanofi Alliance Manager, shall enter into a written agreement
with such Third Party substantially in a form approved by Sanofi and such Third Party shall be deemed a Permitted Subcontractor or Researcher under this Agreement. Each Party shall remain liable for any action or failure to act by its Affiliates,
Sublicensees or subcontractors to whom such Party’s obligations under this Agreement have been delegated, subcontracted or sublicensed and which action or failure to act would constitute a breach of this Agreement if such action or failure to
act were committed by such Party. Such Party shall require that such Affiliates, Sublicensees and subcontractors agree in writing to comply with the applicable terms and conditions of this Agreement. Without limiting the foregoing, if a Party first
engages a subcontractor after the Effective Date to perform any activities assigned to it under this Agreement, such Party shall require that such subcontractor be bound by written obligations of confidentiality and
non-use consistent with this Agreement and shall have agreed to assign to the Party engaging such subcontractor (or, if an assignment cannot be made, grant an irrevocable, perpetual, fully-paid, exclusive,
royalty-free, worldwide license to such Party, with the right to sublicense through multiple tiers, to Research, Develop, Manufacture, Commercialize and otherwise exploit SHP2 Inhibitors and Products) under all Program Inventions made by such
subcontractor in the course of performing such subcontracted work that relate to any Products or their use, manufacture or sale. 

  
 27 

 3.5 SHP1-SHP2 Dual Inhibitors. 

(a) Except pursuant to or as expressly permitted by this Agreement, RevMed shall not, shall cause its Affiliates not to, conduct or agree to
conduct, outside of the Collaboration, on its own or together with one or more Third Parties, the Research, Development or Commercialization of any product that contains a SHP2 Inhibitor, including any SHP1-SHP2 Dual Inhibitor that [***]. For
purposes of this Section, [***]. 
 (b) If [***] (such determination, the “SHP1-SHP2 Dual Inhibitor Licensing Decision” and
such Third Party’s rights, the “SHP1-SHP2 Dual Inhibitor License Rights”), then prior to commencing any negotiations with any Third Party with regard to any SHP1-SHP2 Dual Inhibitor License Rights, RevMed shall promptly notify
Sanofi in writing of such SHP1-SHP2 Dual Inhibitor Licensing Decision and provide to Sanofi a detailed summary of the data then in RevMed’s Control regarding the relevant SHP1-SHP2 Dual Inhibitor. Sanofi shall notify RevMed in writing (a
“Notice of Interest”), within [***] after Sanofi’s receipt of such notice, if Sanofi desires to enter into negotiations with RevMed of the terms under which Sanofi would obtain SHP1-SHP2 Dual Inhibitor License Rights. If Sanofi
provides a Notice of Interest to RevMed within [***], then (i) RevMed shall, upon request of Sanofi, provide Sanofi with reasonable access to all other then-existing Know-How in RevMed’s Control that
exists in either paper or electronic form and pertains to the relevant SHP1-SHP2 Dual Inhibitor and (ii) the Parties shall negotiate exclusively in good faith and on a commercially reasonable basis the terms of a definitive agreement under
which Sanofi would be granted SHP1-SHP2 Dual Inhibitor License Rights for [***] after RevMed receives such Notice of Interest (such period, the “SHP1-SHP2 Dual Inhibitor Licensing Negotiation Period”). If Sanofi provides such Notice
of Interest during [***], then RevMed shall not negotiate with any Third Party the terms under which such Third Party would obtain any development or commercialization rights with respect to a SHP1-SHP2 Dual Inhibitor during the SHP1-SHP2 Dual
Inhibitor Licensing Negotiation Period. If (x) Sanofi does not provide a Notice of Interest within [***] or (y) Sanofi does provide a Notice of Interest within [***] but Parties have not entered into an agreement under which Sanofi is
granted SHP1-SHP2 Dual Inhibitor License Rights prior to the expiration of the SHP1-SHP2 Dual Inhibitor Licensing Negotiation Period, then RevMed shall have no further obligations to Sanofi with respect to such SHP1-SHP2 Dual Inhibitor Products, and
RevMed shall have the right to enter into negotiations and execute an agreement with a Third Party under which such Third Party is granted the SHP1-SHP2 Dual Inhibitor License Rights [***]. For clarity, the Parties’ rights and obligations under
this Section 3.5(b) shall apply one time only, upon the occurrence of the first SHP1-SHP2 Dual Inhibitor Licensing Decision. 

3.6 No Implied Licenses. Except as expressly set forth herein, neither Party shall acquire any license or other intellectual
property interest, by implication or otherwise, under or to any trademarks, Patents, Know-How, or other intellectual property rights Controlled by the other Party. For clarity, any exclusive license granted to
each Party under any particular Patent Rights or Know-How Controlled by the other Party shall confer exclusivity to the Party obtaining such license only to the extent the Party granting such license Controls
the exclusive rights to such Patent Rights or Know-How. 

  
 28 

 3.7 Technology Transfers. 

(a) Initial. As of the Effective Date RevMed shall have included in the electronic dataroom for this Agreement: (i) all Know-How in its Control that is necessary or useful to the Research, Development, Manufacture, Commercialization or other exploitation of the Development Candidate on Exhibit I of the Correspondence that
currently exists in either paper or electronic form (the “Initial Know-How”) and (ii) a complete, accurate and detailed index of all other SHP2 Inhibitors which RevMed, as of the
Effective Date, has made or had made and all related Know-How in RevMed’s Control, which consists of the data regarding the structure and biochemical and other characteristics of such SHP2 Inhibitors that
currently exists in RevMed’s database(s) (the “Index”). 
 (b) Ongoing. Following the Effective Date, RevMed
shall disclose to the JRDC on a [***] basis all RevMed Licensed Know-How created, generated, invented or developed by or on behalf of RevMed under the Collaboration. In addition, upon Sanofi’s reasonable
written request, RevMed shall deliver to Sanofi updates to the Index, and related RevMed Licensed Know-How, including the data regarding the structure and biochemical and other characteristics of such SHP2
Inhibitors that then exists in RevMed’s database(s). 
 (c) Breach of Section 3.7(a) or 3.7(b) by
RevMed. Notwithstanding anything to the contrary in Section 12.2(b), in the event Sanofi believes RevMed has materially breached Section 3.7(a) or 3.7(b), Sanofi shall so notify RevMed in writing. RevMed may, within [***]
following receipt of such notice from Sanofi, request that [***]. 
 3.8 Government Approvals. 

(a) Efforts. Each of RevMed and Sanofi will use its commercially reasonable good faith efforts to remove promptly any and all
impediments to consummation of the transaction contemplated by this Agreement, including obtaining government antitrust clearance, cooperating in good faith with any Governmental Authority investigation, promptly producing any documents and
information and providing witness testimony if requested by a Governmental Authority. Notwithstanding anything to the contrary in this Agreement, this Section 3.8 and the term “commercially reasonable good faith efforts” do not
require that either Party (i) offer, negotiate, commit to or effect, by consent decree, hold separate order, trust or otherwise, the sale, divestiture, license or other disposition of any capital stock, assets, rights, products or businesses of
RevMed or Sanofi or its Affiliates, (ii) agree to any restrictions on the businesses of RevMed or Sanofi or its Affiliates, or (iii) pay any amount or take any other action to prevent, effect the dissolution of, vacate, or lift any decree,
order, judgment, injunction, temporary restraining order, or other order in any suit or proceeding that would otherwise have the effect of preventing or delaying the transaction contemplated by this Agreement (collectively, an “Antitrust
Remedy”), where such Antitrust Remedy would represent a Material Adverse Event for RevMed or Sanofi. 
 (b) HSR/Antitrust
Filings. Each of RevMed and Sanofi will, within [***] after the execution of the Agreement (or such later time as may be agreed to in writing by the Parties) file with the U.S. Federal Trade Commission (“FTC”) and the Antitrust
Division of the U.S. Department of Justice (“DOJ”) any HSR/Antitrust Filing required of it under the HSR Act and, as soon as practicable, file with the appropriate Governmental Authority any other

  
 29 

 
HSR/Antitrust Filing required of it under any other Antitrust Law as determined in the reasonable opinion of either Party with respect to the transactions contemplated by the Agreement and
Ancillary Agreements. The Parties shall cooperate with one another to the extent necessary in the preparation of any such HSR/Antitrust Filing. Each Party shall be responsible for its own costs, expenses, and filing fees associated with any
HSR/Antitrust Filing; provided, however, that Sanofi shall bear solely all fees (other than penalties that may be incurred as a result of actions or omissions on the part of a Party, which penalties shall be the sole financial responsibility of such
Party), required to be paid to any Governmental Authority in connection with making any such HSR/Antitrust Filing. In the event that the Parties make an HSR/Antitrust Filing under this Section 3.8, this Agreement shall terminate (i) at the
election of either Party, immediately upon notice to the other Party, in the event that the FTC, DOJ or other Governmental Authority obtains a preliminary injunction or final order under Antitrust Law enjoining the transactions contemplated by the
Agreement, or (ii) at the election of either Party, immediately upon notice to the other Party, in the event that the Antitrust Clearance Date shall not have occurred on or prior to [***] after the date upon which a HSR/Antitrust Filing has
been submitted by each Party to a Governmental Authority in relation to the Agreement. Notwithstanding anything to the contrary contained herein, except for the terms and conditions of this Section 3.8, none of the terms and conditions
contained in this Agreement shall be effective until the “Effective Date,” which is agreed and understood to mean, subject to the Closing Conditions having been fulfilled or waived in accordance with Section 13.6, the later of
(A) if a determination is made pursuant to this Section 3.8 that an HSR/Antitrust Filing is not required to be made under any Antitrust Law for this Agreement, the date of such determination, or (B) if a determination is made pursuant
to this Section 3.8 that an HSR/Antitrust Filing is required to be made under any Antitrust Law for this Agreement, the Antitrust Clearance Date. As used herein: (1) “Antitrust Clearance Date” means the earliest date on which
the Parties have actual knowledge that all applicable waiting periods under the HSR Act and any comparable waiting periods as required under any other Antitrust Law, in each case with respect to the transaction contemplated by this Agreement have
expired or have been terminated; and (2) “HSR/Antitrust Filing” means (x) a filing by RevMed and a filing by Sanofi with the FTC and the DOJ of a Notification and Report Form for Certain Mergers and Acquisitions (as that term
is defined in the HSR Act), together with all required documentary attachments thereto or (y) any comparable filing by RevMed or Sanofi required under any other Antitrust Law, in each case ((x) and (y)) with respect to the transaction
contemplated by this Agreement. 
 (c) Information Exchange. Each of RevMed and Sanofi will, in connection with any HSR/Antitrust
Filing, (i) reasonably cooperate with each other in connection with any communication, filing or submission and in connection with any investigation or other inquiry, including any proceeding initiated by a private party; (ii) keep the
other Party and/or its counsel informed of any communication received by such Party from, or given by such Party to, the FTC, the DOJ or any other U.S. or other Governmental Authority and of any communication received or given in connection with any
proceeding by a private party, in each case regarding the transaction contemplated by this Agreement; (iii) consult with each other in advance of any meeting or conference with the FTC, the DOJ or any other Governmental Authority or, in
connection with any proceeding by a private party, with any other Person, and to the extent permitted by the FTC, the DOJ or such other Governmental Authority or other Person, give the Parties and/or their counsel the opportunity to attend and
participate in such meetings and conferences; and (iv) to the extent practicable, permit the other Party and/or its counsel to review in advance any submission, filing or communication (and documents submitted therewith)

  
 30 

 
intended to be given by it to the FTC, the DOJ or any other Governmental Authority; provided, that materials may be redacted to remove references concerning the valuation of the business of the
disclosing Party or other sensitive information in the judgment of such disclosing Party. RevMed and Sanofi, as each deems advisable and necessary, may reasonably designate any competitively sensitive material to be provided to the other under this
Section 3.8 as “Antitrust Counsel Only Material.” Such materials and the information contained therein shall be given only to the outside antitrust counsel of the recipient and will not be disclosed by such outside counsel to
employees, officers or directors of the recipient unless express permission is obtained in advance from the source of the materials (RevMed or Sanofi, as the case may be) or its legal counsel. 

Article IV. 
 RESEARCH 

4.1 General. Subject to the terms and conditions of this Agreement, the Parties will conduct a research program for the
identification, validation and optimization of SHP2 Inhibitors (including without limitation back-up compound chemistry and characterization, pre-clinical studies, and
translation and biomarker studies) pursuant to a research plan (such plan, the “Research Plan”). 
 4.2
Research Plan. 
 (a) Research Plan and Budget. 

(i) Initial. As of the Effective Date, the Parties have agreed on an initial Research Plan and Research Budget for
Calendar Years 2018, 2019 and 2020, which is set forth in Exhibit H of the Correspondence. 
 A. Calendar Year 2018. The
initial Research Plan and Research Budget for Calendar Year 2018 are final and may only be amended or modified by mutual agreement of the Parties (i.e., Sanofi shall not have the unilateral right, either directly or through its participation in the
JRDC or the JSC, including by exercising its final decision-making power under Section 2.10(b), [***]). 
 B. Calendar Years 2019
and 2020. The initial Research Budget for Calendar Years 2019 and 2020 included in Exhibit H of the Correspondence represents, as of the Effective Date, what the Parties believe to be a reasonable estimate of the Research Budget for
Calendar Years 2019 and 2020 and shall become final only if the Parties mutually agree in writing with respect to the detailed Research activities and timelines to be set forth in the Research Plan for Calendar Years 2019 and 2020. Upon any such
mutual agreement, such Research Plan and Research Budget may only be amended or modified by mutual agreement of the Parties (i.e., Sanofi shall not have the right to exercise its final decision-making power under Section 2.10(b), [***]. If the
Parties do not reach such mutual agreement and Sanofi exercises its final decision-making power under Section 2.10(b) [***]. For clarity, if the Parties mutually agree upon activities under the Research Plan for a Research Budget equal to or
greater than that set forth in Exhibit H of the Correspondence then Section 4.5(b) shall apply and Sanofi shall be responsible for 80% of the Research and Development Costs and RevMed shall be responsible for 20% of the Research and
Development Costs, provided that Sanofi shall be responsible for [***]% of the Research and Development Costs associated with [***]. 

  
 31 

 C. Calendar Year 2021 and Beyond. The Research Plan and Research Budget for Calendar
Year 2021 and any Calendar Year after 2021 shall be subject in all respects to the governance set forth in Article II (including Sanofi’s final decision-making power under Section 2.10(b) and the procedure for amendments set forth in
Section 4.2(a)(ii)). 
 (ii) Amendments. From time to time after the Effective Date, the JRDC may propose any
amendment to the Research Plan, which shall be made in good faith, based on scientific and regulatory judgment. The Research Plan shall set forth: (a) the Research activities to be conducted by either Party; (b) the estimated timelines for
such Research activities; and (c) a detailed budget setting forth the estimated RevMed R&D Costs to be incurred in connection with such activities (the “Research Budget”). If the terms of the Research Plan contradict, or
create inconsistencies or ambiguities with, the terms of this Agreement, then the terms of this Agreement shall govern. 
 (b) Conduct of
Research. Each Party shall perform all Research activities under this Agreement in compliance with all Applicable Law (including GMP, GLP and GCP). In furtherance and not in limitation of the foregoing, RevMed shall use diligent efforts
to conduct its activities under each Research Plan in accordance with the terms of such Research Plan (including timelines), as the same may be amended from time to time (and which basis for comparison shall be tolled until any then-contemplated
or pending amendments are completed or for the duration of any bona fide dispute between the Parties with respect to a Research Plan or amendment thereto), and this Agreement. If Sanofi believes RevMed has materially breached its obligation in the
foregoing sentences with respect to any Product, Sanofi shall so notify RevMed in writing. If either RevMed agrees or it is determined in accordance with [***], that RevMed has committed a material breach of its obligations under this
Section 4.2(b) with respect to such Product, the JRDC shall, within [***] after such agreement on or determination of material breach, meet in person or by teleconference to discuss such material breach and specify reasonable actions that
RevMed should take to cure such material breach. If RevMed fails to commence within [***] after such discussion occurs such actions recommended by the JRDC, or fails to cure any such material breach within [***] after the JRDC meets (or such longer
timeframe as the JRDC decides is necessary to complete the actions specified by the JRDC), then Sanofi shall have the right, without prejudice to any other rights or remedies Sanofi may have under this Agreement or otherwise at law or in equity,
[***]. In such case, RevMed shall, [***], (i) make available [***], (ii) provide [***], and (iii) otherwise provide [***]. 
 4.3
Designation of Development Candidates As of the Effective Date, the Parties agree that the SHP2 Inhibitor set forth on Exhibit I of the Correspondence is deemed a Development Candidate (defined below) under this Agreement. From time to
time, either Party may nominate one or more additional SHP2 Inhibitors to the JRDC for consideration as a candidate for Development under a Development Plan (the “Development Candidate”). Such nomination (and approval thereof by the
JRDC) shall be made prior to the initiation of the IND-enabling studies for such SHP2 Inhibitor(s), unless otherwise permitted by the JRDC. Promptly after such nomination, each Party shall present to the JRDC
the data and results it has obtained with respect to such SHP2 Inhibitor(s) as well as, if requested by the other Party, written records maintained 

  
 32 

 
by or on behalf of such Party or its Affiliates with respect to the discovery or development history of such SHP2 Inhibitor. The JRDC shall determine whether such SHP2 Inhibitor(s) shall be
approved as a Development Candidate under this Agreement. The JRDC may also request that further Research activities be conducted with respect to such SHP2 Inhibitor(s) (under an amended Research Plan), after which activities such SHP2 Inhibitor(s)
may be reconsidered for nomination as a Development Candidate. If the JRDC (or Designated Senior Officers, as applicable) approve a particular SHP2 Inhibitor as a Development Candidate, then the Parties shall proceed to conduct further Development
of such SHP2 Inhibitor (including IND-enabling studies, other pre-clinical and non-clinical studies, and clinical studies)
pursuant to a Development Plan (as further described in Section 5.2) and under the oversight of the JRDC. In addition, at any time after a SHP2 Inhibitor is designated as a Development Candidate, if requested by Sanofi, RevMed shall make
available written records (such as lab notebooks) maintained by or on behalf of RevMed or its Affiliates with respect to the discovery and/or development history of such SHP2 Inhibitor or any Product under Development that contains such SHP2
Inhibitor, provided that such request shall not be made more than once for each SHP2 Inhibitor or each Product, as applicable, except for cause. 

4.4 Research Records and Reports. Each Party shall maintain complete, current and accurate records of all Research activities
conducted by it hereunder, and all data and other information resulting from such activities. Such records shall fully and properly reflect all work done and results achieved in the performance of the Research activities in good scientific manner
appropriate for regulatory and patent purposes. Each Party shall keep the other Party reasonably informed as to its progress in the conduct of the Research activities through meetings of the JRDC. Upon written request from the JRDC, each Party shall
submit to the JRDC a written summary (in slide format unless otherwise agreed by the Parties) of its Research activities since its prior report. 

4.5 Research Costs. 

(a) Calendar Years 2018, 2021 and All Calendar Years After 2021. Sanofi shall be responsible for 100% of the Research and Development
Costs for Calendar Years 2018, 2021 and all Calendar Years after 2021. Sanofi will reimburse RevMed for any RevMed R&D Costs incurred by or on behalf of RevMed after the Execution Date in the performance of its activities under the Research
Plan, provided that such RevMed R&D Costs are incurred per the Research Budget for such activities as approved by the JSC and [***] set forth in the Research Budget for the particular Calendar Quarter. Promptly following the end of each Calendar
Quarter during which RevMed is responsible for activities under the Research Plan, but in no event later than [***] following the end of such Calendar Quarter, RevMed will provide to Sanofi a detailed expense report in form approved by the JRDC with
respect to the RevMed R&D Costs incurred by or on behalf of RevMed during such Calendar Quarter consistent with the previous sentence (including, if requested by Sanofi in writing, copies of receipts or invoices from Third Parties for all RevMed
R&D Out-of-Pocket Costs) together with an invoice for the same, provided that[***]. Sanofi will reimburse RevMed in Dollars all undisputed amounts within such
expense reports under this Section 4.5 within [***] following receipt of the invoice therefor. RevMed shall invoice Sanofi for costs under this Section 4.5 on an accrual basis. 

  
 33 

 (b) Calendar Years 2019 and 2020. Subject to Section 4.2(a)(i)(B), Sanofi shall
be responsible for 80% of the Research and Development Costs for Calendar Years 2019 and 2020 and RevMed shall be responsible for 20% of the Research and Development Costs for Calendar Years 2019 and 2020 (provided that such Research and Development
Costs are incurred per the Research Budget for such activities as approved by the JSC and [***] set forth in the Research Budget for the particular Calendar Quarter). Research and Development Costs shall initially be borne by the Party incurring the
cost or expense. Promptly following the end of each Calendar Quarter during Calendar Years 2019 and 2020, but in no event later than [***] following the end of such Calendar Quarter, each Party will provide to the JRDC a detailed expense report in
form approved by the JRDC with respect to the Research and Development Costs incurred by or on behalf of such Party during such Calendar Quarter consistent with the previous sentence (including, if requested by Sanofi in writing, copies of receipts
or invoices from Third Parties for all RevMed R&D Out-of-Pocket Costs). The Party that incurs more than its share of the total Research and Development Costs during
any such Calendar Quarter shall deliver an invoice to the other Party for an amount of cash sufficient to reconcile to the invoicing Party’s agreed percentage of Research and Development Costs. Such other Party will reimburse the invoicing
Party in Dollars all undisputed amounts within such expense reports under this Section 4.5 in accordance with Section 9.5 mutatis mutandis. 

Article V. 
 DEVELOPMENT

 5.1 General. Subject to the terms and conditions of this Agreement, the Parties will collaborate on the Development of
the Products in the Field for Regulatory Approval under the direction of the JRDC and pursuant to the Development Plan, as set forth in more detail below. 

5.2 Development. 

(a) Development Plan and Budget. As of the Effective Date, the Parties have agreed on an initial Development Plan and Development
Budget (each as defined below), which is set forth in Exhibit J of the Correspondence. After the Effective Date, for the Development Candidate listed in Exhibit J of the Correspondence, and at the time any other SHP2 Inhibitor is
designated as a Development Candidate by the JRDC, the JRDC shall prepare and approve a Development plan for Products containing such SHP2 Inhibitor through Regulatory Approval of the Product from the FDA, EMA, or PMDA, as applicable, that includes
the items described below (the “Development Plan”). The Development Plan for each Product shall set forth the timeline and details of: (i) all clinical Development activities to be conducted by the Parties that are designed to
generate data sufficient to present to the FDA, EMA, and PMDA or other Regulatory Authority at the Pre-Registrational Meetings; (ii) the protocol synopsis for each Clinical Trial included in such Development Plan; (iii) a Manufacturing
plan for the Manufacturing of the Product for such Clinical Trials; (iv) all additional clinical Development activities to be conducted by the Parties that are designed to generate data sufficient to seek Regulatory Approval of the Product from
the FDA, EMA, or PMDA, as applicable, for the indication(s) to be pursued; (v) any other Development activities to be performed in order to obtain Regulatory Approval by the FDA, EMA, PMDA or the Regulatory Authority of any other jurisdiction;
(vi) a detailed budget setting forth the estimated RevMed R&D Costs to be incurred in connection with such activities (the “Development Budget”); and (vi) the Party responsible for conducting each Development activity
under such Development Plan. 

  
 34 

 (b) Conduct of Development. Each Party shall perform all Development
activities under this Agreement in compliance with all Applicable Law (including GMP, GLP and GCP). In furtherance and not in limitation of the foregoing, RevMed shall use diligent efforts to conduct its activities under each Development Plan in
accordance with the terms of such Development Plan (including timelines), as the same may be amended from time to time (and which basis for comparison shall be tolled until any then-contemplated or pending amendments are completed or for the
duration of any bona fide dispute between the Parties with respect to a Development Plan or amendment thereto), and this Agreement. If either RevMed agrees or it is determined in accordance with [***] that RevMed has committed a material breach of
its obligations under this Section 5.2(b) with respect to any Clinical Trial of a Product, the JSC shall, within [***] after such agreement on or determination of material breach, meet in person or by teleconference to discuss such material
breach and specify reasonable actions that RevMed should take to cure such material breach. If RevMed fails to commence within [***] after such discussion occurs such actions recommended by the JSC, or fails to cure any such material breach within
[***] after the JSC meets (or such longer timeframe as the JSC decides is necessary to complete the actions specified by the JSC), then Sanofi shall have the right, without prejudice to any other rights or remedies Sanofi may have under this
Agreement or otherwise at law or in equity[***]. In such case, RevMed shall, [***], (i) make available [***], (ii) provide [***], (iii) provide [***], and (iv) otherwise provide [***]. 

(c) Pre-Registrational Meeting. After obtaining early Development data and results under the Development Plan for a
particular Product, in the event the JRDC determines to further Develop such Product for Marketing Approval, the JRDC shall develop a package setting forth such data and results, a planned regulatory strategy for the Development of such Product for
a defined indication in the Field, the protocol synopses for each Registrational Clinical Trial included in the applicable Registration Program, any other Development activities to be conducted in support of such regulatory strategy, any other
materials as may be required by the FDA, EMA, or PMDA or other Regulatory Authority for the Pre-Registrational Meetings for the applicable Products, and the Party responsible for conducting each Development activity under such package (the
“Data Package”). After developing such Data Package, the Parties shall conduct the Pre-Registrational Meetings as set forth in Section 6.3(a). 

(d) Development Plan Amendments. From time to time during the Term, the JRDC shall prepare amendments, as appropriate, to the
then-current Development Plan. Subject to the foregoing, the JRDC shall have the right to approve amendments to the Development Plan, with final decision-making authority as provided in Section 2.10. Once approved by the JRDC, such amended
Development Plan shall replace the prior Development Plan. 
 5.3 Combination Therapies. 

(a) The JRDC shall discuss whether to include in the Development Plan for a Product the Development of such Product for use with other
products to the extent not already provided for in the Development Plan (each, a “Combination Therapy”), including products developed or sold by a Third Party or that are in the public domain. Subject to this Section 5.3, each
Party shall have the right to propose to the JRDC studies for co-development of Products with other products under the applicable Development Plan. 

  
 35 

 (b) The Development Plan shall address the conduct of any Clinical Trial for a Combination
Therapy and shall (i) specify which Party will be responsible for each activity for the Development of such Combination Therapy and (ii) specify which Party will be responsible for obtaining supplies of the Product or other product in such
Combination Therapy as necessary. The JRDC shall review and approve the terms of any agreement with a Third Party in connection with any supply or other aspect of Development of such Combination Therapy. 

5.4 Conflicts. If the terms of a Development Plan contradict, or create inconsistencies or ambiguities with, the terms of this
Agreement, then the terms of this Agreement shall govern. 
 5.5 Development Costs. 

(a) Sanofi will reimburse RevMed for RevMed R&D Costs incurred by or on behalf of RevMed after the Execution Date in the performance of
its activities under the Development Plan, as applicable, provided that such RevMed R&D Costs are incurred per the Development Budget, as applicable, for such activities as approved by the JSC and do not exceed [***]% of the applicable amounts
set forth in the Development Budget for the particular Calendar Quarter. Promptly following the end of each Calendar Quarter during which RevMed is responsible for activities under any Development Plan, but in no event later than [***] following the
end of such Calendar Quarter, RevMed will provide to Sanofi a detailed expense report in form approved by the JRDC with respect to the RevMed R&D Costs incurred by or on behalf of RevMed during such Calendar Quarter consistent with the previous
sentence (including, if requested by Sanofi in writing, copies of receipts or invoices from Third Parties for all RevMed Out-of-Pocket Costs) together with an invoice
for the same, provided that [***]. Sanofi will reimburse RevMed in Dollars all undisputed amounts within such expense reports under this Section 5.5 within [***] following receipt of the invoice therefor. RevMed shall invoice Sanofi for costs
under this Section 5.5 on an accrual basis. 
 5.6 RevMed Studies. 

(a) RevMed or its Affiliates may propose to the JRDC that the Parties conduct a Clinical Trial of a Product in the Field that is not included
in the Development Plan for such Product, in which case RevMed shall present the proposed design and projected costs of such Clinical Trial to the JRDC. If Sanofi agrees to include such Clinical Trial and related costs in the Development Plan and
Development Budget for such Product, the Parties shall prepare an updated Development Plan and Development Budget and such Clinical Trial shall become part of the Collaboration and subject to this Agreement. 

(b) In the event Sanofi, through the JRDC, decides not to pursue a Clinical Trial that RevMed presents in accordance with Section 5.6(a),
then (i) the matter will be escalated pursuant to Section 2.10 and (ii) notwithstanding anything to the contrary in Section 2.10(b), if such matter remains unresolved after the matter is escalated to Designated Senior Officers,
then RevMed, subject to this Section 5.6(b), may elect to conduct such study, on its own and at its own expense, provided that if such study [***], RevMed shall not have the right to conduct such study unless Sanofi agrees in writing that
RevMed may conduct such study (any such study so conducted, a “RevMed Study”). For purposes of determining whether subsections (x), (y) or (z) apply, RevMed shall, prior to commencing a RevMed Study, submit to the JRDC
for comment and review 

  
 36 

 
the protocol for such RevMed Study. Any disagreement among the JRDC members as to whether subsections (x), (y) or (z) apply shall be submitted for resolution to the Designated Senior
Officers, provided that if the Designated Senior Officers do not agree on such matter, then RevMed shall not conduct such study. Provided that RevMed is permitted to conduct a RevMed Study, RevMed shall report to the JRDC on an ongoing basis any and
all data arising from a RevMed Study (the “RevMed Study Data”) and provide the JRDC with updates and any other information pertaining to any RevMed Study as may be requested by the JRDC. 

A. Sanofi shall have rights to use, at no additional cost, any RevMed Study Data in its performance of its obligations and exercise of its
rights under the Collaboration except in connection with filing of MAAs for the Indication and Product Treatment Regimen that were the subject of such RevMed Study. 

B. If Sanofi wishes to use, or actually uses, RevMed Study Data in support of filing a MAA for the Indication and Product Treatment Regimen
that were the subject of such RevMed Study, it shall notify RevMed in writing and shall make a buy-in payment to RevMed in Dollars equal to [***] within [***] after the date that Sanofi receives a detailed
invoice from RevMed setting forth [***]. In such case the RevMed Study shall be deemed a Clinical Trial under the Collaboration for all purposes, including that all Know-How conceived, reduced to practice,
developed, made or otherwise generated by or on behalf of RevMed or its Affiliates in the course of the RevMed Study activities shall be deemed Program Inventions hereunder. 

C. Each Party shall have rights to use RevMed Study Data for internal research and development outside the scope of the Collaboration. 

5.7 Diligence. Consistent with [***] or as otherwise agreed by the Parties, Sanofi shall use Commercially Reasonable Efforts
[***] to file and seek approval for an MAA for at least one Product in all of such countries or, in the case of the Major Market Countries in the European Union, through the centralized European Union approval process. If Sanofi materially breaches
its obligation set forth in this Section 5.7, [***]. 
 5.8 Development Records. Each Party shall maintain complete,
current and accurate records of all Development activities conducted by it hereunder, and all data and other information resulting from such activities, for at least [***] after the expiration or termination of this Agreement in its entirety or for
such longer period as may be required by Applicable Law. Such records shall fully and properly reflect all work done and results achieved in the performance of the Development activities in good scientific manner appropriate for regulatory and
patent purposes. Each Party shall document all non-clinical studies and Clinical Trials for Products in formal written study reports in accordance with Applicable Law and national and international guidelines
(e.g., GCP, GLP, and GMP). Each Party shall have the right to review and copy such records maintained by the other Party at reasonable times and to obtain access to the original to the extent necessary for regulatory and patent purposes or
for other legal proceedings. 
 5.9 Data Exchange and Development Reports. In addition to adverse event and safety data
reporting obligations pursuant to Section 6.5, each Party shall promptly provide the other Party with copies of all data and results generated by or on behalf of such Party in the course of performing the Development activities hereunder,
including, in each case of data arising from 

  
 37 

 
Clinical Trials for Products, or in such form as the JRDC may agree from time to time. Each Party shall provide the JRDC with regular reports detailing its Development activities for the
Products, and the results of such activities at each regularly scheduled JRDC meeting. The Parties shall discuss the status, progress and results of each Party’s Development activities at such JRDC meetings. 

5.10 Clinical Samples. The Party who sponsors the applicable Clinical Trial of SHP2 Inhibitors shall retain and archive all
clinical samples obtained by such Party in the course of such Clinical Trial, and shall provide the other Party reasonable access to such retained clinical samples.  

Article VI. 
 REGULATORY

 6.1 Regulatory Responsibilities. Subject to the Parties’ cooperation as set forth in Section 6.3, and except
as otherwise set forth in a Development Plan or this Article VI, Sanofi shall have the sole right and responsibility to perform all regulatory activities under the Collaboration (including conducting all correspondence and communications with
Regulatory Authorities and filing all Marketing Authorization Applications and other filings with Regulatory Authorities). The Development Plan shall set forth the regulatory strategy for seeking Regulatory Approval for the Products in the Field by
the FDA, EMA and other Regulatory Authorities in the Major Market Countries. 
 6.2 Regulatory Materials and Database. All
INDs in existence as of the Effective Date related to a Product shall be solely owned and held in the name of RevMed or its Affiliate for so long as necessary for RevMed to conduct any Clinical Trial for such Product it is responsible for under the
Development Plan for such Product. Following the Effective Date, each Party shall file and hold the IND and NDA for all Products in Clinical Trials conducted by it. Once RevMed has completed conducting all Clinical Trials for a Product
assigned to it under the Development Plan for such Product, RevMed agrees to assign, and hereby does assign, to Sanofi all of its rights, title and interests in and to all Regulatory Approvals (including INDs and NDAs) for such Product. 

6.3 Cooperation. For each Product, each Party shall cooperate reasonably with the other Party with respect to all regulatory
activities under the Research Plan or Development Plans relating to the Products. Without limiting the foregoing, for such activities, each Party: 

(a) shall meet and discuss with the other Party through the JRDC the timing, strategy and presentation of the Pre-Registrational Meeting with
the goal of developing the Registration Program and setting the regulatory path to obtain Regulatory Approval for the Product from the FDA, EMA, and PMDA; 

(b) shall consult with each other with respect to the preparation of the Data Package; 

(c) shall consult with the other Party through the JRDC regarding material regulatory matters pertaining to all Regulatory Materials of the
Products in the United States, European Union and the Major Market Countries outside the European Union, including plans, strategies, filings, reports, updates and supplements in connection therewith and perform its responsibilities in connection
with the preparation of the portion of such Regulatory Materials allocated to such Party for preparation in the Development Plan; 

  
 38 

 (d) shall provide the other Party with drafts of any Regulatory Materials for the Products
to be submitted by such Party to any Regulatory Authority in the United States, European Union and the Major Market Countries outside the European Union within a reasonable time (but in no event less than [***], unless impractical) prior to
submission for review and comment, and shall consider in good faith any comments received from the other Party; 
 (e) shall provide the
other Party with copies in electronic format (e.g., eCTD format) of any Regulatory Materials submitted to and any correspondence received from any Regulatory Authority in the United States, European Union and the Major Market Countries outside the
European Union pertaining to the Products promptly after its submission or receipt by such Party; and 
 (f) shall provide the other Party
written minutes or other records of any material oral discussions with any Regulatory Authority in the European Union and the Major Market Countries outside the European Union pertaining to the Products promptly after any such discussion. 

If any Regulatory Material to be provided under this Section 6.3 was originally created in a language other than the English language, if
requested by the receiving Party, the providing Party shall provide an English translation along with the original document to the receiving Party at the receiving Party’s cost if such translation would not normally be made by the providing
Party in accordance with its standard operating procedures. 
 6.4 Meetings with Regulatory Authorities. The Development Plan
shall set forth which Party shall lead and present at each meeting or teleconference with Regulatory Authorities for the applicable Product, provided that, notwithstanding the foregoing, RevMed shall lead and present at such meetings or
teleconferences with respect to any RevMed Studies and for Clinical Trials conducted under RevMed’s IND while RevMed remains the holder of such IND. The Party leading such regulatory interactions shall provide the other Party with advance
notification of any in-person meeting or teleconference with the Regulatory Authorities that relates to the Development of any Product as promptly as possible after such meeting has been scheduled, but in no
event less than [***] before the meeting is scheduled to occur. The Party leading such regulatory interactions shall, as applicable, seek permission from the Regulatory Authority for representatives of the other Party to attend any such meeting or
teleconference, and such other Party shall have the right, but not the obligation, to have its representatives attend (but, unless otherwise requested by the Party responsible for such meeting, not participate in) such meetings. 

6.5 Adverse Events Reporting. Following the Effective Date, but in any case prior to the Initiation of the first Clinical Trial
for a Product or earlier upon the written request of either Party, the Parties shall enter into a pharmacovigilance agreement setting forth the worldwide pharmacovigilance procedures for the Parties with respect to the Products, such as safety data
sharing, adverse events reporting and safety profile monitoring (the “Pharmacovigilance Agreement”). Such procedures shall be in accordance with, and enable the Parties to fulfill, local and national regulatory reporting obligations
under Applicable Law. Each Party shall be responsible for reporting quality complaints, adverse events and safety data related to the Products 

  
 39 

 
to the applicable Regulatory Authorities in its territory, as well as responding to safety issues and to all requests of Regulatory Authorities related to the Products in its territory, in each
case at its own cost. The initial global safety database shall be established by RevMed using its Permitted Contractors or Researchers, and RevMed shall, at RevMed’s sole cost and expense, transfer such global safety database to Sanofi upon
Sanofi’s written request reasonably in advance of the desired transfer date, which transfer date shall be no later than [***] prior to the initiation of Sanofi’s first Clinical Trial for a Product and in the form requested by
Sanofi. Prior to such transfer RevMed shall provide to Sanofi all safety information obtained by RevMed for the Products prior to Sanofi’s assumption of the global safety database. Each Party agrees to comply with its respective obligations
under the Pharmacovigilance Agreement and to cause its Affiliates, and Sublicensees to comply with such obligations. 
 6.6
Notification of Threatened Action. Each Party shall immediately notify the other Party of any information it receives regarding any threatened or pending action, inspection or communication by any Regulatory Authority, which may affect the
safety or efficacy claims of any Product or the continued marketing of any Product. Upon receipt of such information, the Parties shall promptly consult with each other in an effort to arrive at a mutually acceptable procedure for taking appropriate
action. 
 6.7 Remedial Actions. Each Party shall notify the other immediately, and promptly confirm such notice in writing,
if it obtains information indicating that any Product may be subject to any recall, corrective action, market withdrawal or other similar regulatory action with respect to the Product taken by virtue of Applicable Law (a “Remedial
Action”). The Parties shall fully assist each other in gathering and evaluating such information as is necessary to determine the necessity of conducting a Remedial Action. Each Party shall, and shall ensure that its Affiliates,
Sublicensees, (sub)contractors and Distributors shall, maintain adequate records to permit the Parties to trace the Manufacture, distribution and use of the Products, as required by Applicable Law. Sanofi shall have sole discretion with respect to
any matters relating to any Remedial Action in the Licensed Territory, including the decision to commence such Remedial Action and the control over such Remedial Action, at its sole cost and expense; provided that to the extent such Remedial Action
results from (a) the breach of RevMed’s obligations hereunder or under any Ancillary Agreement or (b) the negligence, recklessness or willful misconduct of RevMed or its Affiliate, in each case, RevMed shall bear the costs and
expenses of such Remedial Action. 
 6.8 Compassionate Use. Promptly after the Pre-Registrational Meeting with the FDA, EMA,
and PMDA for a particular Product (or in the case in which a Product is only being developed for the US or the EU, but not both, after the applicable FDA, EMA or PMDA Pre-Registrational Meeting) or at a time otherwise agreed by the Parties, the JRDC
shall decide on a procedure for managing Product requests for compassionate use. 
 6.9 Audit Vendors &
Contractors. Each Party shall have in place standard operating procedures for their vendor management processes (including with respect to compliance). Each Party shall notify the other Party of any inspections of such Party or any of its
Affiliates or subcontractors conducted by any Regulatory Authority or other government entity and any related findings to the extent that such inspections relate to the activities conducted hereunder. In addition, Sanofi shall have the right to
conduct customary reviews and audits of RevMed and its Affiliates and subcontractors (provided that, with respect to Permitted Contractors or Researchers that 

  
 40 

 
RevMed entered into a written agreements with prior to the Effective Date, such right of Sanofi shall be to the extent RevMed has the right to permit Sanofi to do so under such written
agreements, and provided further, that RevMed shall use Commercially Reasonable Efforts to secure such right for Sanofi where one does not exist). 

Article VII. 
 MANUFACTURING AND
SUPPLY 
 7.1 General. The Manufacture of the SHP2 Inhibitors and Products, including all process and formulation
development in connection therewith, including Chemistry, Manufacturing and Controls (CMC) activities, shall be overseen and coordinated by (a) RevMed for clinical supply related to Phase 1 Clinical Trials, and Phase 2 Clinical Trials that are
not Registrational Clinical Trials, and (b) Sanofi for supply of all Clinical Trials other than those set forth in clause (a) and all supply associated with Commercialization. If requested by the JMC, each Party shall provide reports
summarizing its Manufacturing activities and the results of such activities. 
 7.2 Transfer of Manufacturing Know-How. Upon Sanofi’s request, RevMed shall transfer to Sanofi or its designee Know-How Controlled by RevMed that is necessary or useful to enable the Manufacture
of each SHP2 Inhibitor that is nominated or designated as a Development Candidate pursuant to Section 4.3, Development Candidate and Product, including regulatory starting materials and key starting materials, as set forth in this
Section 7.2. Sanofi may also request such Know-How for backup SHP2 Inhibitors that Sanofi is considering for nomination or designation as a Development Candidate, and RevMed shall transfer such Know-How to Sanofi (to the extent any exists). RevMed shall (a) at [***] cost, provide copies or samples of relevant documentation (including, but not limited to, documentation listed in Exhibit K of the
Correspondence), materials and other embodiments of such Know-How, (b) at [***] cost (calculated on [***]), make available RevMed’s qualified technical employees, and use Commercially Reasonable
Efforts to make available the qualified technical personnel of RevMed’s independent manufacturing contractors, in each case, on a reasonable basis to consult with Sanofi or its designee with respect to such
Know-How, and (c) if requested by Sanofi, at [***] cost, use Commercially Reasonable Efforts to support Sanofi in the establishment of its own supply agreements with Third Party suppliers of RevMed. 

7.3 Supply Agreement. In each case where one Party shall Manufacture Product for the other Party for clinical use or commercial
use, (with the cost and expense of the commercial supply of Product for the U.S. being subject to Section 9.4), the Parties shall negotiate in good faith to enter into a supply agreement (a “Supply Agreement”) and a quality
agreement (a “Quality Agreement”) for such Manufacture on commercially reasonable terms. Such Supply Agreement shall cover the documentation and other quality requirements for the acceptance of previously manufactured supply of
Product for use by the other Party. The price charged by the manufacturing Party under any Supply Agreement shall be equal to [***] unless otherwise agreed by the Parties. 

  
 41 

 Article VIII. 

COMMERCIALIZATION 

8.1 General. Subject to Section 8.7 and unless otherwise delegated to RevMed by the JCC, Sanofi shall have the sole right
and responsibility, at its own expense, for all aspects of the Commercialization of the Products in the Field in the Licensed Territory including: (a) developing and executing a commercial launch and
pre-launch plan, (b) negotiating with applicable Governmental Authorities regarding the pricing and reimbursement status of the Products; (c) marketing and promotion (including promotional
materials); (d) booking sales and distribution and performance of related services; (e) handling all aspects of order processing, invoicing and collection, inventory and receivables; (f) providing customer support, including handling
medical queries, and performing other related functions; and (g) conforming its practices and procedures to Applicable Law relating to the marketing, detailing and promotion of the Products. 

8.2 Commercialization Plan. Promptly after the formation of the JCC, Sanofi shall prepare and provide to the JCC for review and
discussion a written plan for the Commercialization of such Product in the Licensed Territory (the “Commercialization Plan”). Each Commercialization Plan shall include a reasonably detailed description of (a) [***]; (e) non-binding sales and marketing forecasts in the U.S.; (f) non-binding net sales projections in the U.S.; (g) [***]; (h) non-binding
sales and marketing forecasts and non-binding net sales projections, in each case, outside of the U.S. (i) [***], and in such case the Parties shall amend the Profit/Loss Share Agreement accordingly. Sanofi
shall periodically (at least [***]) prepare updates and amendments to its Commercialization Plan to reflect changes in its plans, including in response to changes in the marketplace, relative success of the Products and other relevant factors
influencing such plans and activities. Sanofi shall submit all updates and amendments to each Commercialization Plan to the JCC for review and discussion before adopting such updates and amendments. 

8.3 Distributorships. Sanofi shall have the right, in its sole discretion, to appoint its Affiliates, and Sanofi and its
Affiliates shall have the right, in its sole discretion, to appoint any other Persons, in the Licensed Territory to distribute, market, and sell the Products (with or without packaging rights), in circumstances where the Person purchases its
requirements of Products from Sanofi or its Affiliates but does not otherwise make any royalty or other payment to Sanofi or its Affiliates with respect to its intellectual property or other proprietary rights. Where Sanofi or its Affiliates
appoints such a Person and such Person is not an Affiliate of Sanofi, that Person shall be a “Distributor” for purposes of this Agreement. The term “packaging rights” in this Section means the right for the Distributor to
package Products supplied in unpackaged bulk form into individual ready-for-sale packs. 

8.4 Pricing Approvals. Sanofi shall control all pricing and reimbursement approvals for Products in the Licensed Territory.
RevMed shall provide Sanofi with reasonable assistance and cooperation with respect to obtaining pricing and reimbursement approvals for the Products, at Sanofi’s request and expense. 

  
 42 

 8.5 Patent Marking. Each Party shall mark all Products in accordance with the
applicable patent marking laws, and shall require all of its Affiliates, Sublicensees and Distributors to do the same. 
 8.6
Reports. Each Party shall update the JCC at each regularly scheduled JCC meeting regarding its Commercialization activities with respect to the Products. Each such update shall be in a form to be agreed by the JCC by mutual agreement of its
representatives (without application of any final decision-making right of either Party) and shall summarize such Party’s (either by itself or through its Affiliates and its Sublicensees) Commercialization activities with respect to the
Products. 
 8.7 Co-Promotion of Products in the United States. 

(a) RevMed shall have the one-time exclusive right to elect to assume up to [***]% (but not less than
[***]%) of the Detailing effort for all Products in the United States (such geography, the “Co-Promotion Territory”; such right, the
“Co-Promotion Option”; such Products that are co-promoted by the Parties, the “Co-Promotion
Product”); provided that (i) [***] and (ii) RevMed shall provide to Sanofi, at the time of RevMed’s exercise of the Co-Promotion Option pursuant to Section 8.7(b), a plan demonstrating
to Sanofi’s reasonable satisfaction that RevMed has, or will have on a timely basis, the necessary resources in place sufficient to Detail the applicable Co-Promotion Products in a manner consistent with
and within the timelines required under the applicable Commercialization Plan. RevMed shall be obligated to perform the activities set forth in such plan within the timelines provided therein. 

(b) Sanofi shall notify RevMed of the anticipated launch date for the first Product in the
Co-Promotion Territory at least [***] in advance thereof. If RevMed wishes to exercise its one-time Co-Promotion Option, it shall
so notify Sanofi in writing at least [***] prior to the anticipated launch of such Product in the Co-Promotion Territory. If (i) RevMed does not provide the above election notice in compliance with the
requirements of this Section 8.7(b), or (ii) RevMed provides notice to Sanofi that it does not intend to exercise its one-time Co-Promotion Option, then RevMed
shall be deemed to have waived such one-time right to co-promote any and all Products in the Co-Promotion Territory. For clarity,
once RevMed has exercised its Co-Promotion Option pursuant to this Section 8.7(b), RevMed’s right to co-promote Products shall apply to all other existing and
subsequent Products in the Co-Promotion Territory. 
 (c) If RevMed exercises the Co-Promotion Option for the Co-Promotion Territory, the Parties shall negotiate in good faith terms and conditions of a co-promotion
agreement pursuant to which they will co-promote Products in the Co-Promotion Territory (the “Co-Promotion
Agreement”). The Co-Promotion Agreement will contain the terms and conditions set forth in Exhibit L of the Correspondence and other terms and conditions as are reasonable and customary for the
co-promotion of similar products in the Co-Promotion Territory. The Parties shall use Commercially Reasonable Efforts to enter into the
Co-Promotion Agreement no later than [***] following the date upon which RevMed exercises the Co-Promotion Option, or such later date as the Parties may agree in
writing. 

  
 43 

 Article IX. 

FINANCIAL PROVISIONS 

9.1 Upfront Payment. Sanofi shall pay to RevMed a one-time, non-refundable, non-creditable upfront payment of $50,000,000 within [***] Business Days after the Effective Date. 

9.2 Milestone Payments. Upon first achievement of a milestone event described below in this Section 9.2 (a
“Milestone Event”) by Sanofi or any of its Affiliates or Sublicensees, Sanofi shall notify RevMed of such achievement and RevMed will issue an invoice to Sanofi for the corresponding one-time,
non-refundable and non-creditable milestone payment (a “Milestone Payment”). RevMed will also have the right to notify Sanofi in writing if RevMed
believes a Milestone Event has been achieved even if Sanofi has not provided such notice to RevMed, and unless Sanofi notifies RevMed within [***] Business Days after receipt of such notice from RevMed that such Milestone Event has not been
achieved, RevMed may issue an invoice to Sanofi for the corresponding Milestone Payment. Subject to the terms and conditions of this Agreement, Sanofi will pay to RevMed the following Milestone Payments within [***] after receipt of such invoice
therefor as follows: 
  

					
	 Milestone Event
	  	Milestone
Payment	 
	 (a) [***]
	  	 	[	***] 
	 (b) [***]
	  	 	[	***] 
	 (c) [***]
	  	 	[	***] 
	 (d) [***]
	  	 	[	***] 
	 (e) [***]
	  	 	[	***] 
	 (f) [***]
	  	 	[	***] 
	 (g) [***]
	  	 	[	***] 
	 (h) [***]
	  	 	[	***] 
	 (i) [***]
	  	 	[	***] 
	 (j) [***]
	  	 	[	***] 
	 (k) [***]
	  	 	[	***] 
	 (l) [***]
	  	 	[	***] 

  
 44 

					
	 Milestone Event
	  	Milestone
Payment	 
	 (m) [***]
	  	 	[	***] 
	 (n) [***]
	  	 	[	***] 
	 (o) [***]
	  	 	[	***] 
	 (p) [***]
	  	 	[	***] 
	 In no event shall the total Milestone Payments under this Agreement exceed:
	  	$	520,000,000	 

 Each Milestone Payment is due only once and will be payable only upon the first Product to achieve the
corresponding Milestone Event for the first time. 
 *For purposes of determining whether a Milestone Event has occurred with respect to the
EMA, a Marketing Approval must be obtained [***]. 
 The Milestone Payments shall be payable with respect to Initiation of any RevMed Study
only if [***]. 
 9.3 Royalty Payments for Products. 

(a) Royalty Rates for Royalties Payable by Sanofi on Net Sales outside the United States. Subject to the other terms of this
Section 9.3, during the Royalty Term, Sanofi shall make quarterly royalty payments to RevMed on aggregate Net Sales of each Product sold outside the United States during a Calendar Year at the applicable royalty rates as set forth below. For
clarity, royalties shall only be payable once on any sale of Product under this Agreement. 
  

					
	 Aggregate Net Sales of each Product outside the United States during
a Calendar Year
	  	Royalty Rate	 
	 Portion of aggregate Net Sales of each Product outside the United States during a Calendar Year
less than or equal to $[***]
	  	 	[	***]% 
	 Portion of aggregate Net Sales of each Product outside the United States during a Calendar Year
greater than $[***] and less than or equal to $[***]
	  	 	[	***]% 
	 Portion of aggregate Net Sales of each Product outside the United States during a Calendar Year
greater than $[***] and less than $[***]
	  	 	[	***]% 
	 Portion of aggregate Net Sales of each Product outside the United States during a Calendar Year
greater than $[***]
	  	 	[	***]% 

  
 45 

 (b) Royalty Term. Sanofi’s royalty payment obligations under this
Section 9.3 with respect to a particular Product and country shall commence upon the First Commercial Sale of such Product in such country (by Sanofi or its Affiliates or Sublicensees) and shall continue, on a Product-by-Product and country-by-country basis, until the latest of (i) the date on which there is no Valid Claim that
would be infringed by the sale of such Product in such country; (ii) the expiration of any Regulatory Exclusivity granted with respect to such Product in such country[***] (the “Royalty Term” for such Product and
country). 
 (c) Royalty Reductions. 

(i) In any country in which there is no Valid Claim and no Regulatory Exclusivity for such Product, at the time of sale of such
Product in such country during the applicable Royalty Term, Sanofi’s obligation to pay royalties under Section 9.3(a) on Net Sales of such Product in such country shall be reduced to [***]% of the rates otherwise payable under such
section. 
 (ii) If during the Royalty Term for a Product in a country, one or more Generic Products of such Product are sold
in such country, and during any Calendar Quarter following the Calendar Quarter in which such Generic Product(s) are first sold in such country (the “Launch Quarter”) Net Sales of such Product in such country during any Calendar
Quarter following the Launch Quarter are less than the Designated Percentage (as defined below) of average Net Sales occurring during the [***] immediately preceding the Launch Quarter (such average Net Sales during such Calendar Quarters, the
“Base Net Sales”), then the royalty rates provided in Section 9.3(a) for such Product shall be reduced in such country by the “Applicable Reduction Percentage” set forth below for such Calendar Quarter and for
all future Calendar Quarters, unless and until the Generic Product is no longer sold or the Net Sales increase above the Base Net Sales in a Calendar Quarter. If Net Sales of the applicable Product in a country in a Calendar Quarter following the
Launch Quarter for such country are: 
 A. lower than or equal to [***]%, but more than [***]%, of Base Net Sales of the applicable Product
in such country, then the Applicable Reduction Percentage shall be [***]%; or 
 B. lower than or equal to [***]% of Base Net Sales of the
applicable Product in such country, then the Applicable Reduction Percentage shall be [***]%. 
 (iii) If Sanofi enters into
an agreement with a Third Party in order to obtain a license or other right to a Third Party Right that is reasonably necessary to manufacture, use or sell a Product (or the SHP2 Inhibitor contained therein) in a country pursuant to
Section 10.7, Sanofi shall be entitled to deduct from the royalties payable under Section 9.3(a) with respect to such Product in such country in a particular Calendar Quarter [***] paid by Sanofi to such Third Party in respect of such
agreement for such Calendar Quarter, in each case to the extent reasonably allocable to such Third Party Right and such Product and country; provided that in no event shall the royalties payable for such Product and country in any Calendar Quarter
be reduced to less than [***]% of the amount otherwise due under Section 9.3(a) (the “Royalty Floor”). If any of such amounts cannot be offset against royalties due with respect to a Product for any Calendar Quarter because
they would result in royalties payable to RevMed being lower than the Royalty Floor, Sanofi shall have 

  
 46 

 
the right to carry forward and offset such excess amount against royalties or any other payments otherwise due to RevMed in subsequent Calendar Quarters up to a maximum reduction for each Quarter
of [***]% of the amounts owed in respect of such subsequent Calendar Quarter. Upon RevMed’s written request Sanofi shall provide a summary to RevMed with respect to the scope of the licensed rights and payments due pursuant to such Third Party
license, provided that RevMed may only make such a request one time for each Third Party license. 
 (d) Royalty Reports and Payment.

 (i) Within [***] after each Calendar Quarter, commencing with the Calendar Quarter during which the First Commercial Sale
of the first Product is made anywhere in the Licensed Territory, Sanofi shall provide RevMed with a report that contains the following information for the applicable Calendar Quarter: (i) on a country-by-country and Product-by-Product basis, the amount of Net Sales of the Products (which may be provided in Dollars or
Euros), (ii) on a country-by-country basis and on a Product-by-Product basis, a
calculation of the royalty payment due on such sales, and (iii) the exchange rate for such country. Within [***] following delivery of the applicable quarterly report, Sanofi shall pay in Dollars all royalties due to RevMed with respect to Net
Sales by Sanofi, its Affiliates and their respective Sublicensees for such Calendar Quarter. 
 (ii) Within [***] after each
Calendar Year, commencing with the Calendar Year during which the First Commercial Sale of the first Product is made anywhere in the Licensed Territory, Sanofi shall provide RevMed with [***]. 

(e) Clarifications. For the purpose of calculating the aggregate Net Sales of a particular Product for an applicable country to
determine the applicable royalty rate under Section 9.3, all Products containing the same SHP2 Inhibitor shall be deemed a single Product, regardless of form, formulation, dosage, packaging, other active ingredient or component, label or
intended patient population. All royalty payments under this Section 9.3 are non-refundable and non-creditable. 

9.4 U.S. Profit/Loss Share. No later than the Initiation of the first Registrational Clinical Trial for the first Product,
Sanofi and RevMed shall enter into a profit/loss share agreement (the “Profit/Loss Share Agreement”) pursuant to which the Parties shall equally share the Net Profit and Net Loss (as defined in Exhibit M of the
Correspondence) applicable with respect to Commercialization of Products (but, for clarity, not any costs of Development) of Products in the U.S. The Profit/Loss Share Agreement for a Product in the U.S. shall continue in effect until the expiration
of the Royalty Term for such Product in the U.S. and shall contain the terms and conditions set forth in Exhibit M of the Correspondence and other terms and conditions as are reasonable and customary for the sharing of profits and losses with
respect to similar products in the United States (including that each Party shall bear its own income taxes, that each Party is entitled to withhold any tax on behalf of the other Party on payments made to the other Party as required by Applicable
Law (taking into account any legally available reduction or elimination of such tax pursuant to an applicable tax treaty or otherwise), and each Party shall indemnify the other Party with respect to any withholding taxes asserted or assessed by any
taxing authority on amounts received directly by, or deemed allocable to, such other Party. 

  
 47 

 9.5 Payment Terms; Exchange Rate. Notwithstanding any term to the contrary of
this Agreement, RevMed shall deliver an invoice to Sanofi for all payments owed by Sanofi to RevMed under this Agreement. Sanofi will make all payments owed to RevMed within [***] after the date on which Sanofi receives an undisputed invoice for
such owed amount, except where a different timeframe is expressly provided in another Section of this Agreement (e.g., for the reimbursement of RevMed R&D Costs pursuant to Sections 4.5 and 5.5; the payment of the
buy-in payment pursuant to Section 5.6(b)B; the upfront payment set forth in Section 9.1; the royalties payable pursuant to Section 9.3, the payment of VAT pursuant to Section 9.7(b); and
the payment of unpaid or overpaid amounts pursuant to Section 9.9(b)). All payments to be made by a Party to the other Party under this Agreement shall be made in Dollars by bank wire transfer in immediately available funds to a bank account
designated by written notice from the Party that receives the payment. Conversion of Net Sales or reimbursable costs incurred hereunder that are recorded in local currencies to Dollars by a Party, its Affiliates or its or their Sublicensees shall be
performed in a manner consistent with its normal practices used to prepare its audited financial statements for internal and external reporting purposes. 

9.6 Late Payments. If a Party does not receive payment of any undisputed sum due to it on or before the due date therefor, then
it shall notify the paying Party. The paying Party shall pay interest on any undisputed late payments (before and after any judgment) at an annual rate (but with interest accruing on a daily basis) of the lesser of (a) [***] percent above the London
Interbank Offered Rate for deposits in Dollars having a maturity of one month published by the British Bankers’ Association, as adjusted from time to time on the [***] of each month, such interest to run from the date on which payment of such
sum became due until payment thereof in full together with such interest or (b) the maximum rate permitted by Applicable Law. 

9.7 Taxes. 
 (a)
General. Each Party shall be solely responsible for the payment of all income taxes imposed on its share of income arising directly or indirectly from the activities of the Parties under this Agreement. In the event that Sanofi is required,
under Applicable Law, to withhold any deduction or tax from any payment due to RevMed under this Agreement (taking into account any legally available reduction or elimination of such tax pursuant to an applicable tax treaty or otherwise), such
amount will be deducted from the payment to be made by Sanofi, paid to the proper taxing authority, and Sanofi will notify RevMed and upon RevMed’s request promptly provide RevMed with copies of any tax certificate or other documentation
evidencing such withholding, provided, however, that in the event that any such withholding tax arises as a result of Sanofi’s re-domiciliation, assignment of its rights or obligations hereunder to an
Affiliate, or use of any Third Party subcontractor, payments to RevMed hereunder shall be made on a grossed-up basis to ensure that RevMed receives the same amount it would have in the absence of such
withholding. Each Party agrees to cooperate with the other Party in claiming exemptions from such deductions or withholdings under any agreement or treaty from time to time in effect. 

(b) Value Added Tax. Notwithstanding anything contained in Section 9.7(a), this Section 9.7(b) will apply with respect to
value added tax (or sales, use or indirect tax) (“VAT”). All payments to be made by Sanofi hereunder are exclusive of VAT. If any VAT is chargeable in respect of any such payments, Sanofi will notify RevMed and pay VAT at the applicable
rate in respect of any such payments following the receipt of a VAT invoice in the appropriate form issued by RevMed in respect of those payments or Sanofi shall self-assess and pay such VAT, such VAT to be payable on the later of the due date of
the payment to which such VAT relates and [***] after the receipt by Sanofi of the applicable invoice relating to that VAT payment. 

  
 48 

 9.8 Records. Each Party shall, and shall cause its Affiliates and its and
their Sublicensees to, maintain complete and accurate financial books and records in sufficient detail to permit the other Party to confirm the accuracy of the amount of amounts payable under this Agreement. Each Party shall, and shall cause its
Affiliates and its and their Sublicensees to, retain such books and records until the later of (a) [***] after the end of the period to which such books and records pertain and (b) the expiration of the applicable tax statute of limitations (or
any extensions thereof) or for such longer period as may be required by Applicable Law. 
 9.9 Audit Procedures. 

(a) Upon reasonable prior notice of the other Party, but in any event at least [***] prior notice, each Party shall and shall cause its
Affiliates and its and their Sublicensees to permit an independent auditor of international prominence, selected by the auditing Party and reasonably acceptable to the audited Party, to audit the books and records maintained pursuant to
Section 9.8 for the sole purpose of verifying for the auditing Party the accuracy of the financial reports furnished by the audited Party pursuant to this Agreement or of any payments made, or required to be made, by or to the audited Party
pursuant to this Agreement or any Ancillary Agreement. Such audit shall not occur more than [***] in a given Calendar Year, unless for cause, and shall not concern books and records relating to a period more than [***] preceding the current Calendar
Year. Any failure by a Party to exercise its rights under this Section 9.9 with respect to a Calendar Year within such [***] period shall constitute a waiver by such Party of its right to later object to any payments made by the other Party
under this Agreement during such Calendar Year. 
 (b) Upon completion of the audit, the auditor shall provide a report to both Parties,
which report shall be limited to a description of any failure to comply with the terms of this Agreement and the amount of the financial discrepancy. Such auditor shall not disclose the audited Party’s Confidential Information to the auditing
Party, except to the extent such disclosure is necessary to verify the accuracy of the financial reports furnished by the audited Party or the amount of payments to or by the audited Party under this Agreement. Any amounts shown to be owed but
unpaid, or overpaid and in need of reimbursement, shall be paid or refunded (as the case may be) within [***] after the auditor’s report, plus interest (as set forth in Section 9.6) from the original due date (unless challenged in good
faith by the audited Party in which case any dispute with respect thereto shall be resolved in accordance with Section 15.6). 
 (c)
The auditing Party shall bear the full cost of such audit unless such audit reveals an underpayment by the audited Party that resulted from a discrepancy in the financial report provided by the audited Party for the audited period, which
underpayment was more than [***] percent of the amount set forth in such report, in which case the audited Party shall reimburse the auditing Party for the costs for such audit. 

(d) The auditing Party shall treat all information subject to review under this Section 9.9 in accordance with the confidentiality
provisions of Article XI and the Parties shall cause the auditor to enter into a reasonably acceptable confidentiality agreement with the audited Party obligating such auditor to retain all such financial information in confidence pursuant to such
confidentiality agreement. 

  
 49 

 Article X. 

INTELLECTUAL PROPERTY RIGHTS 

10.1 Ownership. 

(a) [***] Each Party shall ensure that every Third Party performing activities on behalf of such Party in connection with the Collaboration
executes a binding and enforceable invention assignment agreement assigning all of such Third Party’s right, title and interest in and to Program Inventions to such Party, provided that [***], provided that for those Permitted Contractors or
Researchers for whom [***], [***], or [***], provided that [***]. 
 (b) Subject to the other terms and conditions of this Agreement
(including the licenses and other rights granted under this Agreement or any Ancillary Agreement), each Party shall have the right to exploit, including license, the Joint Program Technology, without a duty of accounting or any obligation to seek
consent from the other Party to exploit such Joint Program Technology. To the extent necessary to effect the foregoing in a country other than the United States, each Party grants to the other Party a nonexclusive, irrevocable, perpetual,
fully-paid, worldwide license, with the right to grant sublicenses, under the granting Party’s interest in Joint Program Technology, for any and all purposes, provided that RevMed’s interest therein shall be subject to the other terms and
conditions of this Agreement, including the exclusive licenses granted herein (during the Term) and all payment obligations. 
 (c) Each
Party shall promptly disclose to the other Party in writing and shall cause its Affiliates, and its and their Sublicensees to so disclose, any Joint Program Know-How and any other Program Inventions. Each
Party shall also respond promptly to reasonable requests from the other Party for additional information relating to such Joint Program Know-How and other Program Inventions as reasonably necessary to exercise
such Party’s rights and perform its obligations, hereunder and under any Ancillary Agreement, with respect thereto. 
 10.2
Patent Prosecution. 
 (a) Sanofi Prosecuted Patents. Sanofi shall have the sole and exclusive right [***] to file, prosecute
and maintain the RevMed Licensed Patents and [***] (the “Sanofi Prosecuted Patents”), [***]. Such right shall be subject to [***], provided that [***]. RevMed shall transfer the applicable prosecution files for the RevMed Licensed
Patents to Sanofi within [***] after the Effective Date. Sanofi shall, through the JPC, consult with RevMed and keep RevMed reasonably informed of the status of the Sanofi Prosecuted Patents and shall promptly provide RevMed with all correspondence
received from any patent authorities in connection therewith, including with respect to Sanofi’s proposed timelines for submission of comments to patent authorities (to the extent not shared via the JPC). In addition, Sanofi shall promptly
provide RevMed, through the JPC, with drafts of all proposed material filings and correspondence to any patent authorities with respect to the Sanofi Prosecuted Patents for RevMed’s review and comment reasonably in advance of the intended
submission of such proposed filings and correspondence. Sanofi shall, through the 

  
 50 

 
JPC, confer with RevMed and take into consideration RevMed’s comments prior to submitting such proposed filings and correspondence. If RevMed does not provide such comments at least [***]
prior to the proposed submission date, then RevMed shall be deemed to have no comment to such proposed filings or correspondence. In case of disagreement between the Parties with respect to the filing, prosecution and maintenance of such Sanofi
Prosecuted Patents, the final decision shall be made pursuant to Section 2.10. 
 (b) Collaboration. RevMed shall provide Sanofi
all reasonable assistance and cooperation in the patent prosecution and maintenance efforts under this Section 10.2, including providing any necessary powers of attorney and executing any other required documents or instruments for such
prosecution or maintenance. 
 (c) Patent Listings. As between the Parties, [***]. 

10.3 CREATE Act. Notwithstanding anything to the contrary in this Article X, each Party shall have the right to invoke the
Cooperative Research and Technology Enhancement Act of 2005, 35 U.S.C. §102(c) (the “CREATE Act”) when exercising its rights under this Article X without the prior written consent of the other Party. Where such Party intends to
invoke the CREATE Act, as permitted by the preceding sentence, it shall notify the other Party and the other Party shall cooperate and coordinate its activities with the Party invoking the CREATE Act with respect to any submissions, filings or other
activities in support thereof. The Parties acknowledge and agree that this Agreement is a “joint research agreement” as defined in 35 U.S.C. § 100(h). 

10.4 Patent Enforcement and Defense. 

(a) Each Party shall promptly notify the other Party (but in any case no later than [***] after becoming aware) of any alleged or threatened
infringement by a Third Party of any of the RevMed Licensed Patents or Joint Program Patents, and RevMed shall promptly notify Sanofi (but in any case no later than [***] after becoming aware) of any alleged or threatened infringement by a Third
Party of any of the Sanofi Sole Program Patents, in each case including (i) any such alleged or threatened infringement on account of a Third Party’s manufacture, use or sale of a Product in the Field or (ii) any “patent
certification” filed in the United States under 21 U.S.C. §355(b)(2) or 21 U.S.C. §355(j)(2) or similar provisions in other jurisdictions in connection with an ANDA (an Abbreviated New Drug Application in the United States or a
comparable application for Regulatory Approval under Applicable Law in any country other than the United States) or other MAA for a Product in the Field and (iii) any declaratory judgment action filed by a Third Party that is developing,
manufacturing or commercializing a Product in the Field alleging the invalidity, unenforceability or non-infringement of any of the RevMed Licensed Patents, Joint Program Patents or Sanofi Sole Program Patents
((i)-(iii), collectively, “Product Infringement”). 
 (b) Sanofi, at its sole cost and expense, shall have the sole and
exclusive right, but not the obligation, to bring (or defend) and control any legal action in connection with any Product Infringement at its own expense, as it reasonably determines appropriate. 

(c) RevMed, at its sole cost and expense, shall have the sole and exclusive right to enforce the RevMed Licensed Patents for any infringement
that is not a Product Infringement at its own expense as it reasonably determines appropriate. Each Party shall have the right to enforce the Joint Program Patents for any infringement that is not a Product Infringement at its own expense as it
reasonably determines appropriate. Sanofi shall have the sole and exclusive right to enforce the Sanofi Sole Program Patents at its sole cost and expense. 

  
 51 

 (d) [***] 

(e) At the request of Sanofi, RevMed shall provide reasonable assistance in connection with any such suit or action, including by executing
reasonably appropriate documents, cooperating in discovery and joining as a party to the action if required (at Sanofi’s expense). In connection with a proceeding with respect to a Product Infringement covered by this Section 10.4, Sanofi
shall not enter into any settlement admitting the invalidity of, or otherwise impairing RevMed’s rights in, the RevMed Licensed Patents or Joint Program Patents without the prior written consent of RevMed. 

(f) Any recoveries resulting from an enforcement action relating to a claim of Product Infringement shall be first applied against payment of
each Party’s costs and expenses in connection therewith. Any such recoveries in excess of such costs and expenses (the “Remainder”) shall be shared by the Parties as follows. The Remainder shall, [***]. 

10.5 Trademarks. 

(a) Product Marks. Sanofi shall have the right to Commercialize the Products in the Licensed Territory, in accordance with Applicable
Law, using (i) the corporate Trademarks of Sanofi and its Affiliates, Sublicensees and Distributors and (ii) subject to Section 11.5(a)(ii), any other Trademarks it determines appropriate for such Products in such countries (such
Trademarks in clause (ii), the “Product Marks”), which may vary by country or within a country, provided that the Parties shall coordinate in good faith a global branding strategy with respect to the Products through the JCC
pursuant to Section 2.4(a). Sanofi shall own all rights in the Product Marks and shall have the sole right to register, prosecute and maintain the Product Marks using counsel of its own choice in the countries and regions in the Licensed
Territory that it determines reasonably necessary, at Sanofi’s cost and expense. 
 (b) Trademark Infringement. RevMed
shall provide to Sanofi prompt written notice of any actual or threatened infringement of the Product Marks and of any actual or threatened claim that the use of such Product Marks violates the rights of any Third Party, in each case, of which
RevMed becomes aware. Sanofi shall have the sole right to take such action as Sanofi deems necessary against a Third Party based on any alleged, threatened or actual infringement, dilution, misappropriation or other violation of or unfair trade
practices or any other like offense relating to, the Product Trademarks by a Third Party at its sole cost and expense, subject to Section 9.4, and using counsel of its own choice. Sanofi shall retain any damages or other amounts collected in
connection therewith. 
 (c) Domain Names. Sanofi shall have the sole right to register and shall own and control any domain names
for the Product Marks that it registers in any generic Top Level Domain (e.g., .com, .info, .net or .org) or in any country code Top Level Domain for any country in the Licensed Territory (e.g., .us for the United States and .ca for Canada). 

  
 52 

 10.6 Patent Extensions. 

(a) The Parties shall cooperate in obtaining patent term restoration (under but not limited to the U.S. Drug Price Competition and Patent Term
Restoration Act and its foreign equivalents), supplemental protection certificates or their equivalents, and patent term extensions with respect to the RevMed Licensed Patents and Joint Program Patents in any country or region where applicable. 

(b) Sanofi shall determine the RevMed Licensed Patents and Joint Program Patents for which it shall apply to extend in any country and notify
RevMed of such determination and any such extensions that are granted. Each Party shall provide all reasonable assistance to the other Party in connection with such filings and each Party shall bear its own costs with respect to such assistance.

 10.7 Third Party Rights. 

(a) If either Party reasonably determines, in consultation with the JRDC, that (i) the Research, Development, Manufacture, or
Commercialization of [***] infringes or misappropriates any Patent Right or other intellectual property right of a Third Party, such that such Party or its respective Affiliates or Sublicensees cannot [***] without infringing or misappropriating the
Patent Right or other intellectual property right of such Third Party (a “Third Party Right”) or (ii) [***], such Party shall notify the other Party (such notification, the “Third Party Right Notification”), and
promptly thereafter the Parties shall discuss obtaining a license to the applicable intellectual property right. 
 (b) Sanofi shall have
the first right, but not the obligation, through counsel of its choosing, to negotiate and obtain a license with respect to such Third Party intellectual property right and shall provide RevMed with a copy of such license if it obtains such a
license (to the extent permitted by the terms of such license, provided that Sanofi shall use Commercially Reasonable Efforts to obtain such permission to provide such copy). If Sanofi elects not to obtain such license, or fails to obtain such
license within [***] after the Third Party Right Notification, then RevMed shall have the right to obtain such license, with the right to grant the corresponding sublicense to Sanofi pursuant to Section 10.7(c). The Party negotiating a license
shall keep the other Party reasonably informed of the material terms for such prospective license applicable to the Products and shall consider in good faith the comments of such other Party with respect to such Third Party license. 

(c) If RevMed obtains such license, then notwithstanding anything to the contrary in this Agreement, the Patent Rights and Know-How licensed thereunder will be included in the RevMed Background Technology only if Sanofi provides RevMed with written notice within [***] following its receipt from RevMed of the substantive terms of the
license agreement, in which [***]. Sanofi shall [***] no later than [***] before the applicable due date therefor. 

  
 53 

 Article XI. 

CONFIDENTIALITY; PUBLICATION 

11.1 Duty of Confidence. At all times during the Term and for a period of [***] thereafter, subject to the other provisions of
this Article XI: 
 (a) all Confidential Information of a Party (the “Disclosing Party”) shall be maintained in confidence
and otherwise safeguarded by the other Party (the “Receiving Party”) and its Affiliates, using commercially reasonable efforts, but in any event no less than in the same manner and the same protections with which the Receiving Party
maintains its own confidential information; and 
 (b) the Receiving Party may only use any such Confidential Information for the purposes
of performing its obligations or exercising its rights under this Agreement or any Ancillary Agreement. 
 11.2 Exceptions.
The foregoing obligations shall not apply to the extent that the Receiving Party can demonstrate that any information: 
 (a) is known by the
Receiving Party at the time of its receipt without an obligation of confidentiality with respect to such information, and not through a prior disclosure by the Disclosing Party; 

(b) is in the public domain before its receipt from the Disclosing Party, or thereafter enters the public domain through no fault of the
Receiving Party; 
 (c) is subsequently disclosed to the Receiving Party by a Third Party who may lawfully do so and is not under an
obligation of confidentiality to the Disclosing Party with respect to such information; or 
 (d) is developed by the Receiving Party
independently and without use of or reference to any Confidential Information received from the Disclosing Party. 
 Any combination of features or
disclosures shall not be deemed to fall within the foregoing exclusions merely because individual features are published or available to the general public or in the rightful possession of the Receiving Party unless the combination itself and
principle of operation are published or available to the general public or in the rightful possession of the Receiving Party. 
 11.3
Authorized Disclosures. Notwithstanding the obligations set forth in Sections 11.1 and 11.5, a Party may disclose the other Party’s Confidential Information (including this Agreement and the terms herein) to the extent: 

(a) such disclosure: (i) is reasonably necessary for the filing or prosecuting Patent Rights as contemplated by Article X; (ii) is
reasonably necessary in connection with regulatory filings for the Products in the Field consistent with this Agreement; or (iii) is made to any Third Party bound by written obligations of confidentiality and
non-use similar to those set forth under this Article XI, to the extent otherwise necessary or appropriate in connection with the exercise of its rights or the performance of its obligations hereunder or under
any Ancillary Agreement; 
 (b) such disclosure is reasonably necessary: (i) to its and its Affiliates’, Sublicensees’ and
Distributors’ employees and subcontractors in connection with the exercise of its rights or the performance of its obligations hereunder or under any Ancillary Agreement; (ii) to such Party’s directors, attorneys, independent
accountants or financial advisors for the sole purpose of enabling 

  
 54 

 
such directors, attorneys, independent accountants or financial advisors to provide advice to such Party relating to this Agreement; or (iii) to actual or potential investors or Acquirers of
such Party solely for the purpose of evaluating or carrying out a bona fide investment in or acquisition of such Party; provided that in each case, (i), (ii) and (iii), such party(ies) to whom disclosure is made under this Section 11.3(b) shall
be bound by confidentiality and non-use obligations substantially consistent with those contained in the Agreement; or 

(c) such disclosure is required by Applicable Law, rules of a securities exchange or judicial or administrative process or is reasonably
necessary for prosecuting or defending litigation under Article X or Article XIV; provided that in such event such Party (to the extent legally permissible) shall promptly inform the other Party of such required disclosure and use reasonable efforts
to provide the other Party an opportunity to challenge or limit the disclosure obligations; provided, further that Confidential Information disclosed shall be limited to that information which is required under the relevant Applicable Law, rule,
judicial or administrative process or court or governmental order. Confidential Information that is so disclosed shall remain otherwise subject to the confidentiality and non-use provisions of this Article XI,
provided that the Party disclosing Confidential Information in such situation shall use reasonable efforts, including seeking confidential treatment or a protective order, to seek and obtain continued confidential treatment of such Confidential
Information. 
 11.4 Publications. The JRDC shall, directly or through a subcommittee (a) discuss and approve a
publication strategy and plan with respect to Development activities hereunder (including details of the Parties’ participation in appropriate conferences and scientific or medical publications relating to Products and processes for review of
proposed Publications by each Party) and (b) review and comment on and approve any Publication relating to the scientific or medical aspects of the Products in accordance with such strategy, and if applicable coordinate such review and comment
process with the JCC. The Parties acknowledge RevMed’s interest in publishing the results of the Research and Development activities under this Agreement in order to obtain recognition within the scientific, medical or other applicable
community, to advance the state of knowledge in the field, and RevMed’s need to fulfill its obligations to principal investigators and researchers with respect to publications under its relevant agreements; the need to protect Confidential
Information; and the Parties’ mutual interest in obtaining valid patent protection and protecting reasonable business interests and trade secret information. Consequently, each Party and their Affiliates, employee(s) and consultant(s) shall
deliver to the JRDC or the applicable subcommittee, and if applicable to the JCC, for review and comment a copy of any proposed Publication that pertains to SHP2 inhibition or any SHP2 Inhibitor or Product using Commercially Reasonable Efforts to
provide such copy at least [***] (but in no event less than [***] unless otherwise agreed by the Parties) prior to its intended submission or publication, and in accordance with the applicable strategy determined by the JRDC and the ICMJE guidelines
or other similar guidelines. The non-publishing Party shall have the right to require reasonable modifications of the Publication: (a) to protect the non-publishing
Party’s Confidential Information or trade secrets; or (b) to delay such submission for a reasonable time period (not to exceed [***]) as may be reasonably necessary to seek patent protection for the information disclosed in such proposed
submission to the extent consistent with Article X. 

  
 55 

 11.5 Publicity; Use of Names. 

(a) The Parties have agreed to issue a joint press release or separate press releases announcing this Agreement, subject to mutual agreement
by the Parties with respect to the content thereof and issued at a mutually agreed date and time. Subject to Sections 11.3 and 11.4 above and the remainder of this Section 11.5, (i) no other disclosure of the existence or the terms of this
Agreement or otherwise relating to this Agreement or the activities hereunder may be made by either Party or its Affiliates, and (ii) no Party shall use the name, trademark, trade name or logo of the other Party, its Affiliates or their
respective employees in any publicity, promotion, news release or disclosure relating to this Agreement or its subject matter, except in each case (i) and (ii) as provided in this Section 11.5 or as otherwise provided in this Agreement or
any Ancillary Agreement or with the prior express written permission of the other Party, except as may be required by Applicable Law. 
 (b)
If a Party is required by Applicable Law, rule or regulation to make a securities filing relating to the signing or effectiveness of this Agreement, or to the terms of this Agreement, with the appropriate Governmental Authorities (including the U.S.
Securities and Exchange Commission, and any securities exchange on which securities of such Party are listed), then the Party under such requirement will prepare a draft of such securities filing for review and comment by the other Party. If such
securities filing includes the disclosure of this Agreement and its terms, the Party under such disclosure obligation will submit a confidential treatment request and a proposed redacted version of this Agreement as part of such draft. Such draft
securities filing will, where possible, be provided to the other Party reasonably in advance of the deadline for such securities filing, and the other Party agrees to promptly (and in any event, no less than [***] (or such shorter time to meet any
filing deadline where it was not possible to provide the other Party with [***] notice) after receipt of such confidential treatment request and proposed redactions) give its input in a reasonable manner in order to allow the Party seeking
disclosure to file its request within the timelines proscribed by the regulations of applicable Governmental Authorities or securities exchange. The Party seeking such disclosure will use reasonable efforts to obtain confidential treatment of this
Agreement from the applicable Governmental Authority or securities exchange as represented by the redacted version reviewed by the other Party, provided that the Party seeking such disclosure shall, notwithstanding the foregoing, at all times have
the right to submit such disclosure in accordance with such requirement prior to or on the relevant deadline therefor. 
 (c) At any time
after the release of the initial press release(s) described in Section 11.5(a), each Party shall notify the other Party if it desires to disclose publicly (including on its website) any of the following: [***]. For clarity, this
Section 11.5 does not apply to scientific or medical Publications, which are governed by Section 11.4. If the other Party also desires to make such a public disclosure, the Parties will coordinate and agree upon the form, content and
timing of such disclosure. If the other Party does not desire to make such a public disclosure, the requesting Party may nonetheless make such disclosure so long as it provides the other Party with a draft of such disclosure at least [***] prior to
its intended release for such other Party’s review and comment. The non-disclosing Party shall have the right to require reasonable modifications of the disclosure: (a) to protect the non-publishing Party’s Confidential Information or trade secrets; or (b) to delay such disclosure for a reasonable time period (not to exceed [***]) as may be reasonably necessary to seek patent protection
for the information disclosed in such proposed submission to the extent consistent with Article X. If either Party requests to make any other disclosure with respect to this Agreement or the Collaboration (including any public statement or press
release) that is not otherwise permitted under this Agreement, the other Party shall reasonably consider such request. 

  
 56 

 11.6 Return of Confidential Information. Upon the effective date of the
termination of this Agreement for any reason in its entirety, or with respect to a Product, either Party may request in writing and the non-requesting Party shall (at the
non-requesting Party’s election), with respect to Confidential Information to which such non-requesting Party does not retain rights under the surviving provisions
of this Agreement (if applicable, with respect to the terminated Region or terminated Product) promptly destroy all copies of such Confidential Information in the possession or control of the non-requesting
Party and confirm such destruction in writing to the requesting Party. Notwithstanding the foregoing, the non-requesting Party shall be permitted to retain such Confidential Information (i) to the extent
necessary or useful for purposes of performing any continuing obligations or exercising any ongoing rights hereunder and, in any event, a single copy of such Confidential Information for archival purposes and (ii) any computer records or files
containing such Confidential Information that have been created solely by such non-requesting Party’s automatic archiving and back-up procedures, to the extent
created and retained in a manner consistent with such non-requesting Party’s standard archiving and back-up procedures, but not for any other uses or purposes. All
Confidential Information shall continue to be subject to the terms of this Agreement for the period set forth in Section 11.1. 

11.7 Attorney-Client Privilege. As to any Third Party, neither Party is waiving, nor shall be deemed to have waived or
diminished, any attorney work product protection or attorney-client privilege as a result of disclosing information pursuant to this Agreement, or any Confidential Information (including Confidential Information related to pending or threatened
litigation) to the Receiving Party, regardless of whether the Disclosing Party has asserted, or is or may be entitled to assert, such privileges and protections. The Parties: (a) share a common legal and commercial interest in such information
to the extent available under Applicable Law that is subject to such privileges and protections; (b) are or may become joint defendants in proceedings to which the information covered by such protections and privileges relates; (c) intend
that such privileges and protections remain intact should either Party become subject to any actual or threatened proceeding initiated by or against a Third Party to which the Disclosing Party’s Confidential Information covered by such
protections and privileges relates; and (d) intend that after the Effective Date both the Receiving Party and the Disclosing Party shall have the right to assert such protections and privileges as against a Third Party to the extent available
under Applicable Law. In the event of any litigation (or potential litigation) with a Third Party related to this Agreement or the subject matter hereof, the Parties shall, upon either Party’s request, enter into a reasonable and customary
joint defense agreement. Each Party shall consult in a timely manner with the other Party before producing information or documents in connection with litigation or other proceedings brought by or initiated against a Third Party that would likely
implicate privileges maintained by the other Party. Notwithstanding anything contained in this Section 11.7, nothing in this Agreement shall prejudice a Party’s ability to take discovery of the other Party in disputes between them relating
to the Agreement and no information otherwise admissible or discoverable by a Party shall become inadmissible or immune from discovery, including without limitation based on an assertion of attorney work product protection or attorney-client
privilege, solely by this Section 11.7. 

  
 57 

 11.8 Permitted Disclosure for CREATE Act. In order for a Party to exercise its
rights under Section 10.3, such Party shall be allowed to disclose in a patent application it prepares and files pursuant to this Agreement the names of the Parties to this Agreement, or amends a pending application it is prosecuting pursuant
to this Agreement to state the names of the Parties to this Agreement. 
 Article XII. 

TERM AND TERMINATION 

12.1 Term. The term of this Agreement shall commence upon the Effective Date and, unless earlier terminated pursuant to this
Article XII, shall continue in full force and effect until the expiration of Sanofi’s payment obligations under Article IX or the Profit/Loss Share Agreement, whichever is later (the “Term”). 

12.2 Termination. 

(a) Terminations by Sanofi. 

(i) Termination by Sanofi for Convenience. Sanofi may terminate this Agreement (A) in its entirety by providing
[***] written notice of termination to RevMed or (B) on a country-by-country or
Product-by-Product basis by providing [***] written notice of termination to RevMed; provided that if Sanofi desires to terminate this Agreement under this
Section 12.2(a)(i)B only with respect to the U.S. (for all Products or one or more Products), Sanofi shall provide [***] written notice of termination to RevMed.  

(ii) For a Change of Control of RevMed. RevMed will notify Sanofi in writing as soon as possible after RevMed
announces publicly any information regarding any proposed Change of Control of RevMed (or if the Change of Control will not be publicly announced, then no later than [***] after the signing of the Change of Control). Sanofi will have the option to
either (A) terminate this Agreement in its entirety upon written notice to RevMed provided to RevMed within [***] of the effective date of such Change of Control; or (B) [***]. 

(iii) For Safety. Sanofi will have the right to terminate this Agreement in its entirety or on a country-by-country or Product-by-Product basis, upon [***] prior written notice to RevMed, due
to safety concerns raised by a Regulatory Authority, an Institutional Review Board for a Clinical Trial or by Sanofi’s internal regulatory decision makers acting in accordance with Sanofi’s standard internal policies (any such
entity or group, a “Safety Reviewer”), where such Safety Reviewer recommends cessation of Development or Commercialization of such SHP2 Inhibitor or Product with respect to any SHP2 Inhibitor or Product (and a summary of such
concerns will be stated in the notice of termination). During such [***] notice period, each Party will continue to perform all of its obligations under this Agreement then in effect. 

  
 58 

 (b) Termination for Material Breach. If either Party believes that the other is in
material breach of this Agreement, then the non-breaching Party may deliver notice of such breach to the other Party. For all material breaches other than a failure to make a payment as set forth in this
Agreement, the allegedly breaching Party shall have [***] from such notice to dispute or cure such breach. For any material breach arising from a failure to make a payment set forth in this Agreement, the allegedly breaching Party shall have [***]
from the receipt of the notice to dispute or cure such breach. If the Party receiving notice of material breach under this Agreement fails to cure, or fails to dispute, such breach within the applicable time period set forth above, then the Party
originally delivering the notice of material breach may terminate this Agreement effective on written notice of termination to the other Party. If the allegedly breaching Party in good faith disputes such material breach or disputes the failure to
cure or remedy such material breach and provides written notice of that dispute to the other Party within the applicable period set forth above, the matter shall be addressed under the dispute resolution provisions in Section 15.6. During the
pendency of any such dispute, all of the terms and conditions of this Agreement will remain in effect and the Parties will continue to perform all of their respective obligations hereunder. 

(c) Termination for Insolvency. In the event that either Party (i) files for protection under bankruptcy or insolvency laws,
(ii) makes an assignment for the benefit of creditors, (iii) appoints or suffers appointment of a receiver or trustee over substantially all of its property that is not discharged within [***] after such filing, (iv) proposes a
written agreement of composition or extension of its debts, (v) proposes or is a party to any dissolution or liquidation, (vi) files a petition under any bankruptcy or insolvency act or has any such petition filed against it that is not
charged within [***] of the filing thereof or (vii) admits in writing its inability generally to meet its obligations as they fall due in the general course, then the other Party may terminate this Agreement in its entirety effective
immediately upon writing notice to such Party. 
 (d) Termination for Competing Product of Sanofi. If after [***]: (i) Sanofi or its
Affiliates, alone or with or through a Third Party, develop, manufacture or commercialize a Competing Product and (ii) Sanofi or its Affiliates have not commenced a Registrational Clinical Trial for a Product prior to commencing the activities
in Section 12.2(d)(i), RevMed may terminate this Agreement effective [***] after it delivers written notice to Sanofi that it is exercising its rights under this Section 12.2(d) unless Sanofi elects in writing within such [***] period to
[***]. 
 (e) Termination for Sanofi’s Decision to Cease [***] of Product. 

(i) If at any time during the period commencing on the Effective Date, there is a consecutive [***] period during which Sanofi
[***] and such [***] is not (A) by written agreement of the Parties, (B) a result of [***], (C) as a result of [***], (D) a result of [***], or (E) a direct result, in whole or in part, of [***], then RevMed shall promptly
notify Sanofi in writing upon becoming aware of such [***]. Alternatively, RevMed, no more often than [***], may request for Sanofi to notify RevMed whether there has been any [***] and Sanofi shall respond to such request within [***], providing
reasonable support for any assertion that [***]. Within another [***] following either receipt of notice from RevMed or receipt of any such response from Sanofi confirming [***], as applicable, the Parties shall meet (which may be by teleconference)
to discuss the nature and circumstances surrounding such [***]. Sanofi shall have [***] from such meeting date to cure such [***]. If Sanofi fails to cure such [***] within such [***] period, RevMed may terminate this Agreement upon written notice
to Sanofi.  

  
 59 

 (ii) If RevMed reasonably believes a [***] is likely to occur but it has not
yet been [***], RevMed may, no more than [***] per Calendar Year, request for the Parties to discuss such potential [***] and Sanofi’s intended plans with respect to [***], provided that, for clarity, such discussion shall not be deemed to
accelerate the timeframes specified above in Section 12.2(a). 
 12.3 Effects of Expiration or Termination. 

(a) General. Upon termination or expiration of this Agreement with respect to any particular Product or country, all rights and
obligations of the Parties under this Agreement with respect to such Product or country shall cease except as otherwise set forth in this Section 12.3 or elsewhere in this Agreement, but, for clarity, such termination or expiration shall not
affect the Parties’ rights and obligations under this Agreement with respect to the other Products or countries. 
 (b) Effect of
Expiration. Upon expiration of this Agreement, the licenses granted to Sanofi under Section 3.1 will become fully paid up, royalty free, perpetual and irrevocable. 

(c) Effect of Termination by Sanofi for Convenience, Change of Control or Termination by RevMed for
Sanofi’s Material Breach, Insolvency, Competing Product, or Cessation of [***]. Upon the termination of this Agreement by Sanofi pursuant to Section 12.2(a)(i) (Termination by Sanofi for Convenience) or
Section 12.2(a)(ii)A (Termination by Sanofi for Change of Control of RevMed) or by RevMed pursuant to Section 12.2(b) (Termination for Material Breach), 12.2(c) (Termination for Insolvency), 12.2(d) (Termination for Competing Product of
Sanofi) or 12.2(e) (Termination for Sanofi’s Decision to Cease [***] of Product), the following provisions shall apply: 

(i) License to Sanofi. All licenses and other rights granted to Sanofi under the RevMed Licensed Technology shall
terminate (except as necessary to permit Sanofi to perform its surviving obligations under this Article XII) and all rights thereunder shall revert to RevMed. 

(ii) Licenses. 

A. License Grants. 

1. RevMed License to SHP2 Inhibitors. Sanofi shall, effective upon any such termination of this Agreement, and
hereby does, grant to RevMed [***], under all [***], and [***], to [***]. Notwithstanding the foregoing, [***] shall not include [***], and [***] shall include [***] (to the extent [***]). 

2. RevMed License to Practice Certain Combinations. Sanofi shall, effective upon any such termination of this
Agreement, and hereby does, grant to RevMed [***], under [***], and [***] (but excluding [***]). For the avoidance of doubt, [***] licensed under this Section 12.3(c)(ii)(A)(2) do not [***]. 

  
 60 

 3. Sanofi License to Practice Certain Combinations. [***] RevMed
shall, effective upon any such termination of this Agreement, and hereby does, grant to Sanofi [***], under [***], and [***]. For the avoidance of doubt, [***] licensed under this Section 12.3(c)(ii)(A)(3) do not [***]. If Sanofi [***], Sanofi
shall so notify RevMed in writing, and [***]. 
 B. Third Party Restrictions. If the rights licensed to RevMed pursuant to
subsection A are sublicensed to RevMed under an agreement between Sanofi and a Third Party, then Sanofi shall so notify RevMed within [***] after the effective date of termination of this Agreement, and the foregoing licenses shall be subject to the
applicable provisions of such Third Party agreement (including any applicable payment obligations to the extent arising from the exercise of RevMed’s practice of its license under subsection A). RevMed shall have the right to terminate all or
any portion of the rights granted to it under subsection A, upon written notice to Sanofi. 
 C. Royalties. If this Agreement is
terminated in its entirety or with respect to one or more Products, other than by RevMed pursuant to Section 12.2(b) (Termination for Material Breach) or 12.2(c) (Termination for Insolvency), RevMed shall pay to Sanofi on a Product-by-Product basis royalties on sales of terminated Products (such Products, which for the purpose of clarity shall not include any
Non-SHP2 Product, hereinafter referred to as “Termination Products”), calculated based on worldwide Net Sales (as such term is applied mutatis mutandis to RevMed and including sales in
the U.S.) by RevMed and its Affiliates and Sublicensees of such Termination Products as follows: [***]. RevMed shall pay Sanofi such royalties until the earlier of (x) expiration of the Post-Termination Royalty Term therefor and (y) a
Change of Control of Sanofi. Upon any termination of this Agreement, RevMed shall pay to Sanofi any amounts owed to Third Parties under license agreements to which Sanofi is a party that grant Sanofi a license under such Third Party’s Patent
Rights or Know-How that is sublicensed to RevMed pursuant to Section 12.3(c)(ii)A, unless RevMed declines in writing to obtain such sublicense. “Post-Termination Royalty Term” means:
(I) with respect to a particular country and a particular Termination Product that is the subject of the royalty obligations under Section 12.3(c)(ii)B(1), the period of time commencing upon the First Commercial Sale of such Termination
Product in such country (by RevMed or its Affiliates or sublicensees) and ending upon the latest of (a) the date on which there is no Valid Claim (as such term is applied mutatis mutandis to Sanofi Sole Program Patents) of a Sanofi Sole
Program Patent that would be infringed by the sale of such Termination Product in such country; (b) the expiration of any Regulatory Exclusivity granted with respect to such Termination Product in such country[***] and (II) with
respect to a particular country and a particular Termination Product that is subject of the royalty obligations under Section 12.3(c)(ii)B(2) or Section 12.3(c)(ii)B(3), the period of time commencing upon the First Commercial Sale of such
Termination Product in such country (by RevMed or its Affiliates or sublicensees) and ending upon the latest of (a) the expiration of any Regulatory Exclusivity granted with respect to such Termination Product in such country; and (b) [***].

  
 61 

 (iii) Inventory Sell-Off
Period. In the case of a termination of this Agreement, Sanofi (with respect to the Termination Products in the Licensed Territory), shall be entitled, for a period of [***] after termination, to (i) complete Manufacture of work-in-progress, and (ii) continue conducting Commercialization activities being conducted by Sanofi hereunder as of such termination (if applicable, with respect to the terminated country(ies)), to the extent
related to such Termination Product in Sanofi’s inventory as of such termination (or added to such inventory as a result of the completion described in clause (i)), provided that Sanofi fulfills its payment obligations under this Agreement in
connection with such inventory sell-off, provided further that the sharing of Net Profits and Net Losses under the Profit/Loss Share Agreement shall continue to apply during the
sell-off period. For clarity, from and after the expiration of such [***] period all rights and licenses granted to Sanofi hereunder (if applicable, with respect to the terminated country(ies)) shall terminate
(except as necessary to permit Sanofi to perform its obligations under this Article XII). 
 (iv) Regulatory
Materials; Data. Within [***] after the effective date of such termination for Termination Products for which Regulatory Approval has been obtained prior to the effective date of such termination or [***] for other Termination Products (or as
promptly as practical thereafter, if such period is not practical under Applicable Law), Sanofi shall transfer and assign to RevMed all Regulatory Approvals relating to such Termination Products, and, to the extent not previously provided to RevMed,
transfer other Regulatory Materials including data from preclinical, non-clinical and clinical studies conducted by or on behalf of Sanofi, its Affiliates or Sublicensees on such Termination Products and all
pharmacovigilance data (including all adverse event databases) on such Termination Products. In addition, subject to any applicable provisions of any Third Party contract manufacturing agreement, Sanofi shall, or cause its Affiliate or Third Party
contract manufacturer to, grant RevMed and any of its Affiliates and Third Party contract manufacturer the right to reference any and all drug master files pertaining to Termination Products within the foregoing time period for the relevant
Termination Products. At RevMed’s reasonable request, for a period not to exceed [***] following the effective date of termination, Sanofi shall provide RevMed with assistance up to a total of [***] with any inquiries and correspondence with
Regulatory Authorities relating to any such Termination Product. [***] The foregoing shall not apply to the extent containing proprietary information or technology of any Third Party relating to proprietary active ingredients contained in
Combination Products or any Non-SHP2 Products, provided that Sanofi shall, for any Combination Products, upon written request by RevMed and to the extent permitted by the terms of its Third Party agreements,
provide reasonable assistance to RevMed to enable RevMed to access such information or technology by, for example, facilitating introductions to and discussions with the relevant Third Party with respect to such information or technology, provided
that such assistance shall count toward the [***] total set forth in the preceding sentence. 
 (v) Trademarks. Sanofi
shall transfer and assign, and shall ensure that its Affiliates transfer and assign, to RevMed, at no cost to RevMed, all Product Marks exclusively relating to any Termination Product, provided that such Product Marks do not contain the business
entity names of Sanofi or its Affiliates or variations thereof, except as may otherwise be required by Applicable Law during a transition period to avoid any interruptions in supply of Termination Product to patients. In such case if requested by
Sanofi, RevMed shall sign a non-royalty bearing trademark license agreement in the form mutually agreed by the Parties, as requested by Sanofi. 

  
 62 

 (vi) Transition Assistance. With regard to Termination
Products in countries for which the licenses to Sanofi are terminating, Sanofi shall provide the following transitional assistance, with costs allocated as set forth below: 

A. Each Party shall comply with Section 11.6 with regard to each Party’s Confidential Information. 

B. To the extent Sanofi has the right to do so, Sanofi shall promptly provide RevMed with a copy (which may be redacted in Sanofi’s
discretion if required to protect confidential information of Sanofi or a Third Party) of each license agreement, collaboration agreement or vendor agreement then effective between Sanofi (or its Affiliates) and a Third Party that exclusively
relates to any Termination Product, or the Development, Manufacture and Commercialization thereof, and, upon RevMed’s request, to the extent Sanofi has the right to do so, Sanofi shall assign or sublicense, and shall ensure that its Affiliates
assign or sublicense, to RevMed any such agreement(s). If Sanofi does not have the right to do so, Sanofi will provide RevMed with contact information for such Third Party so that RevMed may pursue an agreement directly with such licensor,
collaborator or vendor with respect to Termination Products. 
 C. Sanofi shall, at RevMed’s request, for a period not to exceed [***]
following the effective date of termination, provide reasonable technical assistance up to a total of [***] and, to the extent not already provided to RevMed, transfer copies of (including when available, in electronic format) all Sanofi Sole
Program Know-How to RevMed or its designee, including without limitation: [***], in each case to the extent such materials are exclusively related to the Termination Product. All such Know-How so provided to RevMed shall be deemed Confidential Information of Sanofi. Furthermore, Sanofi shall within [***] after the effective date of such termination, transfer to RevMed all files and documents
relating to the prosecution, defense or enforcement of the RevMed Licensed Patents or Joint Program Patents and provide reasonable assistance for a period not to exceed [***] following the effective date of termination, up to a total of [***], in
the transfer of the prosecution, defense and enforcement responsibilities to RevMed, including by executing any documents reasonable necessary therefor. 

D. At the end of the sell-off period set forth in Section 12.3(c)(iii), Sanofi shall transfer to
RevMed any and all inventory of SHP2 Inhibitors and Termination Products (including all research materials, final product, bulk drug substance, intermediates,
work-in-process, formulation materials, reference standards, drug product clinical reserve samples, packaged retention samples, and the like) then in the possession of
Sanofi, its Affiliates or Sublicensees, and continue or have continued any ongoing stability studies pertaining to any materials so transferred to RevMed for a reasonable period of time until RevMed can assume responsibility for such activities.
Notwithstanding the allocation of costs described below, all such inventory shall be purchased by RevMed at a price equal to [***]. 
 E.
If at the time of such termination, RevMed or its Affiliates are not Manufacturing a particular Termination Product, then, at RevMed’s request, Sanofi shall: (1) [***], provided that Sanofi shall in no case be obligated to [***], and provided
further that such [***]; and (2) if it has the right to do so, assign or transfer to RevMed any Manufacturing agreement between Sanofi and a Third Party contract manufacturer with respect to such Termination Product; or (3) conduct a
technology transfer analogous to that described in Section 7.2. 

  
 63 

 F. If at the time of such termination, Sanofi or its Affiliates are conducting any Clinical
Trials (including Registrational Clinical Trials) of a Termination Product, then, at RevMed’s election on a trial-by-trial basis, Sanofi shall cooperate, and shall
ensure that its Affiliates cooperate, with RevMed to transfer the conduct of all such Clinical Trials to RevMed within [***] after the effective date of such transfer (to the extent practical in light of applicable regulatory and patient safety
concerns) and RevMed shall assume any and all liability, and is liable, for such Clinical Trials conducted after the effective date of such termination (except to the extent Sanofi has an obligation of indemnification under Article XIV existing for
a claim that arose prior to the effective date of such termination). 
 G. If at the time of such termination, Sanofi or its Affiliates are
Commercializing a particular Termination Product, then, at RevMed’s request, the Parties shall negotiate in good faith a transition services agreement to cover detailing and promotion of such Termination Product (in the same manner and no more
extensive than the then-current detailing and promotional efforts of Sanofi) by Sanofi or its Affiliate or contract sales force pursuant to a transition plan agreed by the Parties for a period not to exceed [***], and RevMed shall pay Sanofi a
commercially reasonable amount to conduct such activities (which amount would include a commercially reasonable per-detail rate). 

H. In addition to the foregoing, Sanofi shall use reasonable efforts with respect to those activities for which it is responsible hereunder
to cooperate with RevMed to achieve an orderly transition of the Development, Manufacturing and Commercialization of Termination Products from Sanofi or its applicable Affiliate to RevMed. 

I. Except as provided in Sections 12.3(c)(vi)D-E, Sanofi’s activities under this
Section 12.3(c)(vi) shall be conducted [***]. 
 (d) Effect of Termination by Sanofi for Safety or for RevMed’s Material Breach
or Insolvency. Upon termination of this Agreement by Sanofi pursuant to Section 12.2(a)(iii) (Termination by Sanofi for Safety), Section 12.2(b) (Termination for Material Breach) or 12.2(c) (Termination for Insolvency), the following
provisions shall apply:  
 (i) License to Sanofi. All licenses and other rights granted to Sanofi under the
RevMed Licensed Technology under this Agreement shall terminate (except as necessary to permit Sanofi to perform its surviving obligations under this Article XII) and all rights thereunder shall revert to RevMed; provided, however, RevMed shall,
effective upon any such termination of this Agreement, and hereby does, grant to Sanofi a non-exclusive, worldwide license, with the right to grant sublicenses to contractors and otherwise only with
RevMed’s prior written consent, under each (1) RevMed Program Invention and (2) [***]. For the avoidance of doubt, the Patent Rights licensed under this Section 12.3(d)(i) do not include any [***]. 

  
 64 

 (ii) Inventory Sell-Off
Period. In the case of a termination of this Agreement, Sanofi (with respect to the Termination Products in the Licensed Territory), shall be entitled, for a period of [***] after termination, to (i) complete Manufacture of work-in-progress, and (ii) continue conducting Commercialization activities being conducted by Sanofi hereunder as of such termination (if applicable, with respect to the
terminated country(ies)), to the extent related to Termination Product in Sanofi’s inventory as of such termination (or added to such inventory as a result of the completion described in clause (i)), provided that Sanofi fulfills its payment
obligations under this Agreement in connection with such inventory sell-off, provided further that the payment of royalties to RevMed and the sharing of Net Profits and Net Losses under the Profit/Loss Share
Agreement shall continue to apply during the sell-off period. For clarity, from and after the expiration of such [***] period all rights and licenses granted to Sanofi hereunder (if applicable, with respect to
the terminated country(ies)) shall terminate (except as necessary to permit Sanofi to perform its obligations under this Article XII). 

(iii) Regulatory Materials; Data. Within [***] of the effective date of such termination (or as promptly as practical
thereafter, if such period is not practical under Applicable Law), [***], Sanofi shall transfer and assign to RevMed all Regulatory Approvals relating to Termination Products, and, to the extent not previously provided to RevMed, transfer other
Regulatory Materials including data from preclinical, non-clinical and clinical studies conducted by or on behalf of Sanofi, its Affiliates or Sublicensees on any Termination Products and all pharmacovigilance
data (including all adverse event databases) on any Termination Products. 
 (iv) Trademarks. [***], Sanofi shall
transfer and assign, and shall ensure that its Affiliates transfer and assign, to RevMed, [***], all Product Marks exclusively relating to any Termination Product, provided that such Product Marks do not contain the business entity names of Sanofi
or its Affiliates or variations thereof. 
 (e) Effect of Termination by Sanofi of [***] for Change of Control of RevMed. Upon
termination of [***] by Sanofi pursuant to Section 12.2(a)(ii)B (Termination by Sanofi for Change of Control) in the case of an Acquiror of RevMed that is a Major Biopharmaceutical Company, RevMed, [***], will (1) make available to Sanofi
copies of [***], (2) provide Sanofi with copies of [***], (3) provide Sanofi with all [***], and (4) otherwise provide Sanofi all reasonable assistance in [***]. Furthermore, in such case, except for [***], all Committees shall [***]. 

12.4 Survival. The following Sections and Articles shall survive the termination or expiration of this Agreement: Articles I
(Definitions) (to the extent necessary to give effect to the other Sections and Articles that survive under this Section 12.4) and XV (General Provisions) and Sections 5.8 (Development Records) (for the period stated therein), 9.8 (Records)
(for the period stated therein), 11.1 (Duty of Confidence), 11.2 (Exceptions), 11.3 (Authorized Disclosures), 11.5(a) and 11.5(b) (Publicity; Use of Names), 11.6 (Return of Confidential Information), 11.7 (Attorney-Client Privilege), 11.8 (Permitted
Disclosures for CREATE Act), 12.3 (Effects of Expiration or Termination), 12.4 (Survival), 12.5 (Accrued Rights and Obligations), 12.6 (Termination Not Sole Remedy), 14.1 (Indemnification by RevMed) (as to activities conducted during the Term), 14.2
(Indemnification by Sanofi) (as to activities conducted during the Term), 14.3 (Indemnification Procedure), 14.4 (Mitigation of Loss), and 14.5 (Limitation of Liability). 

  
 65 

 12.5 Accrued Rights and Obligations. Expiration or termination of this
Agreement shall not diminish either Party’s rights, or relieve either Party of any of its obligations, in each case that have been accrued prior to the effective date of such expiration or termination. 

12.6 Termination Not Sole Remedy. Except as set forth in Section 5.7, termination is not the sole remedy under this
Agreement and, whether or not termination is effected and notwithstanding anything contained in this Agreement to the contrary, all other remedies shall remain available except as agreed to otherwise herein. 

Article XIII. 
 REPRESENTATIONS,
WARRANTIES AND COVENANTS; CLOSING CONDITIONS 
 13.1 Representations and Warranties of Each Party. Each Party hereby
represents and warrants, as of the Execution, and covenants (as applicable) to the other Party as follows: 
 (a) It is a company or
corporation duly organized, validly existing, and in good standing under the laws of the jurisdiction in which it is incorporated, and has the full right, power and authority to enter into this Agreement, to perform its obligations hereunder. 

(b) (i) This Agreement has been duly executed by it and is legally binding upon it, enforceable in accordance with its terms, (ii) it has
taken all necessary corporate action on its part required to authorize the execution and delivery of this Agreement and, (iii) this Agreement, and the performance of its obligations hereunder, do not conflict with any agreement, instrument or
understanding, oral or written, to which it is a party or by which it may be bound, nor violate any material law or regulation of any court, governmental body or administrative or other agency having jurisdiction over it. 

(c) (i) It is familiar with the provisions and restrictions contained in the FCPA and has adopted and maintains an FCPA policy; (ii) it
shall comply with the FCPA in connection with its activities under this Agreement; (iii) it shall not, in the course of its activities under this Agreement, offer, promise, give, demand, seek or accept, directly or indirectly, any gift or
payment, consideration or benefit in kind that would or could be construed as an illegal or corrupt practice; and (iv) it is not a government official (as the term is defined in the FCPA) or affiliated with any government official. 

(d) (i) Neither it nor any of its Affiliates has been debarred or is subject to debarment pursuant to Section 306 of the FFDCA or
analogous provisions of Applicable Law outside the United States or listed on any Excluded List and (ii) neither it nor any of its Affiliates has, to its knowledge, used in any capacity, in connection with the activities to be performed under
this Agreement, any individual or entity that has been debarred pursuant to Section 306 of the FFDCA or analogous provisions of Applicable Law outside the United States, or that is the subject of a conviction described in such Section or
analogous provisions of Applicable Law outside the United States, or listed on any Excluded List. 
 (e) It will maintain throughout the
Term all permits, licenses, registrations and other forms of authorizations and approvals from any Governmental Authority, necessary or required to be obtained or maintained by such Party in order for such Party to execute and deliver this Agreement
and to perform its obligations hereunder in a manner which complies with all Applicable Law. 

  
 66 

 13.2 Representations and Warranties by RevMed. Except as disclosed in the
Disclosure Schedule to this Agreement in Exhibit N of the Correspondence, RevMed represents and warrants to Sanofi as of the Execution Date that: 

(a) RevMed has not had any Affiliates prior to the Execution Date and does not have any Affiliates as of the Execution Date; 

(b) RevMed is the sole and exclusive owner of all of the RevMed Background Technology, free and clear or all liens and encumbrances, and no
Third Party owns or possesses any right, title or interest in or to any of the RevMed Licensed Technology existing as of the Execution Date; 

(c) RevMed has not previously agreed to or otherwise committed to assign, transfer or convey or otherwise encumber its rights, title and
interests in and to RevMed Licensed Technology existing as of the Execution Date; 
 (d) To the Knowledge of RevMed, all Patent Rights owned
or Controlled by RevMed, existing as of the Execution Date, and reasonably necessary or useful for conducting the Collaboration or otherwise necessary or useful for Researching, Developing, Manufacturing, Commercializing or otherwise exploiting
Product in the Field, including the Development or Manufacture of the Products as contemplated in the initial Research Plan and Development Plan attached to this Agreement as of the Execution Date and Commercialization of the Products, as provided
hereunder are listed in Exhibit O of the Correspondence; 
 (e) RevMed has the right to grant the licenses and other rights expressly
granted herein to Sanofi, and it has not granted any license, right or interest in, to or under the RevMed Licensed Technology to any Third Party (or agreed to make any such grant) to exploit SHP2 Inhibitors or Products in the Field; 

(f) To RevMed’s Knowledge, the research and development of the Development Candidate and use of RevMed Background Know-How in connection therewith does not infringe the claims of any issued Patent or published patent application of any Third Party; 

(g) The research and development of the SHP2 Inhibitors and use of RevMed Background Know-How in
connection therewith does not misappropriate the Know-How of any Third Party; 
 (h) The research
and development of SHP2 Inhibitors (including pursuant to the activities set forth in the initial Research Plan and initial Development Plan) does not breach any obligation of confidentiality or non-use owed
by RevMed to a Third Party; 
 (i) To RevMed’s Knowledge, no Third Parties are misappropriating the RevMed Background Know-How and there are no activities by Third Parties that are infringing the RevMed Background Patents; 

  
 67 

 (j) There are no judgments or settlements against or owed by RevMed, and to RevMed’s
Knowledge, there are no pending claims or litigation or written threats of possible claims or litigation, in each case relating to the SHP2 Inhibitors or otherwise to RevMed Background Technology; 

(k) The issued RevMed Background Patents are valid, enforceable and subsisting, and the pending applications included in the RevMed Background
Patents are being prosecuted in accordance with Applicable Law in all material respects, and RevMed has presented all relevant references, documents and information of which it and the inventors are aware to the relevant patent examiners and patent
offices that are required to be so submitted under Applicable Law; 
 (l) The RevMed Background Patents have been filed and maintained
properly and correctly and all applicable fees have been paid on or before the due date for payment in all material respects; 
 (m) RevMed
has not received any written notice alleging that the RevMed Background Patents, existing as of the Execution Date, are or would be invalid or unenforceable or that the applications included in such RevMed Background Patents will not proceed to
grant; 
 (n) There (i) are no actual, pending or, to RevMed’s Knowledge, alleged or threatened, adverse actions, suits, claims,
interferences, re-examinations, oppositions, inventorship challenges or formal governmental investigations involving the RevMed Background Technology that are in or before any Governmental Authority, and
(ii) are no actual, pending or, to RevMed’s Knowledge, alleged or threatened, adverse actions, suits, claims, interferences, re-examinations, oppositions, inventorship challenges or formal
governmental investigations involving the RevMed Licensed Technology; 
 (o) The inventions claimed or covered by the RevMed Licensed
Technology (i) were not conceived, discovered, developed or otherwise made in connection with any research activities funded, in whole or in part, by the federal government of the United States or any agency thereof, (ii) are not a
“subject invention” as that term is described in 35 U.S.C. § 201(e), (iii) are not otherwise subject to the provisions of the Patent and Trademark Law Amendments Act of 1980, as amended, codified at 35 U.S.C. §§ 200-212, as amended, as well as any regulations promulgated pursuant thereto, including in 37 C.F.R. part 401, and (iv) are not the subject of any licenses, options or other rights of any other Governmental
Authority, within or outside the United States, due to such Governmental Authority’s funding of research and development or otherwise (other than the right to receive payments or any law of general application that applies to personal property
generally, e.g., takings laws); 
 (p) None of the RevMed Background Patents are licensed to RevMed from a Third Party; 

(q) There are no exclusivity provisions or any other restrictions in any agreement between RevMed or its Affiliates, on the one hand, and any
Third Party, on the other hand, of any SHP2 Inhibitor or Product, that would limit Sanofi’s ability to exercise its rights under this Agreement; 

  
 68 

 (r) All current and former officers, employees, and consultants of RevMed who are inventors
of or have otherwise contributed in a material manner to the creation or development of any RevMed Background Technology have executed and delivered to RevMed an assignment or other agreement regarding the protection of proprietary information and
the assignment to RevMed of inventions or work product created or generated in the course of employment by or providing services for RevMed, the current forms of which has been made available for review by Sanofi; 

(s) The portions of RevMed Background Know-How that are proprietary to RevMed and unpublished as of
the Execution Date and material to Research, Development, Manufacture or Commercialization of SHP2 Inhibitors or Products in the Field have been kept confidential by RevMed and have only been disclosed to Third Parties under obligations of
confidentiality, and to the Knowledge of RevMed, no such Third Party has breached any such confidentiality obligation to RevMed; 
 (t)
RevMed has included in the electronic dataroom for this Agreement all information in its possession that is material to the Research, Development, Manufacture or Commercialization of the Development Candidate as of the Execution Date, and such
information does not contain any untrue statement(s) of fact, or omit to state any fact(s), in either case that are collectively material to the Research, Development, Manufacture or Commercialization of the Development Candidate; and 

(u) To RevMed’s Knowledge, RevMed and its contractors and consultants have conducted all research and development of the SHP2 Inhibitors
and Products in material compliance with all Applicable Laws. 
 13.3 Covenants by RevMed. RevMed covenants to Sanofi
that: 
 (a) RevMed will not, and will cause its Affiliates not to, grant a lien on the RevMed Licensed Technology to any Third Party or
knowingly permit a lien to be imposed on the RevMed Licensed Technology other than those disclosed to Sanofi by RevMed and that do not conflict with the rights granted Sanofi hereunder. 

(b) RevMed will not, and will cause its Affiliates and (sub)contractors not to, use any government or not-for-profit organization funding that would encumber the RevMed Licensed Technology without the prior written consent of Sanofi, which consent may be withheld in Sanofi’s sole discretion. For clarity,
this Section 13.3(b) does not apply to Permitted Contractors and Researchers. 
 (c) At any time upon written request from Sanofi, if
the Parties mutually agree that an agreement between RevMed and a Permitted Contractor or Researcher should be amended to optimize language regarding assignment of inventions or intellectual property to ensure conformance with the principles
relating thereto set forth in this Agreement, RevMed will use Commercially Reasonable Efforts to cause such Permitted Contractors or Researchers to sign written agreements substantially in the form agreed upon by the Parties. 

  
 69 

 (d) With respect to the sponsored research agreements of RevMed in effect as of the
Effective Date, if after the Effective Date, there is a material amendment or modification to any such sponsored research agreement or work plan thereunder, and if Sanofi in good faith desires to assume and perform the subject research in-house and if Sanofi reasonably possesses the relevant expertise, capacity and applicable materials necessary for such research at such time (the “Capabilities”), then Sanofi shall notify
RevMed and if RevMed does not give notice to terminate such sponsored research agreement to the applicable Third Party under such agreement within [***] after Sanofi reasonably demonstrates that it has the Capabilities for such research activities,
then RevMed shall obtain a license to the intellectual property rights in any inventions arising out of such sponsored research such that they are “Controlled” by RevMed for purposes of this Agreement and RevMed shall [***]. 

13.4 Mutual Covenants. 

(a) No Debarment. In the course of the Research, Development, Manufacture and Commercialization of the Products, neither Party nor its
Affiliates shall use any employee or consultant who has been debarred by any Regulatory Authority or, to such Party’s or its Affiliates’ Knowledge, is the subject of debarment proceedings by a Regulatory Authority. Each Party shall notify
the other Party promptly upon becoming aware (in the case of Sanofi, by its compliance department) that any of its or its Affiliates’ employees or consultants has been debarred or is the subject of debarment proceedings by any Regulatory
Authority. 
 (b) Compliance. Each Party and its Affiliates shall comply in all material respects with all Applicable Law (including
all anti-bribery laws and laws applicable to the manufacture of human pharmaceuticals) in the Research, Development, Manufacture and Commercialization of the Products and performance of its obligations under
this Agreement and the Ancillary Agreements. 
 (c) Information. In addition to the requirements of Section 6.5, each Party will
provide the other Party with all information in its control reasonably necessary or desirable for such other Party to comply with its pharmacovigilance responsibilities in all countries in the Territory, including, as applicable, any adverse drug
experiences (including those events or experiences that are required to be reported to the FDA under 21 C.F.R. §§ 312.32 or 314.80 or to foreign Regulatory Authorities under corresponding Applicable Law outside the United States of
America) from pre-clinical or clinical laboratory, animal toxicology, pharmacology studies and clinical studies, in each case in the form reasonably requested by such other Party. 

13.5 No Other Warranties. EXCEPT AS EXPRESSLY STATED IN THIS ARTICLE XIII, (A) NO REPRESENTATION, CONDITION OR WARRANTY
WHATSOEVER IS MADE OR GIVEN BY OR ON BEHALF OF SANOFI OR REVMED; AND (B) ALL OTHER CONDITIONS AND WARRANTIES WHETHER WRITTEN OR ORAL OR EXPRESS OR IMPLIED ARE HEREBY EXPRESSLY EXCLUDED, INCLUDING ANY CONDITIONS AND WARRANTIES OF
MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE OR NON-INFRINGEMENT. 

  
 70 

 13.6 Closing Conditions. The obligations of each Party to
consummate the transactions contemplated by this Agreement and the Ancillary Agreements (the “Contemplated Transactions”) is subject to the fulfillment, or, to the extent permitted by Applicable Law, waiver by such Party, of each of
the following conditions (collectively, the “Closing Conditions”): 
 (a) The representations and warranties of the other
Party contained in this Agreement (i) that are not qualified by materiality, material adverse effect, substantial compliance or similar materiality qualifier will be true and correct in all material respects both when made and at the closing
with the same force and effect as if made on the Effective Date and (ii) that are qualified by materiality, material adverse effect, substantial compliance or similar materiality qualifier will be true and correct in all respects both when made
and at the closing with the same force and effect as if made on the Effective Date, except, in each of (i) and (ii) as would not reasonably be expected, individually or in the aggregate, to have a material impact on the transaction contemplated
by this Agreement. 
 (b) All actions by (including any authorization, consent or approval) in respect of (including notice to), or filings
with, any Governmental Authority or other Person that are required to be obtained pursuant to Section 3.8 to consummate the Contemplated Transactions (including any HSR/Antitrust Filing) will have been obtained or made, in a manner reasonably
satisfactory in form and substance to such Party, and no such authorization, consent or approval will have been revoked. 
 (c) No Material
Adverse Event shall have occurred or arisen since the Execution Date. 
 Article XIV. 

INDEMNIFICATION; LIABILITY; INSURANCE 

14.1 Indemnification by RevMed. RevMed shall indemnify, defend and hold harmless Sanofi, its Affiliates and their
respective officers, directors, agents and employees (“Sanofi Indemnitees”) from and against any Third Party Claims and Losses arising therefrom under or related to this Agreement against any of them to the extent arising or
resulting from:  
 (a) the negligence, recklessness or willful misconduct of any of the RevMed Indemnitees; or 

(b) the material breach of any of the warranties or representations made by RevMed to Sanofi under this Agreement or any Ancillary Agreement;
or 
 (c) the material breach by RevMed of any of its obligations pursuant to this Agreement or any Ancillary Agreement; 

except in each case ((a) through (c)), to the extent the applicable Third Party Claim and Losses arising therefrom arise or result from
(i) the negligence, recklessness or willful misconduct of any Sanofi Indemnitee; (ii) the breach of any of the warranties or representations made by Sanofi to RevMed under this Agreement or any Ancillary Agreement; or (iii) any breach
by Sanofi of its obligations pursuant to this Agreement or any Ancillary Agreement. 
 14.2 Indemnification by Sanofi. Sanofi
shall indemnify, defend and hold harmless RevMed, its Affiliates, and their respective officers, directors, agents and employees (“RevMed Indemnitees”) from and against any Third Party Claims and Losses arising therefrom
under or related to this Agreement against any of them to the extent arising or resulting from: 
 (a) (i) the Research, Development or
Manufacture of any Products by or on behalf of Sanofi or any of its Affiliates, Sublicensees or contractors (other than by RevMed or its Affiliates), or (ii) the Commercialization of Products by or on behalf of Sanofi; or 

  
 71 

 (b) the negligence, recklessness or willful misconduct of any of the Sanofi Indemnitees; or

 (c) the material breach of any of the warranties or representations made by Sanofi to RevMed under this Agreement or any Ancillary
Agreement; or 
 (d) the material breach by Sanofi of any of its obligations pursuant to this Agreement or any Ancillary Agreement; 

except in each case ((a) through (d)), to the extent the applicable Third Party Claim and Losses arising therefrom arise or result from
(i) the negligence, recklessness or willful misconduct of any RevMed Indemnitee; (ii) the breach of any of the warranties or representations made by RevMed to Sanofi under this Agreement or any Ancillary Agreement; or (iii) any breach
by RevMed of its obligations pursuant to this Agreement or any Ancillary Agreement. 
 14.3 Indemnification Procedure. 

(a) Notice of Claim. All indemnification claims in respect of any Sanofi Indemnitee or RevMed Indemnitee seeking indemnity under
Section 14.1 or Section 14.2 (collectively, the “Indemnitees” and each an “Indemnitee”) will be made solely by the corresponding Party (the “Indemnified Party”). The Indemnified Party will
give the indemnifying Party (the “Indemnifying Party”) prompt written notice (an “Indemnification Claim Notice”) of any Losses or discovery of fact upon which such Indemnified Party intends to base a request for
indemnification under Section 14.1 or Section 14.2, but failure to provide prompt notice will not relieve the Indemnifying Party from its obligation to indemnify the Indemnitee hereunder except to the extent any Losses result from such
delay in providing such notice. Each Indemnification Claim Notice must contain a description of the claim and the nature and amount of such Loss (to the extent that the nature and amount of such Loss are known at such time). Together with the
Indemnification Claim Notice, the Indemnified Party will furnish promptly to the Indemnifying Party copies of all notices and documents (including court papers) received by any Indemnitee in connection with the Third Party Claim. 

(b) Control of Defense. At its option, the Indemnifying Party may assume the defense of any Third Party Claim subject to
indemnification as provided for in Section 14.1 or Section 14.2 by giving written notice to the Indemnified Party within [***] after the Indemnifying Party’s receipt of an Indemnification Claim Notice. Upon assuming the defense of a
Third Party Claim, the Indemnifying Party may select and appoint the lead legal counsel for the defense of the Third Party Claim. Should the Indemnifying Party assume the defense of a Third Party Claim, the Indemnifying Party will not be liable to
the Indemnified Party or any other Indemnitee for any legal expenses subsequently incurred by such Indemnified Party or other Indemnitee in connection with the analysis, defense or settlement of the Third Party Claim. 

  
 72 

 (c) Right to Participate in Defense. Without limiting Section 14.3(b), any
Indemnitee will be entitled to participate in, but not control, the defense of such Third Party Claim and to employ counsel of its choice for such purpose; provided, however, that such employment will be at the Indemnitee’s own expense unless
(a) the employment thereof has been specifically authorized by the Indemnifying Party in writing, or (b) the Indemnifying Party has failed to assume the defense and employ counsel in accordance with Section 14.3(b) (in which case the
Indemnified Party will control the defense). 
 (d) Settlement. With respect to any Losses relating solely to the payment of money
damages in connection with a Third Party Claim and that will not result in the Indemnitee’s becoming subject to injunctive or other relief or otherwise adversely affect the business of the Indemnitee in any manner, and as to which the
Indemnifying Party has acknowledged in writing the obligation to indemnify the Indemnitee hereunder, the Indemnifying Party will have the sole right to consent to the entry of any judgment, enter into any settlement or otherwise dispose of such
Loss, on such terms as the Indemnifying Party, in its sole discretion, will deem appropriate. The Indemnifying Party will pay all amounts on behalf of the Indemnified Party at or prior to the time of the entry of judgment. With respect to all other
Losses in connection with Third Party Claims, where the Indemnifying Party has assumed the defense of the Third Party Claim in accordance with Section 14.3(b), the Indemnifying Party will have authority to consent to the entry of any judgment,
enter into any settlement or otherwise dispose of such Loss provided it obtains the prior written consent of the Indemnified Party (which consent will be at the Indemnified Party’s sole and absolute discretion). The Indemnifying Party that has
assumed the defense of the Third Party Claim in accordance with Section 14.3(b) will not be liable for any settlement or other disposition of a Loss by an Indemnitee that is reached without the written consent of such Indemnifying Party.
Regardless of whether the Indemnifying Party chooses to defend any Third Party Claim, no Indemnitee will admit any liability with respect to, or settle, compromise or discharge, any Third Party Claim without first offering to the Indemnifying Party
the opportunity to assume the defense of the Third Party Claim in accordance with Section 14.3(b). 
 (e) Cooperation. If the
Indemnifying Party chooses to defend any Third Party Claim, the Indemnified Party will, and will cause each other Indemnitee to, cooperate in the defense thereof and will furnish such records, information and testimony, provide such witnesses and
attend such conferences, discovery proceedings, hearings, trials and appeals as may be reasonably requested in connection with the defense of such Third Party Claim. Such cooperation will include access during normal business hours afforded to the
Indemnifying Party to, and reasonable retention by the Indemnified Party of, records and information that are reasonably relevant to such Third Party Claim, and making Indemnitees and other employees and agents available on a mutually convenient
basis to provide additional information and explanation of any material provided hereunder. The Indemnifying Party will reimburse the Indemnified Party for all its reasonable
out-of-pocket costs in connection with such cooperation. 

(f) Expenses. Except as provided above, the reasonable and verifiable costs and expenses, including fees and disbursements of counsel,
incurred by the Indemnified Party in connection with any claim will be reimbursed on a [***] by the Indemnifying Party, without prejudice to the Indemnifying Party’s right to contest the Indemnified Party’s right to indemnification and
subject to refund in the event the Indemnifying Party is ultimately held not to be obligated to indemnify the Indemnified Party. 

  
 73 

 14.4 Mitigation of Loss. Each Indemnified Party shall take and shall procure
that its Affiliates take all such reasonable steps and action as are reasonably necessary or as the Indemnifying Party may reasonably require in order to mitigate any Third Party Claims (or potential losses or damages) under this Article XIV.
Nothing in this Agreement shall or shall be deemed to relieve any Party of any common law or other duty to mitigate any losses incurred by it. 

14.5 Limitation of Liability. NEITHER PARTY SHALL BE LIABLE TO THE OTHER FOR ANY SPECIAL, CONSEQUENTIAL, INCIDENTAL, PUNITIVE,
OR INDIRECT DAMAGES OR LOST PROFITS ARISING FROM OR RELATING TO ANY BREACH OF THIS AGREEMENT, REGARDLESS OF ANY NOTICE OF THE POSSIBILITY OF SUCH DAMAGES. NOTWITHSTANDING THE FOREGOING, NOTHING IN THIS SECTION 14.5 IS INTENDED TO OR SHALL LIMIT OR
RESTRICT THE INDEMNIFICATION RIGHTS OR OBLIGATIONS OF ANY PARTY UNDER SECTION 14.1 OR SECTION 14.2, OR DAMAGES AVAILABLE FOR A PARTY’S BREACH OF ITS OBLIGATIONS RELATING TO CONFIDENTIALITY UNDER ARTICLE XI OR INTELLECTUAL PROPERTY UNDER ARTICLE
X. 
 14.6 Insurance. Each Party shall procure and maintain insurance, including product liability insurance, with respect to
its activities hereunder and under the Ancillary Agreements and which is consistent with normal business practices of companies similarly situated at all times during which any SHP2 Inhibitors or Product is being clinically tested in human subjects
or commercially distributed or sold. Sanofi may fulfill such obligation through self-insurance. Each Party shall provide the other Party with evidence of such insurance upon request and, in the case of RevMed, shall provide Sanofi with written
notice at least [***] prior to the cancellation, non-renewal or material changes in such insurance. It is understood that such insurance shall not be construed to create a limit of either Party’s
liability with respect to its indemnification obligations under this Article XIV. 
 Article XV. 

GENERAL PROVISIONS 

15.1 Force Majeure. Neither Party shall be held liable to the other Party nor be deemed to have defaulted under or breached this
Agreement for failure or delay in performing any obligation under this Agreement to the extent such failure or delay is caused by or results from causes beyond the reasonable control of the affected Party, including embargoes, war, acts of war
(whether war be declared or not), acts of terrorism, insurrections, riots, civil commotions, strikes, lockouts or other labor disturbances (whether involving the workforce of the nonperforming Party or of any other Person), fire, floods, earthquakes
or other acts of God, or acts, generally applicable action or inaction by any governmental authority (but excluding any government action or inaction that is specific to such Party, its Affiliates or Sublicensees, such as revocation or non-renewal of such Party’s license to conduct business), or omissions or delays in acting by the other Party, or unavailability of materials related to the Manufacture of the Products (each cause, an event of
“Force Majeure”). The affected Party shall give notice to the other Party in writing as soon as reasonably practical but no later than [***] after the occurrence of the event of Force Majeure, specifying the nature and extent of the
event of Force Majeure, its anticipated duration and any 

  
 74 

 
action being taken to avoid or minimize its effect. The suspension of performance allowed hereunder shall be of no greater scope and no longer duration than is reasonably required, and the
affected Party shall promptly undertake and continue diligently all reasonable efforts necessary to cure such force majeure circumstances or to perform its obligations in spite of the ongoing circumstances. In the event that RevMed is the non-performing Party and the Force Majeure continues for more than [***] (which period, in its entirety or a portion thereof, is prior to the commencement of the Registration Program for a Product, which Development
thereof is impacted by such Force Majeure), Sanofi’s payment obligations under Article IX shall be suspended until notification by RevMed to Sanofi of the termination of such Force Majeure Event (and any related triggers and deadlines shall be
similarly suspended). 
 15.2 Assignment; Change of Control. 

(a) Neither Party may assign this Agreement or any of its rights or obligations hereunder, except as expressly permitted hereunder, or
delegate any of its obligations under this Agreement, whether by operation of law or otherwise, in whole or in part, without the consent of the other Party, except as follows: 

(i) Sanofi may, without consent of RevMed, assign this Agreement or its rights and obligations hereunder in whole or in part to
any Affiliate of Sanofi, and RevMed may, with the consent of Sanofi (not to be unreasonably withheld, delayed or conditioned), assign this Agreement or its rights and obligations hereunder in whole or in part to any Affiliate of RevMed; and 

(ii) Either Party may, without consent of the other Party, assign this Agreement in whole to (i) in the case of RevMed,
its successor in interest or assignee or purchaser, as applicable, in the case of a Change of Control or (ii) in the case of Sanofi, its successor in interest or assignee or purchaser, as applicable, in connection with the sale of all or
substantially all of its assets to which this Agreement relates, or in connection with a merger, acquisition or similar transaction. In the case of Sanofi the intellectual property owned or controlled by any such successor in interest or assignee or
purchaser (such successor in interest or assignee or purchaser, as applicable, an “Acquiror”) or its Acquiror Family prior to the applicable Change of Control or other similar transaction immediately prior to such acquisition (other
than as a result of a license from the acquired Party) or thereafter developed outside the scope of this Agreement in accordance with this Agreement shall be excluded from [***] and the Acquiror Family shall be excluded from “Affiliate”
solely for purposes of the applicable components of the intellectual property definitions set forth herein. In the case of RevMed, the intellectual property owned or controlled by any such Acquiror or its Acquiror Family prior to the applicable
Change of Control or other similar transaction immediately prior to such acquisition (other than as a result of a license from the acquired Party) or is thereafter developed outside the scope of this Agreement in accordance with this Agreement shall
be excluded from the RevMed Licensed Technology, in each case only for so long as the remainder of the conditions of this Section 15.2 are met, and the Acquiror Family shall be excluded from “Affiliate” solely for purposes of the
applicable components of the intellectual property definitions set forth herein, in all such cases if and only if: (A) the acquired Party remains a wholly-owned subsidiary of the Acquiror; (B) all intellectual property of the Acquired
Party Family and 

  
 75 

 
all research and development assets and operations of the Acquired Party Family, in each case relating to SHP2 Inhibitors and Products, remain with the Acquired Party Family and are not licensed
or otherwise transferred to the Acquiror Party Family for any purpose; (C) the scientific and Development activities with respect to SHP2 Inhibitors and Products of the Acquired Party Family and Competing Products of the Acquiror Family (if
any) are maintained separate and distinct, and (D) there is no exchange of Know-How relating to SHP2 Inhibitors and Products between the Acquired Party Family and the Acquiror Family. Any attempted
assignment not in accordance with this Section 15.2 shall be null and void and of no legal effect. Any permitted assignee shall assume all assigned obligations of its assignor under this Agreement. The terms and conditions of this Agreement
shall be binding upon, and shall inure to the benefit of, the Parties and their respected successors and permitted assigns. For clarity, any assignment by Sanofi shall be subject to Section 9.7(a). 

(b) Except as part of a transaction permitted under this Section 15.2, in no event shall RevMed assign or transfer, or agree to assign or
transfer to any Third Party, any or all of the RevMed Licensed Patents without the consent of Sanofi, not be unreasonably withheld or conditioned. 

15.3 Severability. If any provision of this Agreement is held to be illegal, invalid or unenforceable under any present or
future law and if the rights or obligations of either Party under this Agreement will not be materially and adversely affected thereby, (i) such provision shall be fully severable, (ii) this Agreement shall be construed and enforced as if
such illegal, invalid or unenforceable provision had never comprised a part hereof, (iii) the remaining provisions of this Agreement shall remain in full force and effect and shall not be affected by the illegal, invalid or unenforceable
provision or by its severance here from and (iv) in lieu of such illegal, invalid or unenforceable provision, there shall be added automatically as a part of this Agreement a legal, valid and enforceable provision as similar in terms to such
illegal, invalid or unenforceable provision as may be possible and reasonably acceptable to the Parties. To the fullest extent permitted by Applicable Law, each Party hereby waives any provision of law that would render any provision hereof illegal,
invalid or unenforceable in any respect. 
 15.4 Notices. All notices which are required or permitted hereunder shall be in
writing and sufficient if delivered personally, sent by e-mail (and promptly confirmed by personal delivery, registered or certified mail or overnight courier), sent by an internationally-recognized overnight
courier or sent by registered or certified mail, postage prepaid, return receipt requested, addressed as follows: 
 If to RevMed: 

Revolution Medicines, Inc. 
 700
Saginaw Dr. 
 Redwood City, CA 94063 

USA 
 Attn: General Counsel 

Email: [***] 

  
 76 

 With a copy to: 

[***] 
 Latham & Watkins
LLP 
 140 Scott Drive 
 Menlo
Park, CA 94025 
 Fax: [***] 

If to Sanofi: 
 Sanofi 

50 Binney Street 
 Cambridge, MA
02142 
 Attn: [***] 
 With a
copy to: 
 Sanofi 
 50 Binney
Street 
 Cambridge, MA 02142 

Attn: [***] 
 or to such other
address(es) as the Party to whom notice is to be given may have furnished to the other Party in writing in accordance herewith. Any such notice shall be deemed to have been given: (a) when delivered if personally delivered or sent by facsimile
on a Business Day (or if delivered or sent on a non-Business Day, then on the next Business Day); (b) on the second (2nd) Business Day after dispatch if sent by an internationally-recognized overnight courier;
or (c) on the tenth (10th) Business Day following the date of mailing, if sent by mail. 
 15.5 Governing Law. This
Agreement shall be governed by and construed in accordance with the laws of the State of New York without reference to any rules of conflict of laws. 

15.6 Dispute Resolution. 

(a) Except for matters within the JSC’s authority that are resolved under Section 2.10, including through a Party’s exercise of
its final decision making authority in accordance therewith, and matters resolved pursuant to Section 5.6, any dispute, claim or controversy arising out of or relating to this Agreement, or the breach, termination, enforcement, interpretation
or validity thereof, including the determination of the scope or applicability of this Agreement to arbitrate (a “Dispute”) that is not resolved within [***] after written notice of the Dispute by one Party to the other shall be
determined by arbitration in [***] before [***] arbitrators, unless the Parties mutually agree in writing otherwise. The arbitration shall be administered by JAMS pursuant to its Comprehensive Arbitration Rules and Procedures then in effect and the
Expedited Procedures contained therein, as modified in this paragraph, except (i) to the extent such rules are inconsistent with this Section 15.6(a), in which case, this Section 15.6(a) shall control (including with regard to any
limitations of liability or forms of relief), and (ii) [***] discovery depositions may be 

  
 77 

 
conducted per side. The JAMS Expedited Procedures shall be modified to [***] of such procedures as in effect on the Effective Date, and the [***] shall be modified to provide that [***]. The
language of the arbitration shall be English. The proceedings and decisions of the arbitrator shall be final and binding on the Parties, and judgment on the award may be entered in any court having jurisdiction. 

(b) The Parties shall maintain the confidential nature of the arbitration proceeding and the award, including the hearing, except as may be
necessary to prepare for or conduct the arbitration hearing on the merits, or except as may be necessary in connection with a court application for a preliminary remedy, a judicial challenge to an award or its enforcement, or unless otherwise
required by law or judicial decision. All arbitration proceedings and decisions of the arbitrators under this Section 15.6(b) shall be deemed Confidential Information of both Parties under Article XI. 

(c) Within [***] after the commencement of arbitration, each Party shall select [***] within [***] of the commencement of the arbitration. If
the arbitrator selected by the Parties are unable or fail to agree upon [***] within the allotted time, [***] shall be appointed by JAMS in accordance with its rules. All arbitrators shall serve as a neutral, independent and impartial arbitrators.
Each arbitrator shall have not less than [***] years of experience in biotechnology or pharmaceutical industry disputes. 
 (d) The award
shall be rendered within [***] of the constitution of the arbitral tribunal, unless the arbitrators determine that the interest of justice requires that such limit be extended. 

(e) The arbitrators may award to the prevailing Party, if any, as determined by the arbitrators, the costs and attorneys’ fees reasonably
incurred by the prevailing Party in connection with the arbitration. If the arbitrators determine a Party to be the prevailing Party under circumstances where the prevailing Party won some but not all of the claims and counterclaims, the arbitrators
may award the prevailing Party an appropriate percentage of the costs and attorneys’ fees reasonably incurred by the prevailing Party in connection with the arbitration. 

(f) The arbitrators are not empowered to award punitive or exemplary damages, and the Parties waive any right to recover any such damages.

 (g) Unless the Parties otherwise agree in writing, during the period of time that any arbitration proceeding is pending under this
Agreement, (i) the Parties shall continue to comply with all those terms and provisions of this Agreement that are not the subject of the pending arbitration proceeding; and (ii) in the event that the subject of the dispute relates to the
exercise by a Party of a termination right hereunder, including in the case of a material breach of this Agreement, the effectiveness of such termination shall be stayed until the conclusion of the proceedings under this Section 15.6. 

(h) Notwithstanding the foregoing, any dispute, controversy or claim relating to the scope, validity, enforceability or infringement of any
Patent Rights or Trademark covering the manufacture, use, importation, offer for sale or sale of Products shall be submitted to a court of competent jurisdiction in the country in which such Patent Rights or Trademark were granted or arose. 

  
 78 

 (i) Notwithstanding anything to the contrary in Section 15.6(c), any dispute relating
to the ownership of any Program Invention shall be finally adjudicated, according to U.S. patent law, by an independent U.S. patent counsel with appropriate expertise that is jointly appointed by Sanofi and RevMed. Some adjudication shall be
completed within [***] after such counsel is appointed, and such counsel must be appointed within [***] after submission of the issue for resolution. 

(j) Nothing in this Section 15.6 will preclude either Party from seeking equitable relief or interim or provisional relief from a court
of competent jurisdiction, including a temporary restraining order, preliminary injunction or other interim equitable relief, either prior to or during any arbitration. 

15.7 Rights in Bankruptcy. All rights and licenses granted under or pursuant to this Agreement by Sanofi or RevMed are and shall
otherwise be deemed to be, for purposes of Section 365(n) of the U.S. Bankruptcy Code or any analogous provisions in any other country or jurisdiction, licenses of right to “intellectual property” as defined under Section 101 of
the U.S. Bankruptcy Code. The Parties agree that the Parties, as licensees of such rights under this Agreement, shall retain and may fully exercise all of their rights and elections under the U.S. Bankruptcy Code or any analogous provisions in any
other country or jurisdiction. The Parties further agree that, in the event of the commencement of a bankruptcy proceeding by or against either Party under the U.S. Bankruptcy Code or any analogous provisions in any other country or jurisdiction,
the Party hereto that is not a Party to such proceeding shall be entitled to a complete duplicate of (or complete access to, as appropriate) any such intellectual property and all embodiments of such intellectual property, which, if not already in
the non-subject Party’s possession, shall be promptly delivered to it (i) upon any such commencement of a bankruptcy proceeding upon the non-subject
Party’s written request therefor, unless the Party subject to such proceeding elects to continue to perform all of its obligations under this Agreement or (ii) if not delivered under clause (i) above, following the rejection of this
Agreement by or on behalf of the Party subject to such proceeding upon written request therefor by the non-subject Party. The Parties acknowledge and agree that payments made under Section 9.1 and
Section 9.2 or pursuant to the Co-Promotion Agreement shall not (x) constitute royalties within the meaning of Section 365(n) of the U.S. Bankruptcy Code or any analogous provisions in any other
country or jurisdiction or (y) relate to licenses of intellectual property hereunder. 
 15.8 No Action. In no event
shall either Party be obligated under the Agreement to take any action or omit to take any action that such Party believes, in good faith, would cause it to be in violation of any Applicable Law. 

15.9 Entire Agreement; Amendments. This Agreement, together with the Correspondence and the Exhibits hereto and thereto,
contains the entire understanding of the Parties with respect to the collaboration and the licenses granted hereunder. Any other express or implied agreements and understandings, negotiations, writings and commitments, either oral or written, in
respect to the collaboration and the licenses granted hereunder are superseded by the terms of this Agreement. The Exhibits to this Agreement and the Correspondence are incorporated herein by reference and shall be deemed a part of this Agreement.
This Agreement may be amended, or any term hereof modified, only by a written instrument duly executed by authorized representatives of both Parties hereto. The Parties agree that, effective as of the Effective Date,

  
 79 

 
that certain Confidentiality Agreement between an Affiliate of Sanofi and RevMed dated as of June 21, 2017, as amended (“Confidentiality Agreement”) shall be superseded by
this Agreement, and that disclosures made prior to the Effective Date pursuant to the Confidentiality Agreement shall be subject to Article XI. 

15.10 Exhibits/Ancillary Agreements. In the event there is a conflict or inconsistency between or among the terms of this
Agreement, the terms of the Correspondence, the terms of any Exhibit hereto or thereto, or the terms of any Ancillary Agreement, the order of precedence for resolution of such conflict or inconsistency in descending order shall be as follows:
(i) this Agreement, (ii) the Correspondence, (iii) any Exhibit or Schedule of this Agreement or the Correspondence; (iii) any Ancillary Agreement; and (iv) any exhibit or schedule of any Ancillary Agreement. 

15.11 Headings. The captions to the several Articles, Sections, subsections and Exhibits hereof are not a part of this
Agreement, but are merely for convenience to assist in locating and reading the several Articles, Sections, subsections and Exhibits hereof. 

15.12 Independent Contractors. It is expressly agreed that RevMed and Sanofi shall be independent contractors and that the
relationship between the two Parties shall not constitute a partnership, joint venture or agency. Neither RevMed nor Sanofi shall have the authority to make any statements, representations or commitments of any kind, or to take any action, which
shall be binding on the other Party, without the prior written consent of the other Party. 
 15.13 Waiver. The waiver by
either Party hereto of any right hereunder, or of any failure of the other Party to perform, or of any breach by the other Party, shall not be deemed a waiver of any other right hereunder or of any other breach by or failure of such other Party
whether of a similar nature or otherwise. 
 15.14 Cumulative Remedies. No remedy referred to in this Agreement is intended to
be exclusive, but each shall be cumulative and in addition to any other remedy referred to in this Agreement or otherwise available under law. 

15.15 Waiver of Rule of Construction. Each Party has had the opportunity to consult with counsel in connection with the review,
drafting and negotiation of this Agreement. Accordingly, the rule of construction that any ambiguity in this Agreement shall be construed against the drafting Party shall not apply. 

15.16 Business Day Requirements. In the event that any notice or other action or omission is required to be taken by a Party
under this Agreement on a day that is not a Business Day then such notice or other action or omission shall be deemed to be required to be taken on the next occurring Business Day. 

15.17 Translations. This Agreement is in the English language only, which language shall be controlling in all respects, and all
versions hereof in any other language shall be for accommodation only and shall not be binding upon the Parties. All communications and notices to be made or given pursuant to this Agreement, and any dispute proceeding related to or arising
hereunder, shall be in the English language. If there is a discrepancy between any translation of this Agreement and this Agreement, this Agreement shall prevail. 

  
 80 

 15.18 Further Actions. Each Party agrees to execute, acknowledge and deliver
such further instruments, and to do all such other acts, as necessary or appropriate in order to carry out the purposes and intent of this Agreement. 

15.19 Counterparts. This Agreement may be executed in two or more counterparts by original signature, facsimile or PDF files,
each of which shall be deemed an original, but all of which together shall constitute one and the same instrument. 
 [REMAINDER OF PAGE
INTENTIONALLY LEFT BLANK] 

  
 81 

 IN WITNESS WHEREOF, the Parties intending to be bound have caused this Collaborative
Research, Development and Commercialization Agreement to be executed by their duly authorized representatives as of the Effective Date. 
  

			
	Revolution Medicines, Inc.	 	Aventis, Inc.
		
	By:      /s/ Mark A. Goldsmith, M.D., Ph.D.	 	By:      /s/ Douglas J. McCormack
	Name: Mark A. Goldsmith, M.D., Ph.D.	 	Name: Douglas J. McCormack
	Title:   President & Chief Executive Officer	 	Title:   Vice President

 Aventis, Inc. 

c/o Sanofi 
 50 Binney
Street 
 Cambridge, MA 02142 

August 24, 2018 
 Revolution Medicines, Inc. 

700 Saginaw Dr.
 Redwood City, CA 94063 

Attention: General Counsel 
 Re: Amendment to Collaborative
Research, Development and Commercialization Agreement  
 Dear Revolution Medicines, Inc.: 

Reference is hereby made to that certain Collaborative Research, Development and Commercialization Agreement (the “Collaboration
Agreement”), dated as of June 8, 2018, by and between Revolution Medicines, Inc. (“RevMed”) and Aventis, Inc. (“Sanofi”). Capitalized terms used but not defined in this letter agreement (this
“Letter”) shall have the meanings assigned to them in the Collaboration Agreement. 
 Each of RevMed and Sanofi
acknowledges and agrees as follows: 
 1. Amendment to Section 6.5 of the Collaboration Agreement. The first
sentence of Section 6.5 of the Collaboration Agreement is hereby amended and restated in its entirety as follows: 
 “Following the
Effective Date, but in any case prior to the Initiation of the first Clinical Trial sponsored by Sanofi for a Product, the Parties shall enter into a pharmacovigilance agreement setting forth the worldwide pharmacovigilance procedures for the
Parties with respect to the Products, such as safety data sharing, adverse events reporting and safety profile monitoring (the “Pharmacovigilance Agreement”).” 

2. No Other Amendments. This Letter shall be deemed to be a part of and incorporated into the Collaboration Agreement. In the
event of a conflict between this Letter and the Collaboration Agreement, this Letter shall control. Except as expressly set forth in this Letter, all of the terms and conditions of the Collaboration Agreement shall remain unchanged and are ratified
and confirmed in all respects and remain in full force and effect. 
 3. Entire Agreement. This Letter, together with the
Collaboration Agreement and any exhibits or attachments thereto (including, without limitation, the Correspondence and the Exhibits thereto), constitutes the entire agreement between the Parties regarding the subject matter hereof, and any reference
to the Collaboration Agreement shall refer to the Collaboration Agreement, as amended by this Letter. 
 4. Counterparts. This
Letter may be executed in one (1) or more counterparts, each of which will be deemed an original, but all of which together will constitute one and the same instrument. 

 5. Governing Law. This Letter shall be
governed by and construed in accordance with the laws of the State of New York without reference to any rules of conflict of laws. 

[Remainder of Page Intentionally Left Blank] 

 Please indicate your agreement by countersigning in the space provided below and returning a
copy to my attention. 
 Sincerely, 
 Aventis, Inc.

  

			
	By:	 	/s/ Douglas J. McCormack
	Name:	 	Douglas J. McCormack
	Title:	 	Vice President

 Acknowledged and Agreed:  

Revolution Medicines, Inc. 
  

			
	By:	 	/s/ Mark A. Goldsmith
	Name:	 	Mark A. Goldsmith
	Title:	 	Chief Executive Officer

 [Signature Page to Letter Agreement]EX-10.2

 Exhibit 10.2 

EXECUTION VERSION 
  

 
 REVOLUTION MEDICINES, INC.

 AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT 

June 5, 2019 
  

 

 AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT 

THIS AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT (this “Agreement”), is made as of the 5th day of
June, 2019, by and among REVOLUTION MEDICINES, INC., a Delaware corporation (the “Company”), and each of the investors listed on Schedule A hereto, each of
which is referred to in this Agreement as an “Investor,” and any Additional Purchaser (as defined in the Purchase Agreement) that becomes a party to this Agreement in accordance with Section 6.9
hereof (collectively, “Investors”), and amends and restates that certain Investors’ Rights Agreement, dated as of March 23, 2018, by and among the Company and the investors listed on Schedule A thereto, as amended
(the “Prior Agreement”). 
 RECITALS 

WHEREAS, the Company and certain of the Investors (the “Existing Investors”) are parties to the Prior
Agreement; 
 WHEREAS, the Company and certain of the Investors (the “Participating Investors”) are parties
to the Series C Preferred Stock Purchase Agreement dated June 2, 2019 (the “Purchase Agreement”); 

WHEREAS, in order to induce the Company to enter into the Purchase Agreement and to induce the Participating Investors to invest funds
in the Company pursuant to the Purchase Agreement, the Existing Investors and the Company hereby agree that the Prior Agreement shall be amended and restated in its entirety, and this Agreement shall govern the rights of the Investors to cause the
Company to register shares of Common Stock (as defined below) issuable to the Investors, to receive certain information from the Company, and to participate in future equity offerings by the Company, and shall govern certain other matters as set
forth in this Agreement; and 
 WHEREAS, pursuant to Section 6.6 of the Prior Agreement, the amendment or waiver of any term of
the Prior Agreement requires the written consent of the Company and the holders of at least a majority of the Registrable Securities (as defined in the Prior Agreement) then outstanding. The undersigned, representing the Company and the holders of
at least a majority of the Registrable Securities (as defined in the Prior Agreement) then outstanding, desire to enter into this Agreement in order to amend and restate the Prior Agreement, as set forth more fully below. 

NOW, THEREFORE, the parties hereby agree as follows: 

1. Definitions. For purposes of this Agreement: 

1.1 “Affiliate” means, with respect to any specified Person, any other Person who, directly or
indirectly, controls, is controlled by, or is under common control with such Person, including without limitation any general partner, managing member, officer or director of such Person, or any venture capital fund or other investment fund now or
hereafter existing that is controlled by one or more general partners or managing members of, or shares the same management company or investment advisor with, such Person. 

  
 1 

 1.2 “Common Stock” means shares of the
Company’s common stock, par value $0.0001 per share. 
 1.3 “Damages” means any loss, damage,
claim or liability (joint or several) to which a party hereto may become subject under the Securities Act, the Exchange Act, or other federal or state law, insofar as such loss, damage, claim or liability (or any action in respect thereof) arises
out of or is based upon: (i) any untrue statement or alleged untrue statement of a material fact contained in any registration statement of the Company, including any preliminary prospectus or final prospectus contained therein or any
amendments or supplements thereto; (ii) an omission or alleged omission to state therein a material fact required to be stated therein, or necessary to make the statements therein not misleading; or (iii) any violation or alleged violation
by the indemnifying party (or any of its agents or Affiliates) of the Securities Act, the Exchange Act, any state securities law, or any rule or regulation promulgated under the Securities Act, the Exchange Act, or any state securities law. 

1.4 “Derivative Securities” means any securities or rights convertible into, or exercisable or
exchangeable for (in each case, directly or indirectly), Common Stock, including options and warrants. 
 1.5
“Exchange Act” means the Securities Exchange Act of 1934, as amended, and the rules and regulations promulgated thereunder. 

1.6 “Excluded Registration” means (i) a registration relating to the sale of securities to
employees of the Company or a subsidiary pursuant to a stock option, stock purchase, or similar plan; (ii) a registration relating to an SEC Rule 145 transaction; (iii) a registration on any form that does not include substantially the
same information as would be required to be included in a registration statement covering the sale of the Registrable Securities; or (iv) a registration in which the only Common Stock being registered is Common Stock issuable upon conversion of
debt securities that are also being registered. 
 1.7 “Form
S-1” means such form under the Securities Act as in effect on the date hereof or any successor registration form under the Securities Act subsequently adopted by the SEC. 

1.8 “Form S-3” means such form under the Securities Act as in
effect on the date hereof or any registration form under the Securities Act subsequently adopted by the SEC that permits incorporation of substantial information by reference to other documents filed by the Company with the SEC. 

1.9 “GAAP” means generally accepted accounting principles in the United States. 

  
 2 

 1.10 “Holder” means any holder of Registrable
Securities who is a party to this Agreement. 
 1.11 “Immediate Family Member” means a child,
stepchild, grandchild, parent, stepparent, grandparent, spouse, sibling, mother-in-law,
father-in-law, son-in-law, daughter-in-law, brother-in-law, or
sister-in-law, including, adoptive relationships, of a natural person referred to herein. 

1.12 “Initiating Holders” means, collectively, Holders who properly initiate a registration request
under this Agreement. 
 1.13 “IPO” means the Company’s first underwritten public offering of
its Common Stock under the Securities Act. 
 1.14 “Key Employee” means any executive-level employee
(including, division director and vice president-level positions) as well as any employee who, either alone or in concert with others, develops, invents, programs, or designs any Company Intellectual Property (as defined in the Purchase Agreement).

 1.15 “Major Investor” means any Investor that, individually or together with such Investor’s
Affiliates, holds at least 1,066,666 shares of Registrable Securities (in each case, as adjusted for any stock split, stock dividend, combination, or other recapitalization or reclassification effected after the date hereof). 

1.16 “New Securities” means, collectively, equity securities of the Company, whether or not currently
authorized, as well as rights, options, or warrants to purchase such equity securities, or securities of any type whatsoever that are, or may become, convertible or exchangeable into or exercisable for such equity securities. 

1.17 “Person” means any individual, corporation, partnership, trust, limited liability company,
association or other entity. 
 1.18 “Preferred Director” means any director of the Company that the
holders of record of the Series A Preferred Stock or Series B Preferred Stock are entitled to elect pursuant to the Company’s Certificate of Incorporation. 

1.19 “Preferred Stock” means, collectively, shares of the Company’s Series A Preferred Stock,
Series B Preferred Stock and Series C Preferred Stock. 
 1.20 “Registrable Securities” means
(i) the Common Stock issuable or issued upon conversion of the Preferred Stock; (ii) any Common Stock, or any Common Stock issued or issuable (directly or indirectly) upon conversion, exercise of any other securities of the Company or
both, acquired by the Investors after the date hereof; (iii) any Common Stock issued as (or issuable upon the conversion or exercise of any warrant, right, or other security that is issued as) a dividend or other distribution with respect to,
or in exchange for or in replacement of, the shares referenced in clauses (i) and (ii) above; excluding in all cases, however, any Registrable Securities sold by a Person in a transaction in which the applicable rights under this
Agreement are not assigned pursuant to Subsection 6.1, and excluding for purposes of Section 2 any shares for which registration rights have terminated pursuant to Subsection 2.13 of this Agreement. 

  
 3 

 1.21 “Registrable Securities then outstanding” means
the number of shares determined by adding the number of shares of outstanding Common Stock that are Registrable Securities and the number of shares of Common Stock issuable (directly or indirectly) pursuant to then exercisable and/or convertible
securities that are Registrable Securities. 
 1.22 “Restricted Securities” means the securities of
the Company required to be notated with the legend set forth in Subsection 2.12(b) hereof. 
 1.23
“SEC” means the Securities and Exchange Commission. 
 1.24 “SEC Rule 144”
means Rule 144 promulgated by the SEC under the Securities Act. 
 1.25 “SEC Rule 145” means Rule 145
promulgated by the SEC under the Securities Act. 
 1.26 “Securities Act” means the Securities Act of
1933, as amended, and the rules and regulations promulgated thereunder. 
 1.27 “Selling Expenses”
means all underwriting discounts, selling commissions, and stock transfer taxes applicable to the sale of Registrable Securities, and fees and disbursements of counsel for any Holder, except for the fees and disbursements of the Selling Holder
Counsel borne and paid by the Company as provided in Subsection 2.6. 
 1.28 “Series A Preferred
Stock” means shares of the Company’s Series A Preferred Stock, par value $0.0001 per share. 
 1.29
“Series B Preferred Stock” means shares of the Company’s Series B Preferred Stock, par value $0.0001 per share. 

1.30 “Series C Preferred Stock” means shares of the Company’s Series C Preferred Stock, par value
$0.0001 per share. 
 2. Registration Rights. The Company covenants and agrees as follows: 

2.1 Demand Registration. 

(a) Form S-1 Demand. If at any time after the earlier of (i) five (5) years after the date
of this Agreement or (ii) one hundred eighty (180) days after the effective date of the registration statement for the IPO, the Company receives a request from Holders in the aggregate of a majority of Registrable Securities, (each, as
applicable, the “Preferred Majority”) that the Company file a Form S-1 registration statement with respect to at least forty percent (40%) of the Registrable Securities then
outstanding, then the Company shall (x) within ten (10) days after the 

  
 4 

 
date such request is given, give notice thereof (the “Demand Notice”) to all Holders other than the Initiating Holders; and (y) as soon as practicable, and in any
event within sixty (60) days after the date such request is given by the Initiating Holders, file a Form S-1 registration statement under the Securities Act covering all Registrable Securities that the
Initiating Holders requested to be registered and any additional Registrable Securities requested to be included in such registration by any other Holders, as specified by notice given by each such Holder to the Company within twenty (20) days
of the date the Demand Notice is given, and in each case, subject to the limitations of Subsections 2.1(c) and 2.3. 
 (b)
Form S-3 Demand. If at any time when it is eligible to use a Form S-3 registration statement, the Company receives a request from Holders of at least twenty
percent (20%) of the Registrable Securities then outstanding that the Company file a Form S-3 registration statement with respect to outstanding Registrable Securities of such Holders having an anticipated
aggregate offering price, net of Selling Expenses, of at least $5.0 million, then the Company shall (i) within ten (10) days after the date such request is given, give a Demand Notice to all Holders other than the Initiating Holders;
and (ii) as soon as practicable, and in any event within forty-five (45) days after the date such request is given by the Initiating Holders, file a Form S-3 registration statement under the
Securities Act covering all Registrable Securities requested to be included in such registration by any other Holders, as specified by notice given by each such Holder to the Company within twenty (20) days of the date the Demand Notice is
given, and in each case, subject to the limitations of Subsections 2.1(c) and 2.3. 
 (c) Notwithstanding the foregoing
obligations, if the Company furnishes to Holders requesting a registration pursuant to this Subsection 2.1 a certificate signed by the Company’s chief executive officer stating that in the good faith judgment of the Company’s Board
of Directors it would be materially detrimental to the Company and its stockholders for such registration statement to either become effective or remain effective for as long as such registration statement otherwise would be required to remain
effective, because such action would (i) materially interfere with a significant acquisition, corporate reorganization, or other similar transaction involving the Company; (ii) require premature disclosure of material information that the
Company has a bona fide business purpose for preserving as confidential; or (iii) render the Company unable to comply with requirements under the Securities Act or Exchange Act, then the Company shall have the right to defer taking action with
respect to such filing, and any time periods with respect to filing or effectiveness thereof shall be tolled correspondingly, for a period of not more than ninety (90) days after the request of the Initiating Holders is given; provided,
however, that the Company may not invoke this right more than once in any twelve (12) month period; and provided further that the Company shall not register any securities for its own account or that of any other
stockholder during such ninety (90) day period other than pursuant to a registration relating to the sale of securities to employees of the Company or a subsidiary pursuant to a stock option, stock purchase, or similar plan; a registration on
any form that does not include substantially the same information as would be required to be included in a registration statement covering the sale of the Registrable Securities; or a registration in which the only Common Stock being registered is
Common Stock issuable upon conversion of debt securities that are also being registered. 

  
 5 

 (d) The Company shall not be obligated to effect, or to take any action to effect, any
registration pursuant to Subsection 2.1(a)(i) during the period that is sixty (60) days before the Company’s good faith estimate of the date of filing of, and ending on a date that is one hundred eighty (180) days after the
effective date of, a Company-initiated registration, provided that the Company is actively employing in good faith commercially reasonable efforts to cause such registration statement to become effective; (ii) after the Company has
effected two registrations pursuant to Subsection 2.1(a); or (iii) if the Initiating Holders propose to dispose of shares of Registrable Securities that may be immediately registered on Form S-3
pursuant to a request made pursuant to Subsection 2.1(b). The Company shall not be obligated to effect, or to take any action to effect, any registration pursuant to Subsection 2.1(b) (i) during the period that is thirty
(30) days before the Company’s good faith estimate of the date of filing of, and ending on a date that is ninety (90) days after the effective date of, a Company-initiated registration, provided that the Company is actively
employing in good faith commercially reasonable efforts to cause such registration statement to become effective; or (ii) if the Company has effected two registrations pursuant to Subsection 2.1(b) within the twelve (12) month
period immediately preceding the date of such request. A registration shall not be counted as “effected” for purposes of this Subsection 2.1(d) until such time as the applicable registration statement has been declared effective by
the SEC, unless the Initiating Holders withdraw their request for such registration, elect not to pay the registration expenses therefor, and forfeit their right to one demand registration statement pursuant to Subsection 2.6, in which case
such withdrawn registration statement shall be counted as “effected” for purposes of this Subsection 2.1(d). 
 2.2
Company Registration. If the Company proposes to register (including, for this purpose, a registration effected by the Company for stockholders other than the Holders) any of its securities under the Securities Act in connection with the
public offering of such securities solely for cash (other than in an Excluded Registration), the Company shall, at such time, promptly give each Holder notice of such registration. Upon the request of each Holder given within twenty (20) days
after such notice is given by the Company, the Company shall, subject to the provisions of Subsection 2.3, cause to be registered all of the Registrable Securities that each such Holder has requested to be included in such registration. The
Company shall have the right to terminate or withdraw any registration initiated by it under this Subsection 2.2 before the effective date of such registration, whether or not any Holder has elected to include Registrable Securities in such
registration. The expenses (other than Selling Expenses) of such withdrawn registration shall be borne by the Company in accordance with Subsection 2.6. 

2.3 Underwriting Requirements. 

(a) If, pursuant to Subsection 2.1, the Initiating Holders intend to distribute the Registrable Securities covered by their request by
means of an underwriting, they shall so advise the Company as a part of their request made pursuant to Subsection 2.1, and the Company shall include such information in the Demand Notice. The underwriter(s) will be selected by the Company and
shall be reasonably acceptable to a majority in interest of the Initiating Holders. In such event, the right of any Holder to include such Holder’s Registrable Securities in such registration shall be conditioned upon such Holder’s
participation in such underwriting and the inclusion of such Holder’s Registrable Securities in the underwriting to the extent provided herein. All Holders proposing to distribute their securities through such underwriting shall (together with
the Company as provided in Subsection 2.4(e)) enter into an underwriting agreement in customary form with the underwriter(s) selected for such underwriting. Notwithstanding any other provision of this Subsection 2.3, if the managing
underwriter(s) 

  
 6 

 
advise(s) the Initiating Holders in writing that marketing factors require a limitation on the number of shares to be underwritten, then the Initiating Holders shall so advise all Holders of
Registrable Securities that otherwise would be underwritten pursuant hereto, and the number of Registrable Securities that may be included in the underwriting shall be allocated among such Holders of Registrable Securities, including the Initiating
Holders, in proportion (as nearly as practicable) to the number of Registrable Securities owned by each Holder or in such other proportion as shall mutually be agreed to by all such selling Holders; provided, however, that the number
of Registrable Securities held by the Holders to be included in such underwriting shall not be reduced unless all other securities are first entirely excluded from the underwriting. To facilitate the allocation of shares in accordance with the above
provisions, the Company or the underwriters may round the number of shares allocated to any Holder to the nearest one hundred (100) shares. 

(b) In connection with any offering involving an underwriting of shares of the Company’s capital stock pursuant to Subsection 2.2,
the Company shall not be required to include any of the Holders’ Registrable Securities in such underwriting unless the Holders accept the terms of the underwriting as agreed upon between the Company and its underwriters, and then only in such
quantity as the underwriters in their sole discretion determine will not jeopardize the success of the offering by the Company. If the total number of securities, including Registrable Securities, requested by stockholders to be included in such
offering exceeds the number of securities to be sold (other than by the Company) that the underwriters in their reasonable discretion determine is compatible with the success of the offering, then the Company shall be required to include in the
offering only that number of such securities, including Registrable Securities, which the underwriters and the Company in their sole discretion determine will not jeopardize the success of the offering. If the underwriters determine that less than
all of the Registrable Securities requested to be registered can be included in such offering, then the Registrable Securities that are included in such offering shall be allocated among the selling Holders in proportion (as nearly as practicable
to) the number of Registrable Securities owned by each selling Holder or in such other proportions as shall mutually be agreed to by all such selling Holders. To facilitate the allocation of shares in accordance with the above provisions, the
Company or the underwriters may round the number of shares allocated to any Holder to the nearest one hundred (100) shares. Notwithstanding the foregoing, in no event shall (i) the number of Registrable Securities included in the offering
be reduced unless all other securities (other than securities to be sold by the Company) are first entirely excluded from the offering, or (ii) the number of Registrable Securities included in the offering be reduced below twenty percent (20%)
of the total number of securities included in such offering, unless such offering is the IPO, in which case the selling Holders may be excluded further if the underwriters make the determination described above and no other stockholder’s
securities are included in such offering. For purposes of the provision in this Subsection 2.3(b) concerning apportionment, for any selling Holder that is a partnership, limited liability company, or corporation, the partners, members,
retired partners, retired members, stockholders, and Affiliates of such Holder, or the estates and Immediate Family Members of any such partners, retired partners, members, and retired members and any trusts for the benefit of any of the foregoing
Persons, shall be deemed to be a single “selling Holder,” and any pro rata reduction with respect to such “selling Holder” shall be based upon the aggregate number of Registrable Securities owned by all Persons included in such
“selling Holder,” as defined in this sentence. 

  
 7 

 (c) For purposes of Subsection 2.1, a registration shall not be counted as
“effected” if, as a result of an exercise of the underwriter’s cutback provisions in Subsection 2.3(a), fewer than fifty percent (50%) of the total number of Registrable Securities that Holders have requested to be included in such
registration statement are actually included. 
 2.4 Obligations of the Company. Whenever required under this Section 2 to effect
the registration of any Registrable Securities, the Company shall, as expeditiously as reasonably possible: 
 (a) prepare and file with the
SEC a registration statement with respect to such Registrable Securities and use its commercially reasonable efforts to cause such registration statement to become effective and, upon the request of the Holders of a majority of the Registrable
Securities registered thereunder, keep such registration statement effective for a period of up to one hundred twenty (120) days or, if earlier, until the distribution contemplated in the registration statement has been completed;
provided, however, that (i) such one hundred twenty (120) day period shall be extended for a period of time equal to the period the Holder refrains, at the request of an underwriter of Common Stock (or other securities) of
the Company, from selling any securities included in such registration, and (ii) in the case of any registration of Registrable Securities on Form S-3 that are intended to be offered on a continuous or
delayed basis, subject to compliance with applicable SEC rules, such one hundred twenty (120) day period shall be extended for up to one hundred twenty (120) days, if necessary, to keep the registration statement effective until all such
Registrable Securities are sold; 
 (b) prepare and file with the SEC such amendments and supplements to such registration statement, and the
prospectus used in connection with such registration statement, as may be necessary to comply with the Securities Act in order to enable the disposition of all securities covered by such registration statement; 

(c) furnish to the selling Holders such numbers of copies of a prospectus, including a preliminary prospectus, as required by the Securities
Act, and such other documents as the Holders may reasonably request in order to facilitate their disposition of their Registrable Securities; 

(d) use its commercially reasonable efforts to register and qualify the securities covered by such registration statement under such other
securities or blue-sky laws of such jurisdictions as shall be reasonably requested by the selling Holders; provided that the Company shall not be required to qualify to do business or to file a general
consent to service of process in any such states or jurisdictions, unless the Company is already subject to service in such jurisdiction and except as may be required by the Securities Act; 

(e) in the event of any underwritten public offering, enter into and perform its obligations under an underwriting agreement, in usual and
customary form, with the underwriter(s) of such offering; 
 (f) use its commercially reasonable efforts to cause all such Registrable
Securities covered by such registration statement to be listed on a national securities exchange or trading system and each securities exchange and trading system (if any) on which similar securities issued by the Company are then listed; 

  
 8 

 (g) provide a transfer agent and registrar for all Registrable Securities registered
pursuant to this Agreement and provide a CUSIP number for all such Registrable Securities, in each case not later than the effective date of such registration; 

(h) promptly make available for inspection by the selling Holders, any managing underwriter(s) participating in any disposition pursuant to
such registration statement, and any attorney or accountant or other agent retained by any such underwriter or selected by the selling Holders, all financial and other records, pertinent corporate documents, and properties of the Company, and cause
the Company’s officers, directors, employees, and independent accountants to supply all information reasonably requested by any such seller, underwriter, attorney, accountant, or agent, in each case, as necessary or advisable to verify the
accuracy of the information in such registration statement and to conduct appropriate due diligence in connection therewith; 
 (i) notify
each selling Holder, promptly after the Company receives notice thereof, of the time when such registration statement has been declared effective or a supplement to any prospectus forming a part of such registration statement has been filed; and

 (j) after such registration statement becomes effective, notify each selling Holder of any request by the SEC that the Company amend or
supplement such registration statement or prospectus. 
 In addition, the Company shall ensure that, at all times after any registration
statement covering a public offering of securities of the Company under the Securities Act shall have become effective, its insider trading policy shall provide that the Company’s directors may implement a trading program under Rule 10b5-1 of the Exchange Act. 
 2.5 Furnish Information. It shall be a condition precedent to the
obligations of the Company to take any action pursuant to this Section 2 with respect to the Registrable Securities of any selling Holder that such Holder shall furnish to the Company such information regarding itself, the
Registrable Securities held by it, and the intended method of disposition of such securities as is reasonably required to effect the registration of such Holder’s Registrable Securities. 

2.6 Expenses of Registration. All expenses (other than Selling Expenses) incurred in connection with registrations, filings, or
qualifications pursuant to Section 2, including all registration, filing, and qualification fees; printers’ and accounting fees; fees and disbursements of counsel for the Company; and the reasonable fees and disbursements, not to exceed
$25,000, of one counsel for the selling Holders (“Selling Holder Counsel”), shall be borne and paid by the Company; provided, however, that the Company shall not be required to pay for any expenses of any
registration proceeding begun pursuant to Subsection 2.1 if the registration request is subsequently withdrawn at the request of the Holders in the aggregate of a majority of the Registrable Securities to be registered (in which case all
selling Holders shall bear such expenses pro rata based upon the number of Registrable Securities that were to be 

  
 9 

 
included in the withdrawn registration), unless such Holders agree to forfeit their right to one registration pursuant to Subsections 2.1(a) or 2.1(b), as the case may be;
provided further that if, at the time of such withdrawal, the Holders shall have learned of a material adverse change in the condition, business, or prospects of the Company from that known to the Holders at the time of their request
and have withdrawn the request with reasonable promptness after learning of such information then the Holders shall not be required to pay any of such expenses and shall not forfeit their right to one registration pursuant to Subsections
2.1(a) or 2.1(b). All Selling Expenses relating to Registrable Securities registered pursuant to this Section 2 shall be borne and paid by the Holders pro rata on the basis of the number of Registrable Securities
registered on their behalf. 
 2.7 Delay of Registration. No Holder shall have any right to obtain or seek an injunction restraining
or otherwise delaying any registration pursuant to this Agreement as the result of any controversy that might arise with respect to the interpretation or implementation of this Section 2. 

2.8 Indemnification. If any Registrable Securities are included in a registration statement under this
Section 2: 
 (a) To the extent permitted by law, the Company will indemnify and hold harmless each selling Holder,
and the partners, members, officers, directors, and stockholders of each such Holder; legal counsel, accountants and investment advisers for each such Holder; any underwriter (as defined in the Securities Act) for each such Holder; and each Person,
if any, who controls such Holder or underwriter within the meaning of the Securities Act or the Exchange Act, against any Damages, and the Company will pay to each such Holder, underwriter, controlling Person, or other aforementioned Person any
legal or other expenses reasonably incurred thereby in connection with investigating or defending any claim or proceeding from which Damages may result, as such expenses are incurred; provided, however, that the indemnity agreement
contained in this Subsection 2.8(a) shall not apply to amounts paid in settlement of any such claim or proceeding if such settlement is effected without the consent of the Company, which consent shall not be unreasonably withheld, nor shall
the Company be liable for any Damages to the extent that they arise out of or are based upon actions or omissions made in reliance upon and in conformity with written information furnished by or on behalf of any such Holder, underwriter, controlling
Person, or other aforementioned Person expressly for use in connection with such registration. 
 (b) To the extent permitted by law, each
selling Holder, severally and not jointly, will indemnify and hold harmless the Company, and each of its directors, each of its officers who has signed the registration statement, each Person (if any), who controls the Company within the meaning of
the Securities Act, legal counsel and accountants for the Company, any underwriter (as defined in the Securities Act), any other Holder selling securities in such registration statement, and any controlling Person of any such underwriter or other
Holder, against any Damages, in each case only to the extent that such Damages arise out of or are based upon actions or omissions made in reliance upon and in conformity with written information furnished by or on behalf of such selling Holder
expressly for use in connection with such registration; and each such selling Holder will pay to the Company and each other aforementioned Person any legal or other expenses reasonably incurred thereby in connection

  
 10 

 
with investigating or defending any claim or proceeding from which Damages may result, as such expenses are incurred; provided, however, that the indemnity agreement contained in
this Subsection 2.8(b) shall not apply to amounts paid in settlement of any such claim or proceeding if such settlement is effected without the consent of the Holder, which consent shall not be unreasonably withheld; and provided
further that in no event shall the aggregate amounts payable by any Holder by way of indemnity or contribution under Subsections 2.8(b) and 2.8(d) exceed the proceeds from the offering received by such Holder (net of any Selling
Expenses paid by such Holder), except in the case of fraud or willful misconduct by such Holder. 
 (c) Promptly after receipt by an
indemnified party under this Subsection 2.8 of notice of the commencement of any action (including any governmental action) for which a party may be entitled to indemnification hereunder, such indemnified party will, if a claim in respect
thereof is to be made against any indemnifying party under this Subsection 2.8, give the indemnifying party notice of the commencement thereof. The indemnifying party shall have the right to participate in such action and, to the extent the
indemnifying party so desires, participate jointly with any other indemnifying party to which notice has been given, and to assume the defense thereof with counsel mutually satisfactory to the parties; provided, however, that an
indemnified party (together with all other indemnified parties that may be represented without conflict by one counsel) shall have the right to retain one separate counsel, with the fees and expenses to be paid by the indemnifying party, if
representation of such indemnified party by the counsel retained by the indemnifying party would be inappropriate due to actual or potential differing interests between such indemnified party and any other party represented by such counsel in such
action. The failure to give notice to the indemnifying party within a reasonable time of the commencement of any such action shall relieve such indemnifying party of any liability to the indemnified party under this Subsection 2.8, to the
extent that such failure materially prejudices the indemnifying party’s ability to defend such action. The failure to give notice to the indemnifying party will not relieve it of any liability that it may have to any indemnified party otherwise
than under this Subsection 2.8. 
 (d) To provide for just and equitable contribution to joint liability under the Securities Act in
any case in which either: (i) any party otherwise entitled to indemnification hereunder makes a claim for indemnification pursuant to this Subsection 2.8 but it is judicially determined (by the entry of a final judgment or decree by a
court of competent jurisdiction and the expiration of time to appeal or the denial of the last right of appeal) that such indemnification may not be enforced in such case, notwithstanding the fact that this Subsection 2.8 provides for
indemnification in such case, or (ii) contribution under the Securities Act may be required on the part of any party hereto for which indemnification is provided under this Subsection 2.8, then, and in each such case, such parties will
contribute to the aggregate losses, claims, damages, liabilities, or expenses to which they may be subject (after contribution from others) in such proportion as is appropriate to reflect the relative fault of each of the indemnifying party and the
indemnified party in connection with the statements, omissions, or other actions that resulted in such loss, claim, damage, liability, or expense, as well as to reflect any other relevant equitable considerations. The relative fault of the
indemnifying party and of the indemnified party shall be determined by reference to, among other things, whether the untrue or allegedly untrue statement of a material fact, or the omission or alleged omission of a material fact, relates to
information supplied by the indemnifying party or by the indemnified party and the parties’ relative intent, knowledge, access to information, and opportunity to correct or prevent such statement or

  
 11 

 
omission; provided, however, that, in any such case (x) no Holder will be required to contribute any amount in excess of the public offering price of all such Registrable
Securities offered and sold by such Holder pursuant to such registration statement, and (y) no Person guilty of fraudulent misrepresentation (within the meaning of Section 11(f) of the Securities Act) will be entitled to contribution from
any Person who was not guilty of such fraudulent misrepresentation; and provided further that in no event shall a Holder’s liability pursuant to this Subsection 2.8(d), when combined with the amounts paid or payable by such
Holder pursuant to Subsection 2.8(b), exceed the proceeds from the offering received by such Holder (net of any Selling Expenses paid by such Holder), except in the case of willful misconduct or fraud by such Holder. 

(e) Notwithstanding the foregoing, to the extent that the provisions on indemnification and contribution contained in the underwriting
agreement entered into in connection with the underwritten public offering are in conflict with the foregoing provisions, the provisions in the underwriting agreement shall control. 

(f) Unless otherwise superseded by an underwriting agreement entered into in connection with the underwritten public offering, the obligations
of the Company and Holders under this Subsection 2.8 shall survive the completion of any offering of Registrable Securities in a registration under this Section 2, and otherwise shall survive the termination of this
Agreement. 
 2.9 Reports Under Exchange Act. With a view to making available to the Holders the benefits of SEC Rule 144 and any
other rule or regulation of the SEC that may at any time permit a Holder to sell securities of the Company to the public without registration or pursuant to a registration on Form S-3, the Company shall: 

(a) make and keep available adequate current public information, as those terms are understood and defined in SEC Rule 144, at all times after
the effective date of the registration statement filed by the Company for the IPO; 
 (b) use commercially reasonable efforts to file with
the SEC in a timely manner all reports and other documents required of the Company under the Securities Act and the Exchange Act (at any time after the Company has become subject to such reporting requirements); and 

(c) furnish to any Holder, so long as the Holder owns any Registrable Securities, forthwith upon request (i) to the extent accurate, a
written statement by the Company that it has complied with the reporting requirements of SEC Rule 144 (at any time after ninety (90) days after the effective date of the registration statement filed by the Company for the IPO), the Securities
Act, and the Exchange Act (at any time after the Company has become subject to such reporting requirements), or that it qualifies as a registrant whose securities may be resold pursuant to Form S-3 (at any
time after the Company so qualifies); and (ii) such other information as may be reasonably requested in availing any Holder of any rule or regulation of the SEC that permits the selling of any such securities without registration (at any time
after the Company has become subject to the reporting requirements under the Exchange Act) or pursuant to Form S-3 (at any time after the Company so qualifies to use such form). 

  
 12 

 2.10 Limitations on Subsequent Registration Rights. From and after the date of this
Agreement, the Company shall not, without the prior written consent of the Preferred Majority, enter into any agreement with any holder or prospective holder of any securities of the Company that allow such holder or prospective holder (i) to
include such securities in any registration unless, under the terms of such agreement, such holder or prospective holder may include such securities in any such registration only to the extent that the inclusion of such securities will not reduce
the number of the Registrable Securities of the Holders that are included; or (ii) allow such holder or prospective holder to initiate a demand for registration of any securities held by such holder or prospective holder; provided that
this limitation shall not apply to any additional Investor who becomes a party to this Agreement in accordance with Subsection 6.9. 

2.11 “Market Stand-off” Agreement. Each Holder hereby agrees that it will not, without
the prior written consent of the managing underwriter, during the period ending on the date specified by the Company and the managing underwriter (such period not to exceed one hundred eighty (180) days following the effective date of the
registration statement for the IPO), (i) lend; offer; pledge; sell; contract to sell; sell any option or contract to purchase; purchase any option or contract to sell; grant any option, right, or warrant to purchase; or otherwise transfer or dispose
of, directly or indirectly, any shares of Common Stock or any securities convertible into or exercisable or exchangeable (directly or indirectly) for Common Stock held immediately before the effective date of the registration statement for the IPO
or (ii) enter into any swap or other arrangement that transfers to another, in whole or in part, any of the economic consequences of ownership of such securities, whether any such transaction described in clause (i) or (ii) above is to be
settled by delivery of Common Stock or other securities, in cash, or otherwise. The foregoing provisions of this Subsection 2.11 shall apply only to the IPO, shall not apply to the sale of any shares to an underwriter pursuant to an
underwriting agreement, or the transfer of any shares to any trust for the direct or indirect benefit of the Holder or the immediate family of the Holder, provided that the trustee of the trust agrees to be bound in writing by the
restrictions set forth herein, and provided further that any such transfer shall not involve a disposition for value, and shall be applicable to the Holders only if all officers and directors are subject to the same restrictions and
the Company uses commercially reasonable efforts to obtain a similar agreement from all stockholders individually owning more than 1 percent (1%) of the Company’s outstanding Common Stock (after giving effect to conversion into Common
Stock of all outstanding Preferred Stock). The underwriters in connection with such registration are intended third-party beneficiaries of this Subsection 2.11 and shall have the right, power and authority to enforce the provisions hereof as
though they were a party hereto. Each Holder further agrees to execute such agreements as may be reasonably requested by the underwriters in connection with such registration that are consistent with this Subsection 2.11 or that are necessary
to give further effect thereto. 
 2.12 Restrictions on Transfer. 

(a) The Preferred Stock and the Registrable Securities shall not be sold, pledged, or otherwise transferred, and the Company shall not
recognize and shall issue stop-transfer instructions to its transfer agent with respect to any such sale, pledge, or transfer, except upon the conditions specified in this Agreement, which conditions are intended to ensure compliance with the
provisions of the Securities Act. A transferring Holder will cause any 

  
 13 

 
proposed purchaser, pledgee, or transferee of the Preferred Stock and the Registrable Securities held by such Holder to agree to take and hold such securities subject to the provisions and upon
the conditions specified in this Agreement. Notwithstanding the foregoing, the Company shall not require any transferee of shares pursuant to an effective registration statement or, following the IPO, SEC Rule 144 to be bound by the terms of this
Agreement. 
 (b) Each certificate, instrument, or book entry representing (i) the Preferred Stock, (ii) the Registrable
Securities, and (iii) any other securities issued in respect of the securities referenced in clauses (i) and (ii), upon any stock split, stock dividend, recapitalization, merger, consolidation, or similar event, shall (unless otherwise
permitted by the provisions of Subsection 2.12(c)) be notated with a legend substantially in the following form: 
 THE SECURITIES
REPRESENTED HEREBY HAVE BEEN ACQUIRED FOR INVESTMENT AND HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933. SUCH SHARES MAY NOT BE SOLD, PLEDGED, OR TRANSFERRED IN THE ABSENCE OF SUCH REGISTRATION OR A VALID EXEMPTION FROM THE REGISTRATION
AND PROSPECTUS DELIVERY REQUIREMENTS OF SAID ACT. 
 THE SECURITIES REPRESENTED HEREBY MAY BE TRANSFERRED ONLY IN ACCORDANCE WITH THE TERMS
OF AN AGREEMENT BETWEEN THE COMPANY AND THE STOCKHOLDER, A COPY OF WHICH IS ON FILE WITH THE SECRETARY OF THE COMPANY. 
 The Holders consent
to the Company making a notation in its records and giving instructions to any transfer agent of the Restricted Securities in order to implement the restrictions on transfer set forth in this Subsection 2.12. 

(a) The holder of such Restricted Securities, by acceptance of ownership thereof, agrees to comply in all respects with the provisions of this
Section 2. Before any proposed sale, pledge, or transfer of any Restricted Securities, unless there is in effect a registration statement under the Securities Act covering the proposed transaction or, following the IPO, the
transfer is made pursuant to SEC Rule 144, the Holder thereof shall give notice to the Company of such Holder’s intention to effect such sale, pledge, or transfer. Each such notice shall describe the manner and circumstances of the proposed
sale, pledge, or transfer in sufficient detail and, if reasonably requested by the Company, shall be accompanied at such Holder’s expense by either (i) a written opinion of legal counsel who shall, and whose legal opinion shall, be
reasonably satisfactory to the Company, addressed to the Company, to the effect that the proposed transaction may be effected without registration under the Securities Act; (ii) a “no action” letter from the SEC to the effect that the
proposed sale, pledge, or transfer of such Restricted Securities without registration will not result in a recommendation by the staff of the SEC that action be taken with respect thereto; or (iii) any other evidence reasonably satisfactory to
counsel to the Company to the effect that the proposed sale, pledge, or transfer of the Restricted Securities may be effected without registration under the Securities Act, whereupon the Holder of such Restricted Securities shall be entitled to
sell, pledge, or transfer such Restricted Securities in accordance with the terms of the notice given by the Holder to the Company. The Company will not require such a legal opinion or “no action” letter (x) in any

  
 14 

 
transaction in compliance with SEC Rule 144; or (y) in any transaction in which such Holder distributes Restricted Securities to an Affiliate of such Holder for no consideration; provided
that each, except for transfers pursuant to clause (x) following the IPO, transferee agrees in writing to be subject to the terms of this Subsection 2.12. Each certificate, instrument, or book entry representing the Restricted Securities
transferred as above provided shall be notated with, except if such transfer is made pursuant to SEC Rule 144, the appropriate restrictive legend set forth in Subsection 2.12(b), except that such certificate instrument, or book entry
shall not be notated with such restrictive legend if, in the opinion of counsel for such Holder and the Company, such legend is not required in order to establish compliance with any provisions of the Securities Act. 

2.13 Termination of Registration Rights. The right of any Holder to request registration or inclusion of Registrable Securities in any
registration pursuant to Subsections 2.1 or 2.2 shall terminate upon the earlier to occur of: 
 (a) the closing of a Deemed
Liquidation Event (as such term is defined in the Company’s Certificate of Incorporation); provided, that the consideration (if any) to be provided in such Deemed Liquidation Event consists solely of cash, marketable securities or
securities for which the Company or a third party has agreed to register for resale with the SEC or applicable foreign regulatory authorities; 

(b) following the IPO, such time as Rule 144 or another similar exemption under the Securities Act is available for the sale of all of such
Holder’s shares without limitation during a three-month period without registration; and 
 (c) the fifth (5th) anniversary of the IPO.

 3. Information Rights. 

3.1 Delivery of Financial Statements. The Company shall deliver to each Major Investor, provided that the Board of Directors has
not reasonably determined that such Major Investor is a competitor of the Company: 
 (a) as soon as practicable, but in any event within
ninety (90) days after the end of each fiscal year of the Company (i) a balance sheet as of the end of such year, (ii) statements of income and of cash flows for such year, and a comparison between (x) the actual amounts as of
and for such fiscal year and (y) the comparable amounts for the prior year and as included in the Budget (as defined in Subsection 3.1(d)) for such year, with an explanation of any material differences between such amounts and a schedule
as to the sources and applications of funds for such year, and (iii) a statement of stockholders’ equity as of the end of such year, with such financial statements to be audited and certified by independent public accountants of nationally
recognized standing selected by the Company at such time as requested by the Preferred Majority; 
 (b) as soon as practicable following a
request by a Major Investor, but in any event within forty-five (45) days after the end of each of the first three (3) quarters of each fiscal year of the Company, unaudited statements of income and cash flows for such fiscal quarter, and
an unaudited balance sheet as of the end of such fiscal quarter, all prepared in accordance with GAAP (except that such financial statements may (i) be subject to normal year-end audit adjustments; and
(ii) not contain all notes thereto that may be required in accordance with GAAP); 

  
 15 

 (c) as soon as practicable following a request by a Major Investor, but in any event within
thirty (30) days of the end of each month, an unaudited income statement and statement of cash flows for such month, and an unaudited balance sheet as of the end of such month, all prepared in accordance with GAAP (except that such financial
statements may (i) be subject to normal year-end audit adjustments and (ii) not contain all notes thereto that may be required in accordance with GAAP); 

(d) as soon as practicable following a request by a Major Investor, but in any event at least thirty (30) days before the end of each
fiscal year, a budget and business plan for the next fiscal year (collectively, the “Budget”), approved by the Board of Directors and prepared on a monthly basis, including balance sheets, income statements, and statements of
cash flow for such months and, promptly after prepared, any other budgets or revised budgets prepared by the Company; and 
 (e) such other
information relating to the financial condition, business, prospects, or corporate affairs of the Company as any Major Investor may from time to time reasonably request; provided, however, that the Company shall not be obligated under
this Subsection 3.1 to provide information (i) that the Company reasonably determines in good faith to be a trade secret or confidential information (unless covered by an enforceable confidentiality agreement, in a form acceptable to the
Company); or (ii) the disclosure of which would adversely affect the attorney-client privilege between the Company and its counsel. 

If, for any period, the Company has any subsidiary whose accounts are consolidated with those of the Company, then in respect of such period
the financial statements delivered pursuant to the foregoing sections shall be the consolidated and consolidating financial statements of the Company and all such consolidated subsidiaries. 

Notwithstanding anything else in this Subsection 3.1 to the contrary, the Company may cease providing the information set forth in this
Subsection 3.1 during the period starting with the date thirty (30) days before the Company’s good-faith estimate of the date of filing of a registration statement if it reasonably concludes it must do so to comply with the SEC
rules applicable to such registration statement and related offering; provided that the Company’s covenants under this Subsection 3.1 shall be reinstated at such time as the Company is no longer actively employing its commercially
reasonable efforts to cause such registration statement to become effective. 
 3.2 Inspection. The Company shall permit each Major
Investor (provided that the Board of Directors has not reasonably determined that such Major Investor is a competitor of the Company), at such Major Investor’s expense, to visit and inspect the Company’s properties; examine its
books of account and records; and discuss the Company’s affairs, finances, and accounts with its officers, during normal business hours of the Company as may be reasonably requested by the Major Investor; provided, however, that
the Company shall not be obligated pursuant to this Subsection 3.2 to provide access to any information that it reasonably and in good faith considers to be a trade secret or confidential information (unless covered by an enforceable
confidentiality agreement, in form acceptable to the Company) or the disclosure of which would adversely affect the attorney-client privilege between the Company and its counsel. 

  
 16 

 3.3 ERISA. The Company shall provide notice, in writing, to each Major Investor as
soon as is reasonably practicable upon determining that the assets of the Company are “plan assets” for purposes of the Employee Retirement Income Security Act of 1974, as amended. 

3.4 Intentionally Omitted. 

3.5 Termination of Information Rights. The covenants set forth in Subsection 3.1, Subsection 3.2 and
Subsection 3.3 shall terminate and be of no further force or effect (i) immediately before the consummation of the IPO, or (ii) upon a Deemed Liquidation Event, as such term is defined in the Company’s Certificate of
Incorporation, whichever event occurs first, provided, that, with respect to a Deemed Liquidation Event, the covenants set forth in Subsection 3.1 shall only terminate if the consideration received by the Investors in such Deemed
Liquidation Event is in the form of cash and/or publicly traded securities unless (i) the Investors receive a contractual right to receive financial information from the acquiring company or other successor to the Company comparable to those
set forth in Section 3.1 or (ii) the acquiring company or other successor to the Company is subject to the periodic reporting requirements of Section 12(g) or 15(d) of the Exchange Act. 

3.6 Confidentiality. Each Investor agrees that such Investor will keep confidential and will not disclose, divulge, or use for any
purpose (other than to monitor its investment in the Company) any confidential information obtained from the Company pursuant to the terms of this Agreement (including notice of the Company’s intention to file a registration statement), unless
such confidential information (a) is known or becomes known to the public in general (other than as a result of a breach of this Section 3 by such Investor), (b) is or has been independently developed or conceived by
the Investor without use of the Company’s confidential information, or (c) is or has been made known or disclosed to the Investor by a third party without a breach of any obligation of confidentiality such third party may have to the
Company; provided, however, that an Investor may disclose confidential information (i) to its attorneys, accountants, consultants, and other professionals to the extent necessary to obtain their services in connection with
monitoring its investment in the Company; (ii) to any prospective purchaser of any Registrable Securities from such Investor, if such prospective purchaser agrees to be bound by the provisions of this Subsection 3.6; (iii) to any
existing or prospective Affiliate, partner, member, stockholder, or wholly owned subsidiary of such Investor in the ordinary course of business, provided that such Investor informs such Person that such information is confidential and directs
such Person to maintain the confidentiality of such information; or (iv) as may otherwise be required by law, provided that the Investor promptly notifies the Company of such disclosure and takes reasonable steps to minimize the extent
of any such required disclosure. The Company shall not publicly disclose (on its website, in a press release or other similar public disclosure) the name of SCubed Capital, LLC, Sobrato Family Holdings, LLC, Harvard Management Private Equity
Corporation, PH Investments, LLC, Portland RevMed EP, LLC, Portland RevMed PIA, LLC or Fifth Avenue Private Equity 14 LLC, or any of their Affiliates, or that any such Investor (or any Affiliate of such Investor) is a stockholder of the Company
without the prior written consent of such Investor, except as required by law, rule, regulation or listing standard; provided, that any consent to public disclosure by an Investor shall be deemed to be consent to other disclosures that are
substantially consistent with such other public disclosure to which such Investor has previously consented, unless indicated otherwise by such Investor. 

  
 17 

 4. Rights to Future Stock Issuances. 

4.1 Right of First Offer. Subject to the terms and conditions of this Subsection 4.1 and applicable securities laws, if the
Company proposes to offer or sell any New Securities, the Company shall first offer such New Securities to each Major Investor and The Board of Trustees of the University of Illinois (the “University Investor”). A Major
Investor and the University Investor shall be entitled to apportion the right of first offer hereby granted to it in such proportions as it deems appropriate, among (i) itself, (ii) its Affiliates and (iii) its beneficial interest holders,
such as limited partners, members or any other Person having “beneficial ownership,” as such term is defined in Rule 13d-3 promulgated under the Exchange Act, of such Major Investor. The University
Investor shall be permitted to apportion its right of first offer granted hereby to other individuals or entities that are not competitors of the Company; provided, that the University Investor provides the Company with prior written notice
of such assignment. 
 (a) The Company shall give notice (the “Offer Notice”) to each Major Investor and the
University Investor, stating (i) its bona fide intention to offer such New Securities, (ii) the number of such New Securities to be offered, and (iii) the price and terms, if any, upon which it proposes to offer such New Securities.

 (b) By notification to the Company within twenty (20) days after the Offer Notice is given, each Major Investor and the University
Investor may elect to purchase or otherwise acquire, at the price and on the terms specified in the Offer Notice, up to that portion of such New Securities which equals the quotient determined by dividing (A) (i) the shares of Common Stock then
held by such Major Investor that have been issued or are then issuable (directly or indirectly) upon conversion and/or exercise, as applicable, of the Preferred Stock and any other Derivative Securities then held by such Major Investor (excluding
any University Shares) and (ii) the University Shares, by (B) the total Common Stock of the Company then outstanding (assuming full conversion and/or exercise, as applicable, of all Preferred Stock and other Derivative Securities). At the
expiration of such twenty (20) day period, the Company shall promptly notify each Major Investor that elects to purchase or acquire all the shares available to it (each, a “Fully Exercising Investor”) of any other Major
Investor’s failure to do likewise. During the ten (10) day period commencing after the Company has given such notice, each Fully Exercising Investor may, by giving notice to the Company, elect to purchase or acquire, in addition to the
number of shares specified above, up to that portion of the New Securities for which Major Investors were entitled to subscribe but that were not subscribed for by the Major Investors which is equal to the proportion that the Common Stock issued and
held, or issuable (directly or indirectly) upon conversion and/or exercise, as applicable, of Preferred Stock and any other Derivative Securities then held, by such Fully Exercising Investor bears to the Common Stock issued and held, or issuable
(directly or indirectly) upon conversion and/or exercise, as applicable, of the Preferred Stock and any other Derivative Securities then held, by all Fully Exercising Investors who wish to purchase such unsubscribed shares. The closing of any sale
pursuant to this Subsection 4.1(b) shall occur within the later of ninety (90) days of the 

  
 18 

 
date that the Offer Notice is given and the date of initial sale of New Securities pursuant to Subsection 4.1(c). For purposes of this Agreement, the “University
Shares” means the 500,000 shares of the Company’s common stock issued to the University pursuant to that certain License Agreement with Equity dated December 18, 2014 by and between the Company and the University, as first
amended on August 26, 2016, and subsequently amended and restated on December 19, 2016 (the “License Agreement”), the shares of Series A Preferred Stock issued to Illinois Emerging Technologies Fund III, L.P. on
April 3, 2017 and any subsequent shares issued to the University Investor by the Company. 
 (c) If all New Securities referred to in
the Offer Notice are not elected to be purchased or acquired as provided in Subsection 4.1(b), the Company may, during the ninety (90) day period following the expiration of the periods provided in Subsection 4.1(b), offer and
sell the remaining unsubscribed portion of such New Securities to any Person or Persons at a price not less than, and upon terms no more favorable to the offeree than, those specified in the Offer Notice. If the Company does not enter into an
agreement for the sale of the New Securities within such period, or if such agreement is not consummated within thirty (30) days of the execution thereof, the right provided hereunder shall be deemed to be revived and such New Securities shall
not be offered unless first reoffered to the Major Investors and the University in accordance with this Subsection 4.1. 
 (d) The
right of first offer in this Subsection 4.1 shall not be applicable to (i) Exempted Securities (as defined in the Company’s Certificate of Incorporation); (ii) shares of Common Stock issued in the IPO; and (iii) the issuance of
shares of Series C Preferred Stock pursuant to the Purchase Agreement. 
 4.2 Termination. The covenants set forth in Subsection
4.1 shall terminate and be of no further force or effect (i) immediately before the consummation of the IPO, or (ii) upon a Deemed Liquidation Event, as such term is defined in the Company’s Certificate of Incorporation, whichever
event occurs first. 
 5. Additional Covenants. 

5.1 Tax Treatment. For U.S. income tax reporting purposes, unless otherwise required pursuant to a “determination” as defined
under Section 1313(a) of the Internal Revenue Code of 1986, as amended (the “Code”), a change in law or additional guidance issued by the Internal Revenue Service, or a change in terms or other facts, in each case
applicable to the Preferred Stock, each of the Company and the Investors shall not treat the accrual of the Accruing Dividends (as such term is defined in the Company’s Certificate of Incorporation) pursuant to Section 1 of the
Company’s Certificate of Incorporation as constructive dividends under Section 305 of the Code to the Investors and each of the Company and the Investors shall file tax returns in a manner consistent with such tax treatment. 

5.2 Insurance. The Company has obtained, from financially sound and reputable insurers, Directors and Officers liability insurance in an
amount and on terms and conditions satisfactory to the Board of Directors, and will use commercially reasonable efforts to cause such insurance to be maintained until such time as the Board of Directors determines that such insurance should be
discontinued. 

  
 19 

 5.3 Employee Agreements. The Company will cause each person now or hereafter employed
by it or by any subsidiary (or engaged by the Company or any subsidiary as a consultant/independent contractor) with access to confidential information and/or trade secrets to enter into a nondisclosure and proprietary rights assignment agreement
substantially in the form approved by the Board of Directors. In addition, the Company shall not amend, modify, terminate, waive, or otherwise alter, in whole or in part, any of the above-referenced agreements or any restricted stock agreement
between the Company and any employee, without the consent of a majority of the then-serving Preferred Directors. 
 5.4 Employee
Stock. Unless otherwise approved by the Board of Directors, including a majority of the then-serving Preferred Directors, all future employees and consultants of the Company who purchase, receive options to purchase, or receive awards of shares
of the Company’s capital stock (collectively, “Stock Awards”) after the date hereof shall be required to execute restricted stock or option agreements, as applicable, providing for (i) vesting of shares over a four
(4) year period, with the first twenty-five percent (25%) of such shares vesting following twelve (12) months of continued employment or service, and the remaining shares vesting in equal monthly installments over the following thirty-six (36) months, and (ii) a market stand-off provision substantially similar to that in Subsection 2.11. In addition, unless otherwise approved by the
Board of Directors, including a majority of the then-serving Preferred Directors, the Company shall retain a “right of first refusal” on employee transfers until the Company’s IPO and shall have the right to repurchase unvested shares
at cost upon termination of employment of a holder of restricted stock. 
 5.5 Matters Requiring Investor Director Approval. So long
as the holders of Preferred Stock are entitled to elect Preferred Directors, the Company hereby covenants and agrees with each of the Investors that it shall not, without approval of the Board of Directors, which approval must include the
affirmative vote of a majority of the then-serving Preferred Directors: 
 (a) make, or permit any subsidiary to make, any loan or advance
to, or own any stock or other securities of, any subsidiary or other corporation, partnership, or other entity unless it is wholly owned by the Company; 

(b) make, or permit any subsidiary to make, any loan or advance to any Person, including, without limitation, any employee or director of the
Company or any subsidiary, except advances and similar expenditures in the ordinary course of business or under the terms of an employee stock or option plan approved by the Board of Directors; 

(c) guarantee, directly or indirectly, or permit any subsidiary to guarantee, directly or indirectly, any indebtedness except for trade
accounts of the Company or any subsidiary arising in the ordinary course of business; 
 (d) make any investment inconsistent with any
investment policy approved by the Board of Directors; 

  
 20 

 (e) incur any aggregate indebtedness in excess of $1,000,000 that is not already included in
a budget approved by the Board of Directors, other than trade credit incurred in the ordinary course of business; 
 (f) otherwise enter into
or be a party to any transaction with any director, officer, or employee of the Company or any “associate” (as defined in Rule 12b-2 promulgated under the Exchange Act) of any such Person, including
without limitation any “management bonus” or similar plan providing payments to employees in connection with a Deemed Liquidation Event, as such term is defined in the Company’s Certificate of Incorporation, except for transactions
contemplated by this Agreement, the Purchase Agreement, and that certain Consultant’s Agreement between the Company and Martin Burke, M.D., Ph.D. dated November 25, 2014 and transactions resulting in payments to or by the Company in
an aggregate amount less than $120,000 per year; 
 (g) hire, terminate, or change the compensation of the executive officers, including
approving any option grants or stock awards to executive officers; 
 (h) change the principal business of the Company, enter new lines of
business, or exit the current line of business; 
 (i) sell, assign, license, pledge, or encumber material technology or intellectual
property, other than licenses granted in the ordinary course of business; or 
 (j) enter into any corporate strategic relationship involving
the payment, contribution, or assignment by the Company or to the Company of money or assets greater than $1,000,000. 
 5.6 Board
Matters. The Company shall reimburse the directors for all reasonable out-of-pocket travel expenses incurred (consistent with the Company’s travel policy) in
connection with attending meetings of the Board of Directors. 
 5.7 Successor Indemnification. If the Company or any of its
successors or assignees consolidates with or merges into any other Person and is not the continuing or surviving corporation or entity of such consolidation or merger, then to the extent necessary, proper provision shall be made so that the
successors and assignees of the Company assume the obligations of the Company with respect to indemnification of members of the Board of Directors as in effect immediately before such transaction, whether such obligations are contained in the
Company’s Bylaws, its Certificate of Incorporation, or elsewhere, as the case may be. 
 5.8 Indemnification Matters. The Company
hereby acknowledges that one (1) or more of the directors nominated to serve on the Board of Directors by the Investors (each a “Fund Director”) may have certain rights to indemnification, advancement of expenses and/or
insurance provided by one or more of the Investors and certain of their affiliates (collectively, the “Fund Indemnitors”). The Company hereby agrees (a) that it is the indemnitor of first resort (i.e., its obligations to
any such Fund Director are primary and any obligation of the Fund Indemnitors to advance expenses or to provide indemnification for the same expenses or liabilities incurred by such Fund Director are secondary), (b) that it shall be required to
advance 

  
 21 

 
the full amount of expenses incurred by such Fund Director and shall be liable for the full amount of all expenses, judgments, penalties, fines and amounts paid in settlement by or on behalf of
any such Fund Director to the extent legally permitted and as required by the Company’s Certificate of Incorporation or Bylaws of the Company (or any agreement between the Company and such Fund Director), without regard to any rights such Fund
Director may have against the Fund Indemnitors, and, (c) that it irrevocably waives, relinquishes and releases the Fund Indemnitors from any and all claims against the Fund Indemnitors for contribution, subrogation or any other recovery of any
kind in respect thereof. The Company further agrees that no advancement or payment by the Fund Indemnitors on behalf of any such Fund Director with respect to any claim for which such Fund Director has sought indemnification from the Company shall
affect the foregoing and the Fund Indemnitors shall have a right of contribution and/or be subrogated to the extent of such advancement or payment to all of the rights of recovery of such Fund Director against the Company. 

5.9 Right to Conduct Activities. The Company hereby agrees and acknowledges that Third Rock Ventures IV, L.P., The Column Group III, LP,
The Column Group III-A, LP, Ponoi Capital, LP, Ponoi Capital II, LP, Illinois Emerging Technologies Fund III, L.P., Nextech V Oncology S.C.S., SICAV-SIF, Casdin Partners
Master Fund, L.P., IST3 Manesse PE LP., Schroder Adveq Technology IX S.C.S., Harvard Management Private Equity Corporation, SCubed Capital, LLC, Sobrato Family Holdings, LLC, PH Investments, LLC, Portland RevMed EP, LLC, Portland RevMed PIA, LLC,
Fifth Avenue Private Equity 14 LLC, Greylock XIII Limited Partnership, Boxer Capital, LLC and Deerfield Private Design Fund IV, L.P. and Deerfield Special Situations Fund, L.P. (together with their respective Affiliates, the “VC
Funds”) are professional investment funds, and as such invest in numerous portfolio companies (including publicly traded companies), some of which may be deemed competitive with the Company’s business (as currently conducted or as
currently propose to be conducted). The Company hereby agrees that, to the extent permitted under applicable law, the VC Funds shall not be liable to the Company for any claim arising out of, or based upon, (i) the investment by the VC Funds in
any entity competitive with the Company, or (ii) actions taken by any partner, officer or other representative of the VC Funds to assist any such competitive company, whether or not such action was taken as a member of the board of directors of
such competitive company or otherwise, and whether or not such action has a detrimental effect on the Company; provided, however, that the foregoing shall not relieve (x) any of the Investors from liability associated with the unauthorized
disclosure of the Company’s confidential information obtained pursuant to this Agreement, or (y) any director or officer of the Company from any liability associated with his or her fiduciary duties to the Company. Nothing in this
Agreement shall preclude or create an obligation or duty restricting the VC Funds, as applicable, from evaluating or purchasing securities, include publicly traded securities, of a particular enterprise, whether or not such enterprise has products
or services which complete with those of the Company. 
 5.10 Termination of Covenants. The covenants set forth in this
Section 5, except for Subsections 5.8, 5.9 and 5.10, shall terminate and be of no further force or effect (i) immediately before the consummation of the IPO or (ii) upon a Deemed Liquidation
Event, as such term is defined in the Company’s Certificate of Incorporation, whichever event occurs first. 

  
 22 

 6. Miscellaneous. 

6.1 Successors and Assigns. The rights under this Agreement may be assigned (but only with all related obligations) by a Holder to a
transferee of Registrable Securities that (i) is an Affiliate of a Holder; (ii) is a Holder’s Immediate Family Member or trust for the benefit of an individual Holder or one or more of such Holder’s Immediate Family Members; or
(iii) after such transfer, holds shares of Registrable Securities (subject to appropriate adjustment for stock splits, stock dividends, combinations, and other recapitalizations); provided, however, that (x) the Company is,
within a reasonable time after such transfer, furnished with written notice of the name and address of such transferee and the Registrable Securities with respect to which such rights are being transferred; and (y) such transferee agrees in a
written instrument delivered to the Company to be bound by and subject to the terms and conditions of this Agreement, including the provisions of Subsection 2.11. For the purposes of determining the number of shares of Registrable Securities
held by a transferee, the holdings of a transferee (1) that is an Affiliate or stockholder of a Holder; (2) who is a Holder’s Immediate Family Member; or (3) that is a trust for the benefit of an individual Holder or such
Holder’s Immediate Family Member shall be aggregated together and with those of the transferring Holder; provided further that all transferees who would not qualify individually for assignment of rights shall have a single attorney-in-fact for the purpose of exercising any rights, receiving notices, or taking any action under this Agreement. The terms and conditions of this Agreement inure to
the benefit of and are binding upon the respective successors and permitted assignees of the parties. Nothing in this Agreement, express or implied, is intended to confer upon any party other than the parties hereto or their respective successors
and permitted assignees any rights, remedies, obligations or liabilities under or by reason of this Agreement, except as expressly provided herein. 

6.2 Governing Law. This Agreement shall be governed by the internal law of the State of California without regard to principles of
conflicts of laws. 
 6.3 Counterparts. This Agreement may be executed in two (2) or more counterparts, each of which shall be
deemed an original, but all of which together shall constitute one and the same instrument. Counterparts may be delivered via facsimile, electronic mail (including pdf or any electronic signature complying with the U.S. federal ESIGN Act of 2000,
e.g., www.docusign.com) or other transmission method and any counterpart so delivered shall be deemed to have been duly and validly delivered and be valid and effective for all purposes. 

6.4 Titles and Subtitles. The titles and subtitles used in this Agreement are for convenience only and are not to be considered in
construing or interpreting this Agreement. 
 6.5 Notices. All notices and other communications given or made pursuant to this
Agreement shall be in writing and shall be deemed effectively given upon the earlier of actual receipt or (i) personal delivery to the party to be notified; (ii) when sent, if sent by confirmed electronic mail or facsimile during the
recipient’s normal business hours, and if not sent during normal business hours, then on the recipient’s next business day; (iii) five (5) days after having been sent by registered or certified mail, return receipt requested, postage
prepaid; or (iv) one (1) business day after the business day of deposit with a nationally recognized overnight courier, freight prepaid, specifying next-day delivery, with written verification of receipt.
All communications shall be sent to the respective parties at their addresses as set forth on Schedule A hereto, or to such email address, facsimile number, or address as subsequently modified by written notice given in
accordance with this Subsection 6.5. 

  
 23 

 All communications to the Company shall be sent to: 

REVOLUTION Medicines, Inc. 
 700
Saginaw Drive 
 Redwood City, CA 94063 

Attn: Margaret Horn 
 Email: ###

 with a copy (which shall not constitute notice) to: 

Latham & Watkins LLP 

140 Scott Drive 
 Menlo Park,
California 94025 
 Attn: Mark V. Roeder 

Email: ### 
 6.6 Amendments
and Waivers. Any term of this Agreement may be amended and the observance of any term of this Agreement may be waived (either generally or in a particular instance, and either retroactively or prospectively) only with the written consent of the
Company and Preferred Majority; provided that the Company may in its sole discretion waive compliance with Subsection 2.12(c) (and the Company’s failure to object promptly in writing after notification of a proposed assignment
allegedly in violation of Subsection 2.12(c) shall be deemed to be a waiver); and provided further that any provision hereof may be waived by any waiving party on such party’s own behalf, without the consent of any other
party. Notwithstanding the foregoing, this Agreement may not be amended or terminated and the observance of any term hereof may not be waived with respect to any Investor without the written consent of such Investor, unless such amendment,
termination, or waiver applies to all Investors in the same fashion (it being agreed that a waiver of the provisions of Section 4 with respect to a particular transaction shall be deemed to apply to all Investors in the
same fashion if such waiver does so by its terms, notwithstanding the fact that certain Investors may nonetheless, by agreement with the Company, purchase securities in such transaction). The Company shall give prompt notice of any amendment or
termination hereof or waiver hereunder to any party hereto that did not consent in writing to such amendment, termination, or waiver. Any amendment, termination, or waiver effected in accordance with this Subsection 6.6
shall be binding on all parties hereto, regardless of whether any such party has consented thereto. No waivers of or exceptions to any term, condition, or provision of this Agreement, in any one or more instances, shall be deemed to be or construed
as a further or continuing waiver of any such term, condition, or provision. Pursuant to Section 6.6 of the Prior Agreement, the undersigned Investors who were also parties to the Prior Agreement and constitute the holders of the requisite
number of Registrable Securities to amend the Prior Agreement hereby waive all rights on behalf of themselves and on behalf of all other persons entitled so such rights under Section 4 of the Prior Agreement to which they may be entitled in
connection with the issuance and sale by the Company of shares of Series C Preferred Stock in accordance with the terms of the Purchase Agreement. 

  
 24 

 6.7 Severability. In case any one or more of the provisions contained in this
Agreement is for any reason held to be invalid, illegal or unenforceable in any respect, such invalidity, illegality, or unenforceability shall not affect any other provision of this Agreement, and such invalid, illegal, or unenforceable provision
shall be reformed and construed so that it will be valid, legal, and enforceable to the maximum extent permitted by law. 
 6.8
Aggregation of Stock. All shares of Registrable Securities held or acquired by Affiliates shall be aggregated together for the purpose of determining the availability of any rights under this Agreement and such Affiliates may apportion such
rights as among themselves in any manner they deem appropriate. 
 6.9 Additional Investors. Notwithstanding anything to the contrary
contained herein, and subject to the approval of the Board of Directors, if the Company issues additional shares of Preferred Stock after the date hereof, any purchaser of such shares of Preferred Stock may become a party to this Agreement by
executing and delivering an additional counterpart signature page to this Agreement, and thereafter shall be deemed an “Investor” for all purposes hereunder. 

6.10 Entire Agreement. This Agreement (including any Schedules and Exhibits hereto) constitutes the full and entire understanding and
agreement among the parties with respect to the subject matter hereof, and any other written or oral agreement relating to the subject matter hereof existing between the parties is expressly canceled. Upon the effectiveness of this Agreement,
the Prior Agreement shall be deemed amended and restated and superseded and replaced in its entirety by this Agreement, and shall be of no further force or effect. 

6.11 Dispute Resolution. The parties (a) hereby irrevocably and unconditionally submit to the jurisdiction of the state courts of
California and to the jurisdiction of the United States District Court for the Northern District of California for the purpose of any suit, action or other proceeding arising out of or based upon this Agreement, (b) agree not to commence any
suit, action or other proceeding arising out of or based upon this Agreement except in the state courts of California or the United States District Court for the Northern District of California, and (c) hereby waive, and agree not to assert, by
way of motion, as a defense, or otherwise, in any such suit, action or proceeding, any claim that it is not subject personally to the jurisdiction of the above-named courts, that its property is exempt or immune from attachment or execution, that
the suit, action or proceeding is brought in an inconvenient forum, that the venue of the suit, action or proceeding is improper or that this Agreement or the subject matter hereof may not be enforced in or by such court. 

Each party will bear its own costs in respect of any disputes arising under this Agreement. The prevailing party shall be entitled to
reasonable attorney’s fees, costs, and necessary disbursements in addition to any other relief to which such party may be entitled. Each of the parties to this Agreement consents to personal jurisdiction for any equitable action sought in the
U.S. District Court for the Northern District of California or any court of the State of California having subject matter jurisdiction. 

  
 25 

 6.12 Delays or Omissions. No delay or omission to exercise any right, power, or
remedy accruing to any party under this Agreement, upon any breach or default of any other party under this Agreement, shall impair any such right, power, or remedy of such nonbreaching or nondefaulting party, nor shall it be construed to be a
waiver of or acquiescence to any such breach or default, or to any similar breach or default thereafter occurring, nor shall any waiver of any single breach or default be deemed a waiver of any other breach or default theretofore or thereafter
occurring. All remedies, whether under this Agreement or by law or otherwise afforded to any party, shall be cumulative and not alternative. 

6.13 Acknowledgment. The Company acknowledges that the Investors are in the business of venture capital investing and therefore review
the business plans and related proprietary information of many enterprises, including enterprises that may have products or services that compete directly or indirectly with those of the Company. Nothing in this Agreement shall preclude or in any
way restrict the Investors from investing or participating in any particular enterprise whether or not such enterprise has products or services that compete with those of the Company. 

6.14 University Provisions. Notwithstanding anything to the contrary contained in this Agreement, in no event will the University
Investor be required with respect to the 500,000 shares of common stock of the Company issued to the University Investor issued to it pursuant to the License Agreement (the “License Agreement Shares”): (i) to provide
indemnification or make any contribution in lieu of indemnification, or be required as a condition to exercising its rights as a stockholder of the Company or otherwise, to enter into agreements providing for indemnification or contribution, in each
case to the extent contrary to Illinois law; (ii) to waive any rights under the Illinois Court of Claims Act, 705 ILCS 505/1 et seq., nor be required to enter into agreements under which it waives any such rights; (iii) to submit to
arbitration to resolve any dispute; (iv) to be responsible for any award of fees, costs or expenses to a prevailing party in a dispute unless such fees, costs and expenses are awarded by a court of competent jurisdiction, and the University
Investor shall be responsible only to the extent permitted by Illinois law; (v) to be subject, without University Investor’s prior written consent, to any agreement that materially adversely affects any right or privilege of the University
Investor granted under the License Agreement with respect to the Shares or any subsequent stockholder agreement executed by the University Investor; (vi) to withhold from disclosure confidential information as may be required by law or by order
of court or governmental authority; and (vii) the provisions of this Section 6.14 shall survive any termination of this Agreement and shall not be superseded by any subsequent agreement unless agreed to by the
University Investor in writing. 
 [REMAINDER OF PAGE INTENTIONALLY
LEFT BLANK] 

  
 26 

 IN WITNESS WHEREOF, the parties have executed this Amended and Restated
Investors’ Rights Agreement as of the date first written above. 
  

			
	COMPANY:
	
	REVOLUTION MEDICINES, INC.
		
	By:	 	 /s/ Mark A. Goldsmith, M.D., Ph.D.

	Name:	 	Mark A. Goldsmith, M.D.. Ph.D.
	Title:	 	President and Chief Executive Officer

  

SIGNATURE PAGE TO AMENDED AND RESTATED
INVESTORS’ RIGHTS AGREEMENT 

 IN WITNESS WHEREOF, the parties have executed this Amended and Restated
Investors’ Rights Agreement as of the date first written above. 
  

			
	INVESTOR:
	
	THIRD ROCK VENTURES II, L.P.
	
	By: Third Rock Ventures GP II, L.P., its general partner
	
	By: TRV GP II, LLC, its general partner
		
	By:	 	 /s/ Kevin Gillis

	Name:	 	Kevin Gillis
	Title:	 	CFO / Partner
	
	THIRD ROCK VENTURES III, L.P.
	
	By: Third Rock Ventures GP III, L.P., its general partner
	
	By: TRV GP III, LLC, its general partner
		
	By:	 	 /s/ Kevin Gillis

	Name:	 	Kevin Gillis
	Title:	 	CFO / Partner
	
	THIRD ROCK VENTURES IV, L.P.
	
	By: Third Rock Ventures GP IV, L.P., its general partner
	
	By: TRV GP IV, LLC, its general partner
		
	By:	 	 /s/ Kevin Gillis

	Name:	 	Kevin Gillis
	Title:	 	CFO / Partner

  

SIGNATURE PAGE TO AMENDED AND RESTATED
INVESTORS’ RIGHTS AGREEMENT 

 IN WITNESS WHEREOF, the parties have executed this Amended and Restated
Investors’ Rights Agreement as of the date first written above. 
  

			
	INVESTOR:
	
	THE COLUMN GROUP III, LP
	
	By: The Column Group III GP, LP
	Its: General Partner
	
	By: The Column Group, LLC
	Its: General Partner
		
	By:	 	 /s/ James Evangelista

	Name:	 	James Evangelista
	Title:	 	Chief Financial Officer
	
	THE COLUMN GROUP III-A, LP
	
	By: The Column Group III GP, LP
	Its: General Partner
	
	By: The Column Group, LLC
	Its: General Partner
		
	By:	 	 /s/ James Evangelista

	Name:	 	James Evangelista
	Title:	 	Chief Financial Officer

  

SIGNATURE PAGE TO AMENDED AND RESTATED
INVESTORS’ RIGHTS AGREEMENT 

 IN WITNESS WHEREOF, the parties have executed this Amended and Restated
Investors’ Rights Agreement as of the date first written above. 
  

			
	INVESTOR:
	
	PONOI CAPITAL, LP
	
	By: Ponoi Management, LLC
	Its: General Partner
		
	By:	 	 /s/ James Evangelista

	Name:	 	James Evangelista
	Title:	 	Chief Financial Officer
	
	PONOI CAPITAL II, LP
	
	By: Ponoi II Management, LLC
	Its: General Partner
		
	By:	 	 /s/ James Evangelista

	Name:	 	James Evangelista
	Title:	 	Chief Financial Officer

  

SIGNATURE PAGE TO AMENDED AND RESTATED
INVESTORS’ RIGHTS AGREEMENT 

 IN WITNESS WHEREOF, the parties have executed this Amended and Restated
Investors’ Rights Agreement as of the date first written above. 
  

			
	INVESTOR:
	
	BOXER CAPITAL, LLC
		
	By:	 	 /s/ Aaron Davis

	Name:	 	Aaron Davis
	Title:	 	Chief Executive Officer

  

SIGNATURE PAGE TO AMENDED AND RESTATED
INVESTORS’ RIGHTS AGREEMENT 

 IN WITNESS WHEREOF, the parties have executed this Amended and Restated
Investors’ Rights Agreement as of the date first written above. 
  

			
	 INVESTOR:

	
	 MVA INVESTORS, LLC

		
	By:	 	 /s/ Aaron Davis

	Name:	 	Aaron Davis
	Title:	 	Chief Executive Officer

  

SIGNATURE PAGE TO AMENDED AND RESTATED
INVESTORS’ RIGHTS AGREEMENT 

 IN WITNESS WHEREOF, the parties have executed this Amended and Restated
Investors’ Rights Agreement as of the date first written above. 
  

			
	INVESTOR:
	
	FIDELITY ADVISOR SERIES VII: FIDELITY ADVISOR BIOTECHNOLOGY FUND 
		
	By:	 	 /s/ Adrien Deberghes

	Name: Adrien Deberghes
	Title: Authorized Signatory

  

SIGNATURE PAGE TO AMENDED AND RESTATED
INVESTORS’ RIGHTS AGREEMENT 

 IN WITNESS WHEREOF, the parties have executed this Amended and Restated
Investors’ Rights Agreement as of the date first written above. 
  

			
	INVESTOR:
	
	FIDELITY CAPITAL TRUST: FIDELITY FLEX SMALL CAP FUND - SMALL CAP GROWTH SUBPORTFOLIO
		
	By:	 	 /s/ Adrien Deberghes

	Name: Adrien Deberghes
	Title: Authorized Signatory

  

SIGNATURE PAGE TO AMENDED AND RESTATED
INVESTORS’ RIGHTS AGREEMENT 

 IN WITNESS WHEREOF, the parties have executed this Amended and Restated
Investors’ Rights Agreement as of the date first written above. 
  

			
	INVESTOR:
	
	FIDELITY SECURITIES FUND: FIDELITY SMALL CAP GROWTH FUND 
		
	By:	 	 /s/ Adrien Deberghes

	Name: Adrien Deberghes
	Title: Authorized Signatory

  

SIGNATURE PAGE TO AMENDED AND RESTATED
INVESTORS’ RIGHTS AGREEMENT 

 IN WITNESS WHEREOF, the parties have executed this Amended and Restated
Investors’ Rights Agreement as of the date first written above. 
  

			
	INVESTOR:
	
	FIDELITY SECURITIES FUND: FIDELITY SMALL CAP GROWTH K6 FUND 
		
	By:	 	 /s/ Adrien Deberghes

	Name: Adrien Deberghes
	Title: Authorized Signatory

  

SIGNATURE PAGE TO AMENDED AND RESTATED
INVESTORS’ RIGHTS AGREEMENT 

 IN WITNESS WHEREOF, the parties have executed this Amended and Restated
Investors’ Rights Agreement as of the date first written above. 
  

			
	INVESTOR:
	
	KLP ENTERPRISES, LLC 
		
	By:	 	 /s/ Andrew D. Winjek

	Name: Andrew D. Winjek
	Title: Manager

  

SIGNATURE PAGE TO AMENDED AND RESTATED
INVESTORS’ RIGHTS AGREEMENT 

 IN WITNESS WHEREOF, the parties have executed this Amended and Restated
Investors’ Rights Agreement as of the date first written above. 
  

			
	INVESTOR:
	
	ILLINOIS EMERGING TECHNOLOGIES FUND III, L.P. 
		
	By:	 	 /s/ Nancy Sullivan

	Name: Nancy Sullivan
	Title: Managing Principal

  

SIGNATURE PAGE TO AMENDED AND RESTATED
INVESTORS’ RIGHTS AGREEMENT 

 IN WITNESS WHEREOF, the parties have executed this Amended and Restated
Investors’ Rights Agreement as of the date first written above. 
  

			
	INVESTOR:
	
	CORMORANT PRIVATE HEALTHCARE FUND II, LP
	
	By: Cormorant Private Healthcare GP II, LLC
		
	By:	 	 /s/ Bihua Chen

	Name: Bihua Chen
	Title: Managing Member of the GP
	
	CORMORANT GLOBAL HEALTHCARE MASTER FUND, LP
	
	By: Cormorant Global Healthcare GP, LLC
		
	By:	 	 /s/ Bihua Chen

	Name: Bihua Chen
	Title: Managing Member of the GP
	
	CRMA SPV, LP
	
	By: Cormorant Asset Management, LLC
	Its: Attorney-In-Fact
		
	By:	 	 /s/ Bihua Chen

	Name: Bihua Chen
	Title: CEO/Managing Member

  

SIGNATURE PAGE TO AMENDED AND RESTATED
INVESTORS’ RIGHTS AGREEMENT 

 IN WITNESS WHEREOF, the parties have executed this Amended and Restated
Investors’ Rights Agreement as of the date first written above. 
  

			
	INVESTOR:
	
	NEXTECH V ONCOLOGY S.C.S., SICAV-SIF 
	
	By: Nextech V GP S.à r.l.
	Its: General Partner
		
	By:	 	 /s/ James Pledger

	Name:	 	James Pledger
	Title:	 	Manager

  

SIGNATURE PAGE TO AMENDED AND RESTATED
INVESTORS’ RIGHTS AGREEMENT 

 IN WITNESS WHEREOF, the parties have executed this Amended and Restated
Investors’ Rights Agreement as of the date first written above. 
  

			
	INVESTOR:
	
	CASDIN PARTNERS MASTER FUND, L.P.
	
	By: Casdin Partners GP, LLC, its General Partner
		
	By:	 	 /s/ Eli Casdin

	Name: Eli Casdin
	Title: Managing Member

  

SIGNATURE PAGE TO AMENDED AND RESTATED
INVESTORS’ RIGHTS AGREEMENT 

 IN WITNESS WHEREOF, the parties have executed this Amended and Restated
Investors’ Rights Agreement as of the date first written above. 
  

			
	INVESTOR:
	
	IST3 MANESSE PE L.P.
	
	By: IST3 Manesse PE Management L.P., its general partner
	
	By: Schroder Adveq Management Jersey Ltd, its general partner
		
	By:	 	 /s/ Mark Nieuwenhuis

	Name: Mark Nieuwenhuis
	Title: Director
		
	By:	 	 /s/ Monika Pinel

	Name: Monika Pinel
	Title: Authorized Signatory
	
	SCHRODER ADVEQ TECHNOLOGY IX S.C.S.
	
	By: Schroder Adveq Management Luxembourg S.à.r.l., its general partner
		
	By:	 	 /s/ Catherine Koch

	Name: Catherine Koch
	Title: Manager
		
	By:	 	 /s/ Monika Pinel

	Name: Monika Pinel
	Title: Authorized Signatory

  

SIGNATURE PAGE TO AMENDED AND RESTATED
INVESTORS’ RIGHTS AGREEMENT 

 IN WITNESS WHEREOF, the parties have executed this Amended and Restated
Investors’ Rights Agreement as of the date first written above. 
  

			
	INVESTOR:
	
	SCHRODER ADVEQ TECHNOLOGY VIII, L.P.
		
	By:	 	 /s/ Mark Nieuwenhuis

	Name: Mark Nieuwenhuis
	Title: Director
		
	By:	 	 /s/ Monika Pinel

	Name: Monika Pinel
	Title: Authorized Signatory

  

SIGNATURE PAGE TO AMENDED AND RESTATED
INVESTORS’ RIGHTS AGREEMENT 

 IN WITNESS WHEREOF, the parties have executed this Amended and Restated
Investors’ Rights Agreement as of the date first written above. 
  

			
	INVESTOR:
	
	HARVARD MANAGEMENT PRIVATE EQUITY CORPORATION
		
	By:	 	 /s/ Elise McDonald

	Name: Elise McDonald
	Title: Authorized Signatory
		
	By:	 	 /s/ Kerr Mone

	Name: Kerr Mone
	Title: Authorized Signatory

  

SIGNATURE PAGE TO AMENDED AND RESTATED
INVESTORS’ RIGHTS AGREEMENT 

 IN WITNESS WHEREOF, the parties have executed this Amended and Restated
Investors’ Rights Agreement as of the date first written above. 
  

			
	INVESTOR:
	
	FIFTH AVENUE PRIVATE EQUITY 14 LLC
		
	By:	 	 /s/ Charles D. Bryceland

	Name: Charles D. Bryceland
	Title: Authorized Signer

  

SIGNATURE PAGE TO AMENDED AND RESTATED
INVESTORS’ RIGHTS AGREEMENT 

 IN WITNESS WHEREOF, the parties have executed this Amended and Restated
Investors’ Rights Agreement as of the date first written above. 
  

			
	INVESTOR:
	
	FIFTH AVENUE PRIVATE EQUITY 15 LLC
		
	By:	 	 /s/ Charles D. Bryceland

	Name: Charles D. Bryceland
	Title: Authorized Signer

  

SIGNATURE PAGE TO AMENDED AND RESTATED
INVESTORS’ RIGHTS AGREEMENT 

 IN WITNESS WHEREOF, the parties have executed this Amended and Restated
Investors’ Rights Agreement as of the date first written above. 
  

			
	 INVESTOR:

	
	 SCUBED CAPITAL, LLC

		
	By:	 	 /s/ Mark Stevens

	Name: Mark Stevens
	Title: Trustee

  

SIGNATURE PAGE TO AMENDED AND RESTATED
INVESTORS’ RIGHTS AGREEMENT 

 IN WITNESS WHEREOF, the parties have executed this Amended and Restated
Investors’ Rights Agreement as of the date first written above. 
  

			
	INVESTOR:
	
	PH INVESTMENTS, LLC
		
	By:	 	 /s/ Melinda E. Barber

	Name: Melinda E. Barber
	Title: Managing Director

  

SIGNATURE PAGE TO AMENDED AND RESTATED
INVESTORS’ RIGHTS AGREEMENT 

 IN WITNESS WHEREOF, the parties have executed this Amended and Restated
Investors’ Rights Agreement as of the date first written above. 
  

			
	INVESTOR:
	
	SOBRATO FAMILY HOLDINGS, LLC
		
	By:	 	 /s/ Matthew W. Sonsini

	Name: Matthew W. Sonsini
	Title: Chief Investment Officer, on behalf of Sobrato Family Holdings, LLC

  

SIGNATURE PAGE TO AMENDED AND RESTATED
INVESTORS’ RIGHTS AGREEMENT 

 IN WITNESS WHEREOF, the parties have executed this Amended and Restated
Investors’ Rights Agreement as of the date first written above. 
  

			
	INVESTOR:
	
	PORTLAND REVMED EP, LLC
	
	By: Partners HealthCare Master Trust for ERISA Assets, its managing member
		
	By:	 	 /s/ David Weden

	Name: David Weden
	Title: Authorized Signatory

  

SIGNATURE PAGE TO AMENDED AND RESTATED
INVESTORS’ RIGHTS AGREEMENT 

 IN WITNESS WHEREOF, the parties have executed this Amended and Restated
Investors’ Rights Agreement as of the date first written above. 
  

			
	INVESTOR:
	
	PORTLAND REVMED PIA, LLC
	
	By: Partners HealthCare System Pooled Investment Accounts, LLC, its managing member
		
	By:	 	 /s/ David Weden

	Name: David Weden
	Title: Authorized Signatory

 SIGNATURE PAGE TO AMENDED
AND RESTATED INVESTORS’ RIGHTS AGREEMENT 

 IN WITNESS WHEREOF, the parties have executed this Amended and Restated
Investors’ Rights Agreement as of the date first written above. 
  

					
	INVESTOR:
	
	DEERFIELD PRIVATE DESIGN FUND IV, L.P.
	
	By: Deerfield Mgmt IV, L.P. General Partner
	By: J.E. Flynn Capital IV, LLC General Partner
		
	By:	 	 /s/ David J. Clark

	Name: David J. Clark
	Title: Authorized Signatory
	
	DEERFIELD SPECIAL SITUATIONS FUND, L.P.
	
	By: Deerfield Mgmt, L.P. General Partner
	By: J.E. Flynn Capital, LLC General Partner
		
	By:	 	 /s/ David J. Clark

	Name: David J. Clark
	Title: Authorized Signatory

 SIGNATURE PAGE TO AMENDED
AND RESTATED INVESTORS’ RIGHTS AGREEMENT 

 IN WITNESS WHEREOF, the parties have executed this Amended and Restated
Investors’ Rights Agreement as of the date first written above. 
  

			
	INVESTOR:
	
	VP COMPANY INVESTMENTS 2018, LLC
		
	By:	 	 /s/ Alan C. Mendelson

	Name: Alan C. Mendelson
	Title: Member, Management Committee

 SIGNATURE PAGE TO AMENDED
AND RESTATED INVESTORS’ RIGHTS AGREEMENT 

 IN WITNESS WHEREOF, the parties have executed this Amended and Restated
Investors’ Rights Agreement as of the date first written above. 
  

			
	INVESTOR:
	
	BIOTECHNOLOGY VALUE FUND, LP
		
	By:	 	 /s/ Mark Lampert

	Name: Mark Lampert
	Title: President BVF Inc., General Partner of BVF Partners L.P., itself GP of Biotechnology Value Fund, L.P.

 SIGNATURE PAGE TO AMENDED
AND RESTATED INVESTORS’ RIGHTS AGREEMENT 

 IN WITNESS WHEREOF, the parties have executed this Amended and Restated
Investors’ Rights Agreement as of the date first written above. 
  

			
	INVESTOR:
	
	BIOTECHNOLOGY VALUE FUND II, LP
		
	By:	 	 /s/ Mark Lampert

	Name: Mark Lampert
	Title: President BVF Inc., General Partner of BVF Partners L.P., itself GP of Biotechnology Value Fund II, L.P.

 SIGNATURE PAGE TO AMENDED
AND RESTATED INVESTORS’ RIGHTS AGREEMENT 

 IN WITNESS WHEREOF, the parties have executed this Amended and Restated
Investors’ Rights Agreement as of the date first written above. 
  

			
	INVESTOR:
	
	BIOTECHNOLOGY VALUE TRADING FUND OS, L.P.
		
	By:	 	 /s/ Mark Lampert

	Name: Mark Lampert
	Title: President BVF Inc., General Partner of BVF Partners L.P., itself sole member of BVF Partners OS Ltd., itself GP of Biotechnology Trading Fund OS, L.P.

 SIGNATURE PAGE TO AMENDED
AND RESTATED INVESTORS’ RIGHTS AGREEMENT 

 IN WITNESS WHEREOF, the parties have executed this Amended and Restated
Investors’ Rights Agreement as of the date first written above. 
  

			
	INVESTOR:
	
	MSI BVF SPV, L.L.C.
	
	c/o Magnitude Capital
		
	By:	 	 /s/ Mark Lampert

	Name: Mark Lampert
	Title: President BVF Inc., itself General Partner of BVF Partners L.P., itself attorney-in-fact for MSI BVF SPV, L.L.C.

 SIGNATURE PAGE TO AMENDED
AND RESTATED INVESTORS’ RIGHTS AGREEMENT 

 IN WITNESS WHEREOF, the parties have executed this Amended and Restated
Investors’ Rights Agreement as of the date first written above. 
  

			
	INVESTOR:
	
	VIVO PANDA FUND, L.P.
	
	By: Vivo Panda, LLC, General Partner
		
	By:	 	 /s/ Mahendra Shah

	Name: Mahendra Shah
	Title: Managing Member

 SIGNATURE PAGE TO AMENDED
AND RESTATED INVESTORS’ RIGHTS AGREEMENT 

 IN WITNESS WHEREOF, the parties have executed this Amended and Restated
Investors’ Rights Agreement as of the date first written above. 
  

	
	INVESTOR:
	
	MARK V. ROEDER
	
	 /s/ Mark V. Roeder

	Signature
	Mark V. Roeder

 SIGNATURE PAGE TO AMENDED
AND RESTATED INVESTORS’ RIGHTS AGREEMENT 

 SCHEDULE A 

Schedule of Investors 
 Name and
Address 
 Third Rock Ventures II, L.P. 
 Third Rock
Ventures III, L.P. 
 Third Rock Ventures IV, L.P. 
 29 Newbury
Street 
 Boston, Massachusetts 02116 
 Attn: Dina M. Ciarimboli

 Email: [***] 
 [***] 

Phone: [***] 
 The Column Group III, LP 

The Column Group III-A, LP 

Ponoi Capital, LP 
 Ponoi Capital II, LP 

1700 Owens Street, Suite 500 
 San Francisco, CA 94158 

Attention: Laurence Lasky, 
 James Evangelista 

E-mail: [***] 
 [***] 

Peter Finn 
 117 Tudor Road 

Needham, Massachusetts 02492 
 Email: [***] 

Illinois Emerging Technologies Fund III, L.P. 
 C/O
Illinoisventures Gp III, LLC 
 2242 W. Harrison St., Suite 201 

Chicago, IL, 60612 
 Attention: Nancy Sullivan 

Email: [***] 
 The Board of Trustees of the University Of
Illinois 
 Office of Technology Management 
 319 Ceramics
Building, 105 S. Goodwin Avenue 
 Urbana, Illinois 61801-2901 

 Alexandria Equities No. 2, LLC 

385 E. Colorado Blvd., Suite 299 
 Pasadena, CA 91101 

Email: [***]; [***] 
 Cystic Fibrosis Foundation 

4550 Montgomery Avenue, Suite 1100N 
 Bethesda, MD 20814 

Email: [***] 
 Greylock XIII Limited Partnership 

Greylock XIII Principals LLC 
 Greylock XIII-A Limited Partnership 
 40 Grove Street, Suite 430 

Wellesley, MA 02482 
 Email: [***]; [***]; [***] 

KLP Enterprises, LLC 
 35 Windsor Road 

North Haven, CT 06473 
 Attention: Andrew D. Wingate 

Sanofi Research Invest, LLC 
 3711 Kennett Pike, Suite 200 

Greenville, DE 19807 
 Email:[***]; [***]; [***] 

Nextech V Oncology S.C.S., SICAV-SIF 

8, rue Lou Hemmer 
 L-1748
Luxembourg – Findel 
 Attention: The Managers of Nextech V GP S.à r.l. 

Email: [***]; [***] 
 with a copy (which shall not constitute
notice) to: 
 Wilmer Cutler Pickering Hale and Dorr LLP 

60 State Street 
 Boston, MA 02109

 Attn: Jason L. Kropp 
 Email:
[***] 
 Casdin Partners Master Fund, L.P. 
 1350 Avenue of the
Americas, Suite 2405 
 New York, New York 10019 
 Attention:
Evans Apeadu 
 Email: [***] 

 IST3 Manesse PE LP. 

50 Lothian Road 
 Festival Square 

Edinburgh EH3 9WJ 
 Scotland  

Attention: Erwin Boos 
 Email: [***] 

Schroder Adveq Technology IX S.C.S. 
 Schroder Adveq Technology
VIII, L.P. 
 6c, rue Gabriel Lippmann 
 L-5365 Munsbach 
 Luxembourg  

Attention: Erwin Boos 
 Email: [***] 

Harvard Management Private Equity Corporation 
 600 Atlantic
Avenue 
 Boston, MA 02210 
 Attention: Elise McDonald; Emily
Carroll 
 Email: [***]; [***] 
 Fifth Avenue Private Equity 14
LLC 
 Fifth Avenue Private Equity 15 LLC 
 Bessemer Trust 

Attention: Fifth Avenue Private Equity 14 LLC, 630 Fifth Avenue, 

NY, NY 10111 
 Attention: Charles Bryceland 

Email: [***] 
 SCubed Capital, LLC 

2061 Avy Avenue 
 Menlo Park, CA 94025 

Attention: Mark Stevens 
 Margo Doyle 

Email: [***] 
 [***] 

PH Investments, LLC 
 Pilot House, Lewis Wharf 

Boston, MA 02110 
 Attention: Ben Gomez; John Vander Vort; April
Robinson 
 Email: [***]; [***]; [***] 

 Sobrato Family Holdings, LLC 

10600 N. De Anza Blvd., Suite 200 
 Cupertino, CA 95014 

Phone: 408-446-0700 

Attn: Matt Sonsini and Albert Chiang 
 Email: [***] 

PORTLAND INVESTMENT - EP, LLC 
 PORTLAND INVESTMENT - PIA, LLC

 101 Merrimac Street, Suite 800 
 Boston, MA 02114 

Attention: David Weden 
 Email: [***] 

Gizem Akcay 
 70 Glenwood Rd 

Somerville, MA 02145 
 Email: [***] 

Jae Young Ahn 
 12 Bay State Ave #2 

Somerville, MA 02144 
 Email: [***] 

Lauren Barclay 
 128 Hillside Rd #3 

Watertown, MA 02472 
 Email: [***] 

Cindy Benod 
 37 Clarendon St. 

Newtown, MA 02460 
 Email: [***] 

Zachary Burke 
 59 Chatham Rd. 

Everett, MA 02149 
 Email: [***] 

Lucy Foulston 
 34 Canal St. 

Medford, MA 02155 
 Email: [***] 

Dan Gray 
 64 Orlando Ave. 

Winthrop, MA 02152 
 Email: [***] 

 Simina Grigoriu 

22 John Swift Road 
 Acton, MA 01720 

Email: [***] 
 Meizhong Jin 

34 Priscilla Circle 
 Wellesley, MA 02481 

Email: [***] 
 Dimitrios Kallifidas 

1010 Massachusetts Ave., Apt #54 
 Cambridge, MA 02138 

Email: [***] 
 Kyle Kenyon 

19c Millers Way 
 Sutton, MA 01590 

Email: [***] 
 Anna Kohlmann 

58 Thornberry Rd 
 Winchester, MA 01890 

Email: [***] 
 Seung-Joo
Lee 
 245 Cambridge St. Unit 202 
 Burlington, MA 01803 

Email: [***] 
 Anna Li 

26 Suffolk Street APT 2 
 Cambridge, MA 02139 

Email: [***] 
 Enhu Li 

116 Pearl St 
 Newton, MA 02458 

Email: [***] 
 Christopher Lindblom 

68 Silver Hill Road 
 Sudbury, MA 01776 

Email: [***] 

 Rebecca Littlefield 

271 Mt. Auburn Street 
 Cambridge, MA 02138 

Email: [***] 
 Jason Lowe 

30 Pinewood Path 
 E Bridgewater, MA 02333 

Email: [***] 
 Kathryn Luly 

289 Highland Ave Apt. 302 
 Somerville, MA 02144 

Email: [***] 
 Earl May 

152 Sycamore Street 
 Watertown, MA 02472 

Email: [***] 
 Jay Morgenstern 

452 Beacon Street #3 
 Boston, MA 02115 

Email: [***] 
 Duy Nguyen 

7 Cook Street 
 Shrewsbury, 01545 

Email: [***] 
 Daniel Onea 

2500 Mystic Valley Pkwy. Apt. 707 
 Medford, MA 02155 

Email: [***] 
 Ende Pan 

353 Marrett Rd 
 Lexington, MA 02421 

Email: [***] 
 Kevin Penn 

35 Rindge Avenue 
 Lexington, MA 02420 

Email: [***] 

 Nicholas Perl 

7 Gibbens Street 
 Somerville, MA 02143 

Email: [***] 
 Roy Pollock 

7 Barnard Road 
 Medford, MA 02155 

Email: [***] 
 Laurence E. Reid 

25 Dover Street 
 Cambridge, MA 02140 

Email: [***] 
 Keith Robison 

73 Tewksbury Street 
 Andover, MA 01810 

Email: [***] 
 Surayya Sana 

14 Chestnut Park 
 Melrose, MA 02176 

Email: [***] 
 Alok Sharma 

11 Ashmont Avenue 
 Newton, MA 02458 

Email: [***] 
 Jonathan Sheats 

526 Main Street 
 Sandown, NH 03873 

Email: [***] 
 Alec Silver 

31 St. Margaret Street Apt. 1 
 Dorchester, MA 02125 

Email: [***] 
 Jonah Simon 

64 Unity Ave. 
 Belmont, MA 02478 

Email: [***] 

 Michelle Stewart 

132 Rindge Avenue 
 Cambridge, MA 02140 

Email: [***] 
 Sharon Townson 

12 Dimick Street Unit 2 
 Somerville, MA 02143 

Email: [***] 
 Duke Vo 

28 Sumner Street 
 Milton, MA 02186 

Email: [***] 
 Jessica Whitney 

34 Partridge Ave, Apt 1 
 Somerville, MA 02145 

Email: [***] 
 Ning Yin 

240 Grove Street 
 Lexington, MA 02420 

Email: [***] 
 Susan Yost 

63 Upland Road – Unit 2 
 Cambridge, MA 02140 

Email: [***] 
 Alexander Yuzhakov 

5291 Washington Street 
 Boston, MA 02132 

Email: [***] 
 Minyun Zhou 

43 A Chester 
 Winchester, MA 01890 

Email: [***] 
 Rachel King 

8009 Spring Road 
 Cabin John, MD 20818 

Email: [***] 
 Julian Adams 

673 Boylston St. 
 Boston, MA 02116 

Email: [***] 

 Steven Holtzman 

1201 Commonwealth Avenue 
 West Newton, MA 02465 

Email: [***] 
 Lee Ann Marchionna 

20 Notre Dame Road 
 Bedford, MA 01730l 

Email: [***] 
 John Gaspar 

68 Tamworth Hill Ave 
 Wakefield, MA 01880 

Email: [***] 
 Ganesh Iyer 

23 Beverly Road 
 Arlington, MA 02474 

Email: [***] 
 Greg Verdine 

11 Exeter St. Unit 3 
 Boston, MA 02116 

Email: [***] 
 Matthew J. Nichols 

12 Tremont Street 
 Charlestown, MA 02129 

Email: [***] 
 Alan Rigby 

77 Highland Avenue 
 Glen Ridge, NJ 07028 

Email: [***] 
 Ken Mullen 

160 Cambridgepark Drive, Suite 505 
 Cambridge, MA 02140 

Email: [***] 
 Mat Sowa 

24 Walcott Rd 
 Watertown, MA 02472 

Email: [***] 

 Brian Bowman 

199 Seton Drive 
 New Rochelle, NY 10804 

Email: [***] 
 Mark Mulvihill 

4 Webster Circle 
 Sudbury, MA 01776 

Email: [***] 
 Ronald Vigliotta 

18 Hampden Avenue 
 Burlington, MA 01803 

Email: [***] 
 Christo Shalish 

5 Adams Street 
 Brookline, MA 02446 

Email: [***] 
 Sean Brady 

1161 York Ave Apt. 8E 
 New York, NY 10065 

Email: [***] 
 Susan O’Connor 

44 Elder Brewster Rd 
 Duxbury, MA 02332 

Email: [***] 
 Douglas Saffran 

10 New St. Apt. 1010 
 Boston, MA 02128 

Email: [***] 
 Kim Hazen 

29 Hope Street 
 Auburndale, MA 02466 

Email: [***] 
 Ly Phan 

6 Horton Place 
 Milton, MA 02186 

Email: [***] 

 Di Chanh Phan 

7013 Gentle Oak Dr. 
 Austin, TX 78749 

Email: [***] 
 Neville Anthony 

52 Lawrence Street 
 Northborough, MA 01532 

Email: [***] 
 Lisa Marcaurelle 

3302 Symmes Circle 
 Arlington, MA 02474 

Email: [***] 
 Kien Nguyen 

4 Rodney Road 
 Bedford, MA 01730 

Email: [***] 
 Zhigang Weng 

57 Winthrop Rd No. 1 
 Brookline, MA 02445 

Email: [***] 
 Alka Batycky 

19 Bernard Street 
 Newtown, MA 02461 

Email: [***] 
 Kim Drapkin 

8 Brendan Drive 
 Grafton, MA 01519 

Email: [***] 
 Robert Giacobbe 

499 Boston Road Apt. 3233 
 Billerica, MA 01821 

Email: [***] 
 Kimi Iguchi 

80 Broad St Unit 808 
 Boston, MA 02110 

Email: [***] 

 Michael Fischbach 

950 Casaneuva Place 
 Stanford, CA 94305 

Email: [***] 
 Melanie Maggiacomo 

3 Montego Circle 
 Andover, MA 01810 

Email: [***] 
 Dennis DiTullio 

3 Beth Lee Drive 
 Grafton, MA 01519 

Email: [***] 
 Liping Yang 

53 Wilbur Avenue 
 Arlington, MA 02476 

Email: [***] 
 Richard Baltz 

7636 Andora Drive 
 Sarasota, FL 34238 

Email: [***] 
 George Church 

218 Kent Street 
 Brookline, MA 02446 

Email: [***] 
 Rick Klausner 

883 Robb Rd 
 Palo Alto, CA 94306 

Email: [***] 
 Robert Copeland 

10 Smith Farm Lane 
 Lexington, MA 02421 

Email: [***] 
 Jennifer Petter 

22 Robinwood Lane 
 Stow, MA 01775 

Email: [***] 

 Bill Metcalf 

602 Indigo 
 Savoy, IL 61874 

Email: [***] 
 Jim Wells 

1341 Columbus Ave 
 Burlingame, CA 94010 

Email: [***] 
 Chris Varma 

1390 Westridge Dr. 
 Portola Valley. CA 94028 

Email: [***] 
 Lynne Zydowsky 

300 Beale Street Unit 301 
 San Francisco, CA 94105 

Email: [***] 
 Kasumi Verdine 

500 Atlantic Ave. 18-P 

Boston, MA 02210 
 Cormorant Private Healthcare Fund II, LP 

Cormorant Global Healthcare Master Fund, LP 
 200 Clarendon
Street, 52nd Floor 
 Boston, MA 02116 
 CRMA SPV, LP 

PO Box 309, Ugland House 
 Grand Cayman; KY1-1104 Cayman Islands 
 with a copy (which shall not constitute notice) to: 

Attn: Jake Abdolmohammadi 
 200 Clarendon Street, 52nd Floor 

Boston, MA 02116 
 Boxer Capital, LLC 

MVA Investors, LLC 
 11682 El Camino Real, Suite 320 

San Diego, CA 92130 
 Fidelity Securities Fund: Fidelity Small
Cap Growth Fund 
 Mag & Co. 
 c/o Brown Brothers
Harriman & Co. 
 Attn: Corporate Actions /Vault 

 140 Broadway 

New York, NY 10005 
 Email: [***] 

Fidelity Capital Trust: Fidelity Flex Small Cap Fund 
 - Small
Cap Growth Subportfolio 
 State Street Bank & Trust 

PO Box 5756                 

Boston, Massachusetts 02206 
 Attn: ISLANDMOORING CO FBO Fidelity
Capital Trust: 
 Fidelity Flex Small Cap Fund—Small Cap Growth Subportfolio 

Email: [***] 
 Fax number: [***] 

Fidelity Securities Fund: Fidelity Small Cap Growth K6 Fund 
 BNY
MELLON 
 ONE BNY MELLON CENTER 
 500 GRANT STREET AIM 151-2700 
 PITTSBURGH, PA 15258 

Fidelity Advisor Series VII: Fidelity Advisor Biotechnology Fund 

State Street Bank & Trust 
 PO Box 5756 

Boston, Massachusetts 02206 
 Attn: Bangle & Co fbo
Fidelity Advisor Series VII: 
 Fidelity Advisor Biotechnology Fund 

Email: [***] 
 Fax number: [***] 

Deerfield Private Design Fund IV, L.P. 
 Deerfield Special
Situations Fund, L.P. 
 Deerfield Management Company, L.P. (Series C) 

780 Third Avenue, 37th Floor 
 New York, New York, 10017 

Attn: Lawrence Atinsky 
 Biotechnology Value Fund, LP 

Biotechnology Value Fund II, LP 
 44 Montgomery Street, 40th Floor

 San Francisco, CA 94104 
 Email: [***] 

With a copy to (which shall not constitute notice): 
 Gibson,
Dunn & Crutcher LLP 
 555 Mission Street, Suite 3000 

San Francisco, CA 94105 
 Attention: Ryan A. Murr 

 Biotechnology Value Trading Fund OS, LP 

PO Box 309 Ugland House, Grand Cayman, KY1- 1104, Cayman Islands 

Email: [***] 
 With a copy to (which shall not constitute notice):

 Gibson, Dunn & Crutcher LLP 
 555 Mission Street,
Suite 3000 
 San Francisco, CA 94105 
 Attention: Ryan A. Murr

 MSI BVF SPV LLC 
 200 Park Avenue, 56th Floor 

New York, NY 10166 
 Email: [***] 

With a copy to (which shall not constitute notice): 
 Gibson,
Dunn & Crutcher LLP 
 555 Mission Street, Suite 3000 

San Francisco, CA 94105 
 Attention: Ryan A. Murr 

Vivo Panda Fund, L.P. 
 Mahendra Shah 

c/o Vivo Capital, LLC 
 192 Lytton Avenue 

Palo Alto, CA 94301 
 Email: [***] 

VP Company Investments 2018, LLC 
 c/o Latham & Watkins
LLP 
 555 West Fifth Street, Suite 800 
 Los Angeles, CA 90013

 Mark V. Roeder 
 Latham & Watkins LLP 

140 Scott Drive 
 Menlo Park, CA 94025 

Email: [***]

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00303-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00303-of-00352.parquet"}]]